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“The roads we take are more important than the goals we announce. 
Decisions determine destiny.” 
Frederick Speakman 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iii 
ACKNOWLEDGEMENTS 
Firstly, I would like to express my sincere gratitude to my supervisors. Thank you to Prof. 
Stuart Walker and Prof. Sam Salek for believing in me from day one, as well as for sharing 
their knowledge and enthusiasm, which have been an inspiration. It has been an absolute 
privilege to learn from them and I am grateful for this experience, which has enriched me 
personally and professionally. I am excited for what the future will bring and hope to continue 
our work and friendship.  
 
I am also indebted to my colleagues from the Centre for Innovation in Regulatory Science 
(CIRS), most importantly Dr Neil McAuslane, whose insights, wisdom and impressive 
memory have challenged as well as guided me throughout this project and helped to broaden 
my thinking. I am also grateful to Dr Lawrence Liberti and Prisha Patel for encouraging me to 
take on this task and for being so supportive.  
 
I would like to thank Pat Connelly for her editorial help in publishing my research and whose 
remarkable attention to detail helped me to finally learn to correctly hyphenate (or not) 
‘decision making’. I am also thankful to Sarah Conaway for her help in tabulating a portion of 
the results in Chapter 6 and 7 as well as other colleagues from CIRS: Tina Wang, Gill Hepton 
and Dr Jesmine Cai for cheering me on throughout this endeavour. I am also very grateful to 
Dr Julian Walker for taking the time to carry out the secondary review in Chapter 5 and for 
the kind words of advice.  
 
This research would not have been possible without the contributions from executives within 
the pharmaceutical industry, regulatory authorities and health technology assessment 
agencies, with respect to data provision and discussions. Thank you for facilitating the timely 
completion of this project. 
 
Most importantly, thank you to my family and friends for being my source of strength, 
particularly my dad, for always believing in me and for teaching me the importance of 
education and determination; I owe it all to you! To my life coach, my best friend and my 
love, Nick, as well as his family, particularly Lynda and Omar; thank you for being my rock 
and for encouraging me with words and chocolate. I could not have done this without you! 
Lastly to Selkie for tirelessly sitting at my side and being my companion from dusk to dawn. I 
love you all dearly. 
 
  
  
iv 
PUBLICATIONS AND PRESENTATIONS 
Journal Articles 
Bujar, M., Donelan, R., McAuslane, N., Walker, S. and Salek, S. (2016). Assessing the 
Quality of Decision Making in the Development and Regulatory Review of 
Medicines: Identifying Biases and Best Practices. Therapeutic Innovation & 
Regulatory Science, 51(2), pp.250-256. 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2016). Quality of Regulatory Decision-
Making Practices: Issues Facing Companies and Agencies. Therapeutic Innovation & 
Regulatory Science, 50(4), pp.487-495. 
Bujar, M., McAuslane, N., Walker, S. and Salek, S. (2017). Evaluating Quality of Decision-
Making Processes in Medicines' Development, Regulatory Review, and Health 
Technology Assessment: A Systematic Review of the Literature. Frontiers in 
Pharmacology, 8(189). 
 
Poster presentations 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2016). Innovation in regulatory science: 
Development and validation of an instrument for assessing the quality of decision 
making. Poster presentation at: University of Hertfordshire School of Life and Medical 
Sciences Research Conference, April 5 2016, Hatfield, UK. 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2016). Factors influencing quality 
decision making in medicines development and regulatory review: Biases and best 
practices. Poster presentation at: Drug Information Association (DIA) Annual Meeting, 
June 26-30 2016, Philadelphia, PA, US. First Prize Winner at Student Poster 
Competition. 
Bujar, M., McAuslane, N., Walker, S. and Salek, S. (2017). Quality of decision-making 
process in the development, review and reimbursement of medicines; its importance and 
implication. Poster presentation at: The Organisation for Professionals in Regulatory 
Affairs (TOPRA) Annual Meeting, October 3 2017, London, UK. First Prize Winner at 
Student Poster Competition. 
McAuslane, N., Bujar, M., and Walker, S. (2018). How well do HTA agencies build quality 
into their decision making? Poster presentation at: HTAi 2018 Meeting, June 1-5 2018, 
Vancouver, Canada. 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2018). Assessment of the Quality 
Decision-Making Practices; Case Studies with a Pharmaceutical Company, Regulatory 
and HTA Agency. Poster presentation at: Drug Information Association (DIA) Annual 
Meeting, June 24-28 2018, Boston, MA, US. 
  
v 
Oral presentations 
Bujar, M., McAuslane, N., Walker, S. and Salek, S. (2017). Evaluating quality of decision-
making processes in medicines’ development, regulatory review and health technology 
assessment. Oral presentation at: 6th FIP Pharmaceutical Sciences World 
Congress(PSWC), May 21-24 2017, Stockholm, Sweden. 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2017). What are the key issues for 
companies and agencies (Regulatory and HTA) in their internal decision-making 
processes. Oral presentation at: Centre for Innovation in Regulatory Science (CIRS) 
Workshop, June 15-16 2017, Tysons Corner, VA, US. 
 
Reports 
Bujar, M., McAuslane, N., Salek, S. and Walker, S. (2017). R&D Briefing 61: Building 
Quality into Decision-Making Processes in Medicines’ Development, Regulatory Review 
and Health Technology Assessment. Centre for Innovation in Regulatory Science 
(CIRS). London, UK. Available at http://www.cirsci.org/wp-
content/uploads/2017/01/CIRS-RD-Briefing-61-Decision-making.pdf [Accessed 4 April. 
2018] 
Walker, S., McAuslane, N., Bujar, M., Connelly, P. and Liberti, L. (2018). Quality decision-
making practices: Their application and impact in the development, review and 
reimbursement of medicines. 1st ed. Based on the proceedings of a Workshop convened 
by the Centre for Innovation in Regulatory Science CIRS), June15-16 2017, Tysons 
Corner, Virginia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
vi 
ABSTRACT 
The science of decision making has been established, but research is limited regarding the 
quality and transparency of the decision-making processes through which medicines become 
available. Indeed, it is not always clear what explicit processes pharmaceutical companies, 
regulatory authorities and health technology assessment (HTA) agencies are using to arrive at 
their decisions. Previous research resulted in the development of the ten Quality Decision-
Making Practices (QDMPs), which are considered as the best practices in decision making in 
the lifecycle of medicines, as well the Quality of Decision-Making Orientation Scheme 
(QoDoS), which is a technique that can be used to measure the incorporation of these QDMPs 
in companies and agencies.  
 
The aim of this research, therefore, was to develop a roadmap for improving the quality of 
decision-making processes for key strategic decisions made by pharmaceutical companies, 
regulatory authorities and HTA agencies, by firstly evaluating current processes in place; 
secondly by assessing the ten QDMPs and thirdly by developing approaches for incorporating 
the ten QDMPs into organisational processes. In formalising the study design, various 
methodologies were appraised and it was rationalised that in order to fulfil the aim of the 
study, it would be appropriate to adopt a mixed method approach i.e. combination of self-
administered questionnaires, focus groups as well as case studies. In addition, a systematic 
review of literature was conducted to identify the most robust and psychometrically sound 
technique for assessing the QDMPs. 
 
Results from four questionnaires developed for the purpose of this research demonstrated that 
companies and agencies do not always utilise frameworks for key decision-making processes, 
namely regulatory submission processes, regulatory approvals, HTA submissions and HTA 
appraisals. Moreover, the majority of organisations with established frameworks did not 
incorporate all ten QDMPs into their processes, although all these practices were considered 
relevant. The study also identified challenges in decision making as well as biases, where all 
the participants believed there was room for improvement and suggested a number of 
solutions, which included training and the use of structured processes.   
 
The results also uncovered that organisations do not generally have formal assessments in 
place to measure the quality of decision making. However, a systematic literature review of 
techniques for evaluating the QDMPs during the lifecycle of medicines revealed a paucity of 
available techniques, which could explain why such assessments are not taking place. The 
QoDoS was considered as the most promising technique out of the 13 identified in the review.  
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A subsequent case study with QoDoS demonstrated its reliability and relevance in target 
audiences. Three additional QoDoS case studies, with a company, a regulatory authority and 
an HTA agency, demonstrated its practicality in assessing the consistency of favourable and 
unfavourable practices in organisations.  
 
Finally, three focus groups with individuals from companies, agencies and academia resulted 
in the development of practical approaches for embedding quality into strategic decision-
making processes. These recommendations, as well as the outcomes from the other studies, 
were used to develop a checklist for incorporating the ten QDMPs into a project matrix 
structure including the steps and variables to be documented at the time of decision making.  
 
The methods and approaches developed and validated during this programme of research, 
namely the questionnaires, the QoDoS and the checklist, led to the development of a roadmap 
for improving the quality of decision-making processes within companies and agencies for 
key strategic decisions. The goals are to raise the awareness of the importance of quality 
decision making during the development, regulatory review and HTA of medicines, secondly 
to improve the probability of good outcomes and finally to increase public trust as a result of 
more transparent and consistent decisions. 
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CHAPTER 1 
 
 
 
 
 
 
General Introduction 
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BACKGROUND 
Although the well-established principles of good decision making are common sense, they are 
nevertheless not always common practice and this applies to both how individuals make 
decisions on a daily basis, as well as how organisations make key strategic decisions across a 
range of industries, including the pharmaceutical industry (Spetzler et al., 2016). Indeed, the 
various decisions made around the availability of medicines are under constant scrutiny by 
patients seeking increased access to the most promising therapies. In addition, the process 
through which medicines become available is long and characterised by high risk and 
uncertainty (Pritchard et al., 2003). Despite this, there is a lack of research and insight into the 
decision-making approaches for individuals and organisations involved in medicines research 
and development.  Consequently, there is a need to explore and improve the decision making 
of the three key stakeholders involved in this process, namely the pharmaceutical companies 
that develop the medicines, regulatory authorities which are responsible for pre-market 
assessment of medicines, as well as health technology assessment (HTA) agencies which 
recommend the reimbursement of medicines via national health services (Liberti et al., 2013). 
 
Brief history of decision making and the importance of evaluating the process 
The word “decision”, which originates from Latin, has the same root as the word “scissors”. 
Indeed to decide means to "to cut off” alternatives and pursue a selected course of action 
(Trewatha and Newport, 1982). The research on decision making stretches back over many 
centuries and encompasses a wide range of academic disciplines – from philosophy and 
mathematics to sociology, psychology and economics (Buchanan and O'Connell, 2006). 
Initial application of decision-making principles goes as far as prehistory, where human 
decisions were guided by instincts and the interpretations of nature (Buchanan and O'Connell, 
2006). More recently, in the 17th century, Rene Descartes, a famous philosopher and 
mathematician, established one of the first decision-making tools, namely the “Descartes 
Square”, which structures decision making around four questions “What will happen if this 
happens?”, “What will happen if this doesn’t happen?”, “What won’t happen if this doesn’t 
happen?” and “What won’t happen if this happens?” (Lowy and Hood, 2004). The second 
part of the 17th century and the start of the 18th century mark the introduction of the field of 
decision theory, which is the study of the reasoning underlying an individual’s choice (Steele 
et al., 2015). Here, a number of mathematicians, most notably Blaise Pascal and Daniel 
Bernoulli, developed methods for calculating probabilities for chance events, which laid the 
foundation for risk assessment and utility theory, which is a measure of preferences over 
some set of goods and services (Peters, 1987).   
  
3 
In the 19th and 20th century, the research on decision making evolved further into the field of 
psychology, through the work of Sigmund Freud (1915) on the unconscious influences on 
people’s actions, as well as into the field of economics through the work of Irving Fisher 
(1907) who introduced net present value as a decision-making tool, which indicates how 
much value an investment or projects adds. The 20th and 21st century are characterised by a 
number of notable events and research in the field of decision making as listed in Table 1.1. 
 
Table 1.1 A selection of notable people, events and research in the field of decision 
making during the 20th and 21st century 
1900: Sigmund Freud’s work on the unconscious suggests that people’s actions and decisions 
are often influenced by causes hidden in the mind. 
1907: Economist Irving Fisher introduces net present value as a decision-making tool, 
proposing that expected cash flow be discounted at a rate that reflects an investment’s risk. 
1921: Frank Knight distinguishes between risk, in which an outcome’s probability can be 
known (and insured against) and uncertainty, in which an outcome’s probability is unknowable. 
1938: Chester Barnard separates personal from organisational decision making to explain 
why some employees act in the firm’s interest rather than in their own. 
1950s: Research conducted at the Carnegie Institute of Technology and Massachusetts 
Institute of Technology will lead to the development of early computer-based decision tools. 
1960s: Edmund Learned, C. Roland Christensen, Kenneth Andrews and others develop the 
SWOT (strengths, weaknesses, opportunities, threats) model of analysis, useful for making 
decisions when time is short and circumstances complex. 
1968: Ron Howard’s and Howard Raiffa’s Decision Analysis approach explains many 
fundamental decision-making techniques, including decision trees and the expected value of 
sample (as opposed to perfect) information. 
1972: Irving Janis coins the term “groupthink” for flawed decision making that values 
consensus over the best result. 
1979: Amos Tversky and Daniel Kahneman (Nobel prize winner for Economics in 2002) 
publish their Prospect Theory, which demonstrates that the rational model of economics fails 
to detect the difference between decision utility and experience utility. 
1984: Daniel Isenberg explains that executives often combine rigorous planning with intuition 
when faced with a high degree of uncertainty. 
1995: Anthony Greenwald develops the Implicit Association Test, meant to reveal 
unconscious attitudes or beliefs that can influence judgment. 
2005: In Blink, Malcolm Gladwell explores the notion that our instantaneous decisions are 
sometimes better than those based on lengthy, rational analysis. 
2017: Richard Thaler, one of the founding fathers of “nudge theory” receives a Nobel Prize in 
Economics for his work on behavioural economics. 
Adapted from Buchanan and O'Connell, 2006 
 
More recently, the science of decision making has been established regarding behavioural 
economics to enable better decision making through the pioneering works of Hammond and 
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colleagues (1999), Thaler and Sustein (2009), Kahneman (2011) as well as Howard and 
Abbas (2015) who uncovered interesting patterns and potential biases (heuristics) in the way 
in which people make decisions. According to the research of Hammond and colleagues 
(1999), one of the most fundamental distinctions in decision making is that between the 
process and the outcome. Indeed, in an uncertain world, it is possible to apply a good 
decision-making process that results in unfavourable consequences and, equally, to have a 
bad decision-making approach that will have a favourable outcome. Although a decision-
making process does not always guarantee a favourable outcome, on balance, however, the 
long-running use of good systems for making decisions will give more consistent and 
generally better outcomes (Kahneman, 2011). Consequently, the decision-making processes 
of pharmaceutical companies, regulatory authorities and HTA agencies should be evaluated 
separately in addition to the large volume of projects focusing on decision-making outcomes 
(Patel et al., 2016; Liberti et al., 2017). 
 
Decision making throughout the medicines research and development  
The process through which a new medicine is developed, from molecule to market place, is 
long and complex, lasting a minimum of 11 years on average from initial discovery to 
marketplace (Tufts, 2014). This process involves three key stakeholders, namely the 
pharmaceutical companies, regulatory authorities and finally HTA agencies, where each 
organisation, at certain stages relevant to their role in the process, makes countless decisions 
regarding a medicine. The overall average cost of developing a successful medicine is 
estimated as £2 billion, which also covers the cost of failures, such as the hundreds of 
thousands of compounds initially screened and assessed in the early research and 
development (R&D) process ahead of entering clinical testing. The overall probability of 
success, here defined as the likelihood that a medicine entering clinical testing will eventually 
reach the market, is estimated to be less than 12% (PhRMA, 2015). Nevertheless, this does 
not take into account the fact that certain medicines may be withdrawn from the market 
following initial approval, most frequently due to new evidence emerging regarding the safety 
of a medicine. As a result of the high risk, cost and uncertainty during the development of 
medicines, there is a need to characterise and evaluate the decision-making processes of the 
three key stakeholders and uncover how to improve the efficiency and ultimately increase the 
probability of favourable outcomes.  
The role of pharmaceutical companies during this process is to develop medicines starting 
from early research and discovery phases, through to clinical evaluation, manufacturing and 
finally leading to a decision to file the medicine for regulatory review and HTA. The decision 
making relies on input from a complex network of teams and committees, which are made up 
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of individuals from a range of disciplines, such as research and development, clinical 
development, marketing, legal, finance, regulatory affairs, health economics and outcomes 
research, public policy and senior management. The key decision points are defined often as 
the “go/no-go stage gates”, where teams and committees make decisions regarding whether or 
not a compound should be advanced through the stages of research and clinical trials. An 
example is moving from a Phase 2 trial, where the aim is to evaluate efficacy of a new 
medicine, into the significantly larger and more expensive Phase 3 trial in order to confirm its 
efficacy and safety and compare it with current standard of care. Nevertheless, the ultimate 
decision points are in the end regarding whether or not sufficient and appropriate evidence 
has been generated in order to submit the dossiers to regulatory authorities and HTA agencies 
(Pritchard et al., 2003). Interestingly, improvements in decision making by decreasing the 
influence of cognitive biases, which are subjective shortcuts used by the brain to process 
information that can lead to flawed thinking if not accounted for, have recently been linked to 
significant enhancements of R&D productivity within pharmaceutical companies, but there is 
a need for this to be further explored (Smietana et al., 2015). 
The marketing approval of a medicine depends on the decision making of regulatory 
authorities, which are most commonly national government agencies whose mission is to 
protect public health by recommending only appropriately safe and effective medicines. 
Regulatory authorities make their decisions based on the data submitted by companies, 
particularly data collected from clinical trial phases. The initial assessment is most commonly 
carried out by the authority’s reviewers and a decision is made either by an individual or a 
committee based on the benefit-risk profile of a medicine in order to ensure that the medicine 
has appropriate quality, safety and efficacy. However, regulatory authorities are being 
increasingly challenged to find a balance between the need for rapid patient access to new 
medicinal products and at the same time to ensure availability of comprehensive data on their 
assessment of benefits and risks. Indeed, there is a need to ensure that the processes have 
appropriate transparency, particularly if a different decision about the same product is made 
by regulatory authorities in order to strengthen public accountability and trust (Breckenridge 
et al., 2011; Tafuri, 2013). Consequently, authorities have been looking to improve their 
decision-making practices during the regulatory review. Most notably the US Food and Drug 
Administration (FDA), a leading regulatory authority, recommended “to develop a rigorous 
definition of the science of therapeutic regulatory decision-making and its application to the 
cycles of therapeutic development, marketing approval, post-marketing monitoring and 
modification of indications and safety” (Edlavitch and Salmon, 2015). It has also recently 
committed to enhance its clarity, transparency and consistency of benefit-risk assessment 
decision-making (FDA, 2018). In addition, a recent expert committee report called for the 
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need to improve the regulatory decision-making process of the UK Medicines and Healthcare 
products Regulatory Agency (MHRA) particularly regarding transparency around available 
process flexibilities (such as adaptive licensing) as well as the provision of scientific advice 
and stakeholder interaction (MHRA, 2013). 
Lastly, health technology assessment, which is carried out by HTA agencies, hospital 
formulary committees and other healthcare bodies, aims to evaluate the social, economic, 
organisational and ethical issues of a medicine or a health intervention to inform its 
reimbursement by national health systems. The HTA is generally a two-step decision-making 
process, which first of all involves the clinical and economic assessment of a medicine to 
determine its cost-effectiveness, comparative-effectiveness and budget impact, and secondly 
appraisal of the information by a committee, which involves both technical agency and 
external members as well as lay representatives, patient groups, payers and industry, in order 
to make the final decision.  Nevertheless, it should be noted that the decision made, namely 
whether or not a medicine should be reimbursed under a national health system, in many 
cases is not binding and is consequently referred to as a recommendation (Pichler et al., 
2010). In recent years, HTA has experienced an increase in importance due to pressures from 
governments to ensure efficient spending of national budgets on health care interventions 
(Goodman, 2014). Nevertheless, challenges remain as the current global HTA environment is 
very diverse, particularly the European system which is fragmented compared to the 
harmonised regulatory system under the European Medicines Agency (EMA). Projects are 
already underway to initiate a more efficient and aligned HTA practice and one that is more 
aligned with regulators in terms of process and occulting more closely together in time 
(Breckenridge et al., 2010). These various initiatives also aim to develop tools to support 
decision making in healthcare in order to improve transparency and consistency of HTA 
decisions (Allen et al., 2013; Oortwijn et al., 2017). 
 
THE IMPORTANCE OF A QUALITY DECISION-MAKING PROCESS 
Defining quality of decision making during medicines development, review and HTA 
Despite the considerable interest from pharmaceutical companies, regulatory authorities and 
HTA agencies in ensuring favourable outcomes, there has been limited research into the 
quality of decision-making processes of the three organisations (Tafuri, 2013; Donelan et al., 
2015). Although quality is difficult to define due to its subjective nature, it is nevertheless 
possible to identify the elements of a quality decision-making process. Indeed, the general 
principles and steps for making a quality decision have been characterised by a number of 
academic and consultancy groups (Matheson and Matheson, 1998; Hammond et al., 1999; 
Blenko et al., 2010; SDG, 2011). This include identifying the problem and objectives; having 
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creative implementable options; obtaining meaningful, reliable information upon which to 
base a decision; identifying clear consequences and trade-offs for each supportive element; 
considering uncertainty and eliminating biases; using logically correct reasoning; and making 
a commitment to action. More recently, these principles have been recognised and advocated 
across a number of disciplines such as aviation, economics, environmental protection, clinical 
practice, nuclear safety and government affairs, to facilitate quality decision making (Rafliff 
et al., 1999; Hunink et al., 2001; Dowding and Thompson, 2003; Morton et al., 2009; Thaler 
and Sustein, 2009; Gawande, 2011; Wagner, 2013; Avorn, 2018). However, despite the 
increasing number of publications about the importance of psychology of decision making 
(Kahneman, 2011), research on this topic in the area of medicines development, regulatory 
review and HTA is less well articulated and it is not certain how it is being applied by 
organisations and individuals (Donelan et al., 2015). 
 
In the absence of an alternative evaluation criteria system that captures issues relevant to the 
areas of medicines development, regulatory review and HTA, the best practices for making 
quality decisions during the lifecycle of medicines were characterised (Figure 1.1). These 
Quality Decision-Making Practices (QDMPs) were developed based on the outcomes of semi-
structured interviews by Donelan and colleagues (2015) with 29 key opinion leaders from 
regulatory authorities and pharmaceutical companies to investigate and identify the important 
issues that influence quality decision making during the medicines development and 
regulatory review. Moreover, this set of holistic practices is underpinned by the key 
frameworks used during medicines development, particularly in the area of regulatory 
benefit-risk assessment of medicines (Leong et al., 2015), as well as the science of decision 
making (Matheson and Matheson, 1998; Hammond et al., 1999; Blenko et al., 2010; SDG, 
2011; Heath C and Heath D, 2013). A framework can be defined as a set of principles, 
guidelines and tools to guide decision making in organising, understanding, summarising, 
quantifying and communicating the basis of the decision (Ferguson, 2008). The ten QDMPs 
were thematically organised into four quadrants, ‘Structure and Approach’, ‘Evaluation’, 
‘Impact’ and ‘Transparency and Communication’. 
 
In a subsequent review, these QDMPs were presented to a focus group of companies and 
agencies, and were considered as appropriate and relevant for ensuring quality decision 
making (Patel et al., 2016). However, it is not clear how these practices are theoretically 
incorporated into the formal frameworks of organisations or what markers could a company, a 
regulatory authority or an HTA agency instigate to ensure that these QDMPs are practically 
embedded into the key decision-making processes. One way to measure decision making 
could be based on a pre-specified agreement regarding an anticipated positive outcome.  
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Nevertheless, as previously discussed, an assessment of the outcome only may not be a good 
measure of the decision-making process.  Indeed, this has been recognised by Donabedian 
and colleagues (1988) where information about the quality of healthcare can be drawn from 
three distinct categories: “structure,” “process,” and “outcomes”. These interconnected 
categories provide a framework for examining the quality of health services, where indeed 
increasing the quality of process has been linked to better outcomes.  
 
However, despite the challenges to the direct measurement of the quality of the decision 
making, by understanding the components of quality decision-making practices, it may be 
possible to build a checklist, which would aim to measure performance against each practice 
and ultimately ensure that each QDMP is embedded within organisational and individual 
processes. The checklist could therefore be used to document the outcome of a decision-
making process at the time of decision making. A checklist approach, although having a 
number of potential challenges such as adherence, has successfully transformed the efficiency 
of decision making in medicine, aviation and investing in order to raise awareness of best 
practices, ensure they are consistently and transparently followed and ultimately increase the 
probability best quality outcomes (Gawande, 2011). Such an approach will therefore be 
explored in the pharmaceutical industry through this research. 
 
Figure 1.1 The ten Quality Decision-Making Practices (QDMPs)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, **: These two QDMPs were originally a single QDMP and were separated in subsequent 
phases of this research project 
Adapted from Donelan et al., 2015 
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Challenges to quality decision making 
Many factors can influence an individual’s approach to decision making including subjective 
and subconscious influences. This applies to the area of medicines development, review and 
HTA as well as beyond. Indeed the human mind and intuition work in ways that are 
sometimes in conflict with achieving a quality decision-making process (Hammond et al., 
1999; Kahneman, 2011). As defined by Kahneman (2011), ‘System 1’ thinking is fast and 
emotional and takes numerous shortcuts according to the “What You See Is All There Is” 
principle (WYSIASTI). System 2 thinking is deliberative and analytical and can be used to 
solve complex problems. Nevertheless, in order to avoid biases in the way which minds solve 
complex decision problems, individuals and organisations need to be educated on the topic of 
biases and secondly trained in the types of procedures, interventions and preventions that 
should be applied to prevent them. Figure 1.2 depicts 190 biases that can influence an 
individual’s decision making, whilst a number of additional factors exist such as personality 
and habitual effects, as well as social influences. These 190 biases have been identified and 
catalogued by behavioural scientists in academic studies over the last five decades and new 
classifications are being discovered to date (Benson, 2016).  
 
Figure 1.2 A categorisation of 190 biases into 4 groups: biases that arise from too much 
information, not enough meaning, the need to act quickly and the limits of memory  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Magnifying glass enlarges a portion to illustrate a subset of the content 
Adopted from Benson, 2016 
 
The impact of biases on decision making is high (Kahneman, 2011; Heath C and Heath D, 
2013) and as these biases are frequently subconscious, where many individuals and 
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organisations are not aware of their existence. Spetzler and colleagues (2016) have defined 
six categories used to organise the many individual-level biases, namely: 
• Protection of Mindset: Mindset is the basis of our beliefs and preferences. Individuals 
use their mindset to make judgments and their instinct dictates them to reject evidence 
that conflicts with initial mindset and to accept evidence that agrees with current beliefs, 
referred to as ‘confirmation bias’. Other types of biases are also relevant here, such as 
‘hindsight bias’, when individuals look back and rationalise a present situation based on 
past evidence; ‘self-serving bias’, referring to overestimating positive qualities while 
writing off failures to situational factors or bad luck; and ‘status quo bias’, whereby 
individuals cling to the current position too strongly. In order to overcome biases in this 
category, individuals should gain awareness of these phenomena, thereby learning how to 
maintain an open and flexible mindset.  
• Personality and Habits: Every individual has specific habits and personality traits and 
although this is part of human nature and is not problematic per se, this creates a source 
of bias as we see any decision or situation from a personal point of view (WYSIATI) 
rather than objective ‘as it is’ viewpoint. Individuals can nevertheless uncover and raise 
awareness of their preference-based habits using various personality tests, the most 
popular being the Myers-Briggs Type Indicator (Briggs and Myers, 1987). 
• Faulty Reasoning: Even if individuals are in a careful thinking mode to counter mindset 
and personality related biases, other challenges may arise, for example when dealing with 
large volumes of data or with complex multi-dimensional problems with interrelated 
factors or high uncertainty. Examples include ‘selective attention’ to specific variables or 
data and ‘substitution bias’ to replace a difficult question with an oversimplified one to 
the degree that this becomes a different problem. Finally, with high uncertainty around 
decision making, it is important to realise that overreliance on intuition is not appropriate. 
• Relative Thinking: Individuals tend to make judgments based on connections, 
comparisons and associations and this too can lead to biases. Examples are ‘availability 
bias’, where an event appears more likely because it is easily imagined and ‘narrative 
fallacy bias’, where compelling stories that are not necessarily true can nevertheless 
convince individuals. Solutions include encouraging more scientific reasoning and 
approach to assessing evidence and decision making. 
• Automatic Associations: These refer to distortions in our judgement based on the fact 
that people form associations when making decisions. Examples of biases include ‘halo 
effect bias’, where the overall impression of a person or idea influences how individuals 
feel and think about the entity’s character or properties; ‘anchoring effect bias’ where 
people rely or ‘anchor’ on one trait or piece of information when making decisions, often 
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in the presence of uncertainty; and ‘framing effect bias’ where individuals react to a 
particular choice in different ways depending on how it is presented, for example as a loss 
or a gain. This should be countered by looking at the information objectively and 
holistically. 
• Social Influences: These arise in the presence of the desire for conformity and 
acceptance, such as ‘authority bias’ leading individuals to prefer the opinion of an 
authority figure; ‘groupthink bias’ where individuals discourage diverse views in order to 
minimise conflict and strive for consensus at all cost; and ‘suggestibility’ where a person 
will accept the suggestions of another person and act accordingly. Such biases reduce the 
quality of decision making as they limit the number of alternatives considered and 
therefore should be countered by encouraging debate and dissent.  
In addition to individual-level biases described by Spetzler and colleagues (2016), Lovallo 
and Sibony (2010)  have developed a universal typology of biases, as outlined in Table 1.2, 
that occur most frequently and have the largest impact on the quality of organisational and 
business decisions, such as those made by companies, regulatory authorities and HTA 
agencies.  
Table 1.2 Characteristics and definitions of biases 
Bias type Definition Characteristics 
Action-
oriented 
A bias that drives us to take 
action less thoughtfully than 
we should  
• Excessive optimism 
• Overconfidence 
• Intuition/gut-feeling 
Interest 
A bias that arises in the 
presence of conflicting 
incentives, including 
emotional ones  
• Misaligned individual incentives 
• Inappropriate attachments 
• Misaligned perception of corporate 
goals/hierarchy 
Pattern-
recognition 
A bias that leads us to 
recognise patterns even 
where there are none 
• Confirmation bias to seek out information 
that supports a favoured decision 
• Generalising based on examples that are 
recent or memorable 
• Evaluating a plan or proposal based on the 
track record of the person presenting it, 
more than on the facts supporting it 
Stability 
A bias that creates a 
tendency toward inertia in 
the presence of uncertainty 
• Preference for the status quo in the absence 
of pressure to change it 
• The tendency to feel losses more acutely 
than gains of the same amount 
• Rooting oneself to an initial value, leading 
to insufficient adjustments of subsequent 
estimates. 
Adapted from Lovallo and Sibony, 2010 
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Although certain organisations involved in the development and review of medicines have 
started to investigate the occurrence of specific biases within regulatory authorities (Marangi 
et al., 2014) this has not been carried out in a systematic or comprehensive manner across 
pharmaceutical companies, regulatory authorities and HTA agencies. There is, therefore, 
scope to initially raise the awareness of biases in decision making across the three 
stakeholders and secondly evaluate whether these types of biases occur in the processes of the 
three organisations as well as whether differences and similarities exist across the groups.  
Evaluating quality of decision-making processes 
Routine assessment of the quality of the decision-making process (as opposed to just 
measuring outcomes) has been recognised as key for identifying process challenges and areas 
for improvement in order to ultimately increase the efficiency and productivity of decision 
making within any organisation (Kahneman, 2011). In the apparent absence of an appropriate 
technique, Donelan and colleagues (2015, 2016) initiated a study using a standardised 
approach comprised of qualitative and quantitative techniques to develop and validate an 
instrument, the Quality of Decision-Making Orientation Scheme (QoDoS), for assessing the 
quality of decision making in medicines development and regulatory review. In the initial 
qualitative phase of this research, in-depth structured interviews were conducted with 29 key 
opinion leaders from regulatory authorities and pharmaceutical companies regarding their 
subjective understanding of the approaches, influences and other factors in individual and 
organisational decision making in pharmaceutical development and regulation. Analysis of 
the output from these interviews resulted in the identification of overarching themes. It was 
hypothesised that these emergent themes could provide insight into a framework for quality 
decision making. Consequently, these themes were distilled into the ten QDMPs as described 
earlier. The overarching themes were used to develop 96 initial QoDoS items. 
 
In the quantitative approach used in phase 2 of the research, content validation and 
psychometric evaluation testing of the 96 items from phase 1 resulted in a reduced list of 76 
items. This was followed by content validity testing, using a panel of experts for language 
clarity, completeness, relevance and scaling, resulting in a favourable agreement by panel 
members with an intra-class correlation coefficient value of 0.89 (95% confidence interval = 
0.56, 0.99). Factor analysis was performed on the resulting 76-item instrument and produced 
a 47-item measure with response options on a Likert frequency scale (Figure 1.3).  In order to 
capture the views of the individuals regarding their decision-making competency and that of 
their organisation, this instrument was divided into four sections containing questions 
regarding the individual’s assessment of their organisation's decision-making approach and 
culture as well as their own decision-making competence and style (Donelan et al., 2016).  
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Figure 1.3 The Quality of Decision-Making Orientation Scheme (QoDoS) 
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(continued) Figure 1.3 The Quality of Decision-Making Orientation Scheme (QoDoS) 
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The 47 items of the final instrument can be mapped to the ten QDMPs (Table 1.3). The 
applicability of QoDoS in regulatory authority and pharmaceutical company setting was 
confirmed through a study with 76 participants (50% from regulatory authorities and 50% 
from pharmaceutical companies) to identify differences in decision making between 
individuals and their perception of their organisation as well as between companies and 
agencies across the QDMPs (Bujar et al., 2016).  
 
Table 1.3 Quality of Decision-Making Orientation Scheme (QoDoS) 24 individual and 23 
organisational items mapped to the ten Quality Decision-Making Practices (QDMPs) 
Ten QDMPs 
24 QoDoS  
individual items 
23 QoDoS 
organisational items 
1. Have a systematic, structured approach to aid 
decision making  
24, 25, 27, 30, 32, 
35, 36, 39, 40, 43  
3, 4, 11,  13, 14  
2. Assign clear roles and responsibilities  37  15, 23  
3. Assign values and relative importance to 
decision criteria  
33, 34, 44  6, 7  
4. Evaluate both internal and external 
influences/biases 
38,  42  5, 17, 20, 21  
5. Examine alternative solutions 
28  8, 9  
6. Consider uncertainty  
26,  45  10,  18  
7. Re-evaluate as new information becomes 
available  
46  12, 19  
8. Perform impact analysis of the decision  31, 47  1  
9. Ensure transparency and provide a record trail  29, 41  2, 16  
10. Effectively communicate  the basis of the 
decision  
   22  
Although the work by Donelan and colleagues (2016) led to the development of a robust 
technique for assessing the quality of decision-making processes during medicines 
development and review, there is a further scope for work. This could aim to first of all find 
out directly from companies, regulatory authorities and HTA agencies whether they utilise 
other in-house techniques for measuring quality of decision making and furthermore whether 
other tools have been published in journals or grey literature for the same purpose. A 
systematic assessment of the public domain as well as stakeholder views could demonstrate 
whether QoDoS is indeed the best available technique for measuring the quality of the 
decision-making process throughout the lifecycle of medicines, or perhaps whether other 
instruments exist that could be used in parallel. Furthermore, although, the initial applicability 
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of the instrument in a regulatory authority and pharmaceutical company setting was 
confirmed using a mixed group of participants (Bujar et al., 2016) there is a need to test the 
instrument in terms of its reliability (stability and consistency of scores), as well as to utilise 
the instrument to assess the level of implementation of the QDMPs in organisations and 
consequently determine the practicality of QoDoS for identifying areas of strength and the 
need for improvement. 
Frameworks for improving decision making in companies, regulatory authorities and 
HTA agencies 
As described earlier, pharmaceutical companies, regulatory authorities and HTA agencies 
make many decisions every day with regards to new medicines. Faced with an increasingly 
complex environment, these groups have been incorporating various frameworks and tools in 
order to make their decisions scientifically sound and transparent. Firstly, the area of 
regulatory benefit-risk assessment has adapted certain concepts in decision making through 
the use of qualitative and quantitative tools by pharmaceutical companies and regulatory 
authorities (Guo et al., 2010; EMA, 2011; Tafuri, 2013; Leong et al., 2015; Pignatti et al., 
2015; FDA, 2018). Examples of frameworks include the PrOACT-URL framework utilised 
by EMA, where each letter represents a step in the framework (Problem; Objectives, 
Alternatives, Consequences, Trade-offs, Uncertainty, Risks and Linked decisions); the 
Unified Methodologies for Benefit-Risk Assessment (UMBRA) framework; the US Food and 
Drug Administration (FDA) benefit-risk framework, along with other alternative quantitative 
approaches for assessing the benefit-risk balance of a medicine (EMA, 2011; Walker et al., 
2014; Pignatti et al., 2015). The above frameworks are also underpinned by the use of 
decision trees, which are diagrammatic displays of options, as well as Multi-Criteria Decision 
Analysis (MCDA), which is a qualitative and stepwise process that allows quantification of 
two or more decision alternatives (Dodgson, 2009). In HTA, a number of projects have also 
focused on the various ways to improve the assessment and appraisal methodologies and 
practices (Daniels, 2000; Wahlster et al., 2016;), particularly regarding inclusion of multiple 
decision criteria (Cole et al., 2016) and a structured assessment of comparative added benefit 
of a technology against the cost of treatment (Cherny et al., 2015; Schnipper et al., 2015).  
The second key area that has benefitted from more structured decision making is portfolio 
management, where companies have been using frameworks (Sharpe and Keelin, 1998; Cook 
et al., 2014) as well as quantitative methods and algorithms (Hassanzadeh et al., 2011; 
Jekunen, 2014) in order to analyse and optimise the portfolio of medicines and ultimately 
avoid late terminations in Phase 3 development. Frameworks have also been developed in 
order to provide better structure around evidence generation during medicines development in 
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order to capture the HTA and payer requirements as well as to try and put systems in place to 
better align with regulatory requirements (Dunlop et al., 2016; McAuslane et al., 2016). 
The third area has been around the use of good submission and review practices (GRevP) by 
pharmaceutical companies and regulatory authorities respectively (WHO, 2015) as well as in 
HTA agencies to standardise evidence generation (EUnetHTA, 2016) and to analyse the 
various decision-making systems for the assessment of health technologies (Rogowski et al., 
2008). Finally, pharmaceutical companies, regulatory authorities and HTA agencies have 
developed specific frameworks and guidelines to formalise the decision-making process of 
various committees (EMA, 2007; FDA, 2008; Hassanzadeh et al., 2011; CADTH, 2012; 
NICE, 2015).  
While the above frameworks serve their purpose and describe the specific process steps and 
principles regarding decision making during the development, regulatory review and HTA, 
they do not account for the subjective elements, such as behaviours and influences that affect 
the process with which individuals and organisations arrive at the final decision. Indeed, 
although the regulatory authorities and HTA agencies, as well as companies, already take into 
account the various medical, social, economic and ethical information needed to carry out the 
appraisal of medicines, it is not always obvious how the decisions, which require human 
judgment and interpretation, are made around the data (Cole et al., 2016).  
Furthermore, as the use of frameworks by regulatory authorities and HTA agencies as well as 
companies increases, it is not certain whether these frameworks enable quality and 
transparency. Consequently, there is a need to explicitly define, evaluate and furthermore 
improve the quality of deliberative decision making defined by the ten QDMPs, as advocated 
by the key stakeholders in this area, namely the major pharmaceutical companies, regulatory 
authorities and HTA agencies (McAuslane et al., 2014; Patel et al., 2016). Such an approach 
would seek to utilise QoDoS as an instrument for evaluating quality of key strategic decision-
making processes. A checklist could be then used to establish where improvements could be 
made as it would list the appropriate markers and process features organisations should have 
in place to ensure that the QDMPs are integrated. Ultimately, the various methods and 
approaches, including QoDoS and a checklist, could be brought together into an overarching 
roadmap that organisations could utilise as a strategy for improving the quality of decision-
making processes for key strategic decisions during medicines development, review and 
HTA.  
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AIM AND OBJECTIVES OF THE STUDY 
 
AIM 
The aim of this study is to develop a roadmap for improving the quality of decision-making 
processes for key strategic decisions during the development, regulatory review and health 
technology assessment (HTA) of medicines. 
 
OBJECTIVES 
The objectives across the three stakeholders, namely the pharmaceutical companies, 
regulatory authorities and HTA agencies are to: 
o Identify and evaluate existing decision-making practices and frameworks for 
making key decisions 
o Identify the techniques and measures used to evaluate quality decision-
making practices (QDMPs) 
o Appraise the published techniques for measuring QDMPs in order to 
determine whether the Quality of Decision Making Orientation Scheme 
(QoDoS), developed through previous research, is the most appropriate 
technique for evaluating quality decision making 
o Further validate QoDoS by assessing its reliability and relevance in target 
audience 
o Assess the practicality of QoDoS for evaluating the level of incorporation of 
the ten QDMPs within organisations  
o Identify practical approaches for integrating the ten QDMPs into decision-
making processes, including the development of a checklist that will support 
a timely, transparent, consistent and predictable process. 
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CHAPTER 2 
 
 
 
 
 
 
Study Rationale and Methodological Framework 
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STUDY RATIONALE 
Chapter one highlighted the relative paucity of research in quality decision making during 
medicines development, regulatory review and health technology assessment (HTA), despite 
demand from patients seeking increased access to safe and effective therapies. In addition to 
presenting the study rationale and purpose for carrying out the outlined studies, this chapter 
also reviews the appropriate methodological framework for the research project. 
 
Whilst over the past decade resources have been invested to analyse data requirements and 
outcomes, medicines development, review and HTA are characterised by high uncertainty and 
should be judged not just by the quality of scientific data or the consequences of the decision, 
but also by the quality of the decision-making process, which is the focus of this thesis. Based 
on the information reviewed so far, it is proposed that studies will be carried to: 
• Determine the existing use of frameworks, systematic decision-making processes and 
quality decision-making practices 
• Provide an insight into the decision-making approaches pharmaceutical companies, 
regulatory and HTA agencies 
• Assess the key challenges to quality decision making as well as potential solutions  
• Identify the practical approaches for integrating quality into the decision-making 
processes within pharmaceutical companies, regulatory authorities and HTA agencies, 
including the development of a checklist 
• Develop a roadmap for ensuring process consistency, transparency and quality. 
 
Furthermore, as noted in the introduction, the focus of research by Donelan and colleagues 
(2015, 2016) was to develop a technique for assessing Quality Decision-Making Practices 
(QDMPs), which resulted in the development of the Quality of Decision-Making Orientation 
Scheme (QoDoS), which requires further validation and application in a target audience. 
There is also limited research into identifying what other techniques are available, as well as 
their practical application. Consequently, it is suggested that follow-on studies are carried to: 
• Evaluate the use of techniques, such as tools, surveys, questionnaires and other studies, 
for measuring QDMPs 
• Demonstrate the reliability and relevance of QoDoS to further strengthen its 
measurement properties and appraise the potential for being accepted as a gold standard 
in evaluating quality of decision making during the lifecycle of medicines. 
• Assess the incorporation of the ten QDMPs into decision-making processes  
• Determine the practicality of QoDoS for increasing awareness of the issues in quality 
decision making 
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Study purpose 
Research projects are undertaken for different purposes and can be categorised as exploratory, 
descriptive and explanatory. Exploratory research seeks to determine the nature of the 
problem by exploring new insights into a phenomenon, asking questions and assessing the 
problem in a new light. The purpose of descriptive research is to produce an accurate 
description of variables such as people, events or situations. Finally, explanatory research 
focuses on studying people, events or situations in order to explain relationships between 
variables. Furthermore, descriptive and explanatory research can be combined, known as 
descripto-explanatory studies, in order to draw conclusions from data being described 
(Robson, 2002; Saunders et al., 2009). 
 
Due to the paucity of research on this topic, the purpose here will be therefore predominantly 
exploratory. An advantage of such an approach is flexibility as the purpose can be indeed 
adapted as a result of new data or insights. Nevertheless, as Robson (2002) has described, 
research may have more than one purpose and this may indeed change over time. 
Consequently, although the initial studies, such as the assessment of current decision-making 
approaches of companies and agencies, will be exploratory in nature, subsequent decision-
making studies across organisations will be as descripto-explanatory where the descriptions 
gathered will be used as a precursor to explanation.  
 
METHODOLOGICAL FRAMEWORK 
The choice of a methodological framework, including how each study will be carried out, is 
one of the most crucial decisions made during research (Yin, 2003). Nevertheless, before 
specific methods for gathering and analysing data are decided, it is important to note that the 
choice of such techniques will be influenced by the research philosophy and approach that 
aligns most closely with the objectives of the research. This will in turn influence the research 
strategies, choices and time horizons. This process is represented in the form of a ‘research 
onion’ (Saunders et al., 2009), where each layer represents a step that should be undertaken 
during planning of the research methodology (Figure 2.1). Each layer will be subsequently 
discussed in more detail, as well as decisions made at each step for the purpose of this project. 
 
Philosophy 
Since the aim of a thesis is to develop and examine knowledge in a particular field, it is 
important to define and understand the values and assumptions as defined by the various 
research philosophies. These assumptions form the foundation of research and will underpin 
the research approach and data collection strategies undertaken during the investigation in 
order to create valid findings. Each research philosophy can be characterised by the 
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relationship between knowledge and how it is developed in terms of ontology, epistemology 
and axiology. Ontology is a branch of philosophy which is concerned with what constitutes 
reality and being. Epistemology, which is the theory of knowledge, is concerned with what 
constitutes valid knowledge. Finally, axiology studies judgments about value. The four main 
research philosophies, namely positivism, realism, interpretivism and pragmatism are 
compared in Table 2.1. 
 
Figure 2.1 The ‘research onion’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adopted from Saunders et al., 2009 
 
Selected philosophy 
From these four philosophies, a pragmatic stance seemed the most appropriate in this case. 
Pragmatists argue that the key determinant of epistemology, ontology and axiology adopted 
are the research objectives themselves and no single philosophy by itself can answer them. 
Indeed this philosophical underpinning supports the study of both the objective and subjective 
aspects in quality decision making, thereby fitting more closely with the research purpose and 
rationale outlined above. Moreover, a pragmatic approach could yield better research results 
with the opportunity to use a mixture of different methods throughout the project to meet the 
study objectives which cannot be addressed using a singular method (Bryman, 2006; Gray, 
2014). 
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Table 2.1 A comparison of the four main research philosophies 
 Positivism Realism Interpretivism Pragmatism 
Ontology (the 
researcher’s view 
of the nature of 
reality or being) 
External, objective and 
independent social actors 
Is objective. Exists independently of 
human thoughts and beliefs or 
knowledge of their existence (realist) 
but is interpreted through social 
conditioning (critical realist) 
Socially constructed, 
subjective, may change, 
multiple 
External, multiple, view chosen to 
best enable answering of research 
question 
Epistemology (the 
researcher’s view 
regarding what 
constitutes 
acceptable 
knowledge) 
Only observable 
phenomena can provide 
credible data, facts. Focus 
on causality and law like 
generalisations, reducing 
phenomena to simplest 
elements 
Observable phenomena provide 
credible data, facts. Insufficient data 
means inaccuracies in sensations 
(direct realism). Alternatively, 
phenomena create sensations which are 
open to misinterpretation (critical 
realism). Focus on explaining within a 
context or contexts 
Subjective meanings and 
social phenomena. Focus 
upon the details of 
situation, a reality behind 
these details, subjective 
meanings motivating 
actions 
Either or both observable 
phenomena and subjective 
meanings can provide acceptable 
knowledge dependent upon 
the research question. Focus 
on practical applied research, 
integrating different perspectives to 
help interpret the data 
Axiology (the 
researcher’s view 
of the role of 
values in research) 
Research is undertaken in a 
value-free way, the 
researcher is independent 
of the data and maintains 
an objective stance 
Research is value laden; the researcher 
is biased by world views, cultural 
experiences and upbringing. These will 
impact on the research 
Research is value bound, 
the researcher is part of 
what is being researched, 
cannot be separated and 
so will be subjective 
Values play a large role in 
interpreting results, the researcher 
adopting both objective and 
subjective points of view 
Data collection 
techniques most 
often used 
Highly structured, large 
samples, measurement, 
quantitative, but can use 
qualitative 
Methods chosen must fit the subject 
matter, quantitative or qualitative 
Small samples, in-depth 
investigations, 
qualitative 
Mixed or multiple method designs, 
quantitative and qualitative 
Adopted from Saunders et al., 2009
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Approach 
The second layer is the research approach, which can be classified broadly into inductive and 
deductive. A deductive approach involves the development of a hypothesis based on an 
existing theory and subsequent testing through a structured research strategy in order to either 
reject or accept it on the basis of the evidence. Conversely, an inductive approach involves the 
development of a theory based on observations of empirical data. The aim here is to explore a 
particular field and to generate hypotheses that may be subsequently tested (Collis, 2009; 
Gray, 2014).  
 
Selected approach 
Since the purpose of this research project is exploratory, namely to look for ideas and patterns in 
order to collect data and develop a roadmap for improving the quality of decision-making 
processes, the research approach will be predominantly inductive. Nevertheless, the two 
approaches are not mutually exclusive and an approach that combines induction and deduction 
is becoming more widely used (Saunders et al., 2009). Indeed, a combined approach can 
provide a better understanding of a specific research topic. In this case, in addition to an 
inductive approach that will be used for data collection and generation of theories/hypotheses 
and concepts, a deductive approach will be used during data analysis to evaluate results 
emerging from the various stages of this research, as well as to connect them to the previous 
research concepts, such as those developed by Donelan and colleagues (2015, 2016). 
 
Strategies 
According to Saunders and colleagues (2009), the choice of a research strategy is guided by 
the research objectives, the extent of previous work and the knowledge existing in this area; 
the amount of time and resources available to carry out the project, as well as the 
philosophical underpinnings and approaches discussed above. The main types of research 
strategies are outlined. 
• Experiment is a deductive technique, used to study links between variables. This is 
achieved through defining a hypothesis; selecting and randomly allocating samples; 
introducing a planned intervention; choosing control variables and measuring other 
dependant variables. Although an experiment produces accurate, primarily 
quantitative measurement of the outcomes, the design requirements of experiments 
are complex and demanding, requiring ethical considerations as well as a 
representative captive audience (Saunders et al., 2009). 
• Survey is also a primarily deductive technique used to collect information in a 
structured format from a group of individuals to explore relationships between 
variables and subsequently produce theories. Surveys are often carried out in the form 
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of a questionnaire, though it should be noted that this can be combined with 
interviews. Surveys are popular due to the possibility to collect information 
efficiently and economically, though issues may arise due to dependence on others 
for information, such as timeliness, quality of data obtained as well as achieving a 
high response rate (Robson, 2002). 
• Case study involves the development of in-depth knowledge about a single ‘case’ or a 
small number of related ‘cases’. It provides a rich understanding of individuals and 
variables in a real life context and can be a good source of new research questions, 
despite being seen as less scientific compared to the survey or experiment strategy. A 
case study can be categorised into four groups through two dimensions (Yin, 2003): 
o Single case vs. multiple case, where a single case is used in an extreme or 
unique situation, for example by analysing a single organisation; whereas 
multiple cases are used across several organisations/individuals. This would 
help determine whether the findings from one case can be generalised to 
others. Consequently, a multiple case is seen as preferential. 
o Holistic case vs. embedded case refers to the unit of analysis, where a holistic 
case is one where research is concerned with, for example, an organisation as 
a whole, whereas an embedded case would examine a number of logical sub-
units, such as departments within an organisation.  
• Action research refers to a primarily inductive strategy, where a problem is diagnosed 
in order to generate a list of actions and solutions to a specific problem. As part of 
this, the researcher may become involved and co-operate with practitioners and the 
results of the research should result in a call to action, such as promoting change 
within an organisation (Robson, 2002).  
• Grounded theory is another case of a primarily inductive approach to predict and 
explain behaviour in order to build a theory. This strategy is highly creative and 
interpretative in nature and starts with data being generated from observation as well 
as existing literature and theory on this topic, which is then subsequently tested 
(Wertz, 2011). 
• Ethnography is a strategy derived from anthropology, where the researcher becomes 
part of a community or situation in order to interpret the world through an inductive 
approach over an extended period of time (Saunders et al., 2009).  
• Archival research uses documents and records as sources of data in order to 
formulate research questions and carry out exploratory, explanatory or descriptive 
analysis of data over a period of time. Nevertheless, it is constrained by the quality 
and availability of data (Gray, 2014). 
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Selected strategy 
This project, defined by a pragmatic philosophy as well as a combined inductive and 
conductive approach, will integrate a number of various strategies in order to address the 
previously outlined research objectives. A survey approach will be used to assess use of 
frameworks and techniques within pharmaceutical companies as well as regulatory and HTA 
agencies. Grounded theory will be used as part of this research in order to conceptually 
analyse personal experiences captured through the survey. Conversely, case studies, 
specifically multiple and embedded cases, will be used during quality decision-making 
studies with QoDoS within departments and across multiple companies and agencies. As 
these studies will also be used to further validate QoDoS, an experiment strategy will be 
adapted in order to control variables and ensure the validity of the results. Finally, as this 
research will aim to promote improvements in quality decision making across individuals and 
organisations, action research strategy will also be adopted in order to achieve this. 
 
Choices 
The third layer is the research choice in order to decide how quantitative or qualitative 
methods will be used or combined in research to collect and analyse data.  Quantitative 
research involves numerical data collection and statistical analyses and graphs, whereas 
qualitative research is concerned with non-numerical data collection and the interpretation of 
results in order to generate accounts, opinions and description (Saunders et al., 2009). The 
research choices are illustrated in Figure 2.2, where a mono-method is the use of a single 
method (quantitative or qualitative) as opposed to the use of multiple methods, where either a 
number of methods of the same type (quantitative or qualitative) are used (multi-method) or 
different types of methods are mixed. For the mixed-method research, quantitative data are 
analysed quantitatively and qualitative data are analysed qualitatively, whereas for the mixed-
model research qualitative data may be analysed quantitatively and vice versa. 
 
Selected choice 
In this project, a mixed-method choice will be used in order to combine both qualitative and 
quantitative techniques. For example, both qualitative and quantitative questions will be asked 
in a survey and quantitative data will be analysed quantitatively, whereas qualitative data 
(such as free text responses) will also be analysed quantitatively to determine the frequency of 
emerging themes. In addition, quantitative methods will be used during the studies with 
QoDoS in order to assess the quality of decision-making processes and the implementation of 
the ten QDMPs, as well as during the validation of the technique through the use of various 
statistical tests.  Finally, qualitative methods will be used in the development of a checklist. 
Consequently, both the mixed-method and mixed-model research choices will be used. 
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Figure 2.2 Research choices 
 
 
Adopted from Saunders et al., 2009 
 
There are a number of advantages, as described by Bryman (2006) for the use of a mixed 
approach. Firstly, the use of two or more research strategies helps to capture various aspects 
of an investigation which can complement each other and provide deeper meaning. This 
technique, termed as research triangulation, describes the use of two or more data collection 
methods or research strategies. It ensures comprehensiveness and robustness of the 
knowledge and theories generated, whilst strengthening the validity of the study findings. For 
example, the same research objectives will be used in this project to query the public domain 
as well as the target audience. The use of multiple independent sources of data also provides 
contextual understanding and provides greater interpretability in order to help explain 
relationships between variables. Finally, it also facilitates generalisability (i.e. external 
validity) of the results so that they can be applied to settings other than that in which they 
were originally tested. 
 
Time horizon 
The final aspect to consider prior to deciding the data gathering and analytical tools is the 
timescale. Two main categories exist, firstly cross-sectional research where the data is 
collected using a snapshot approach at one point in time, making it relatively cost- and 
resource effective, and secondly a longitudinal study, which is used to measure a phenomenon 
over an extended period of time with multiple collection points thereby resulting in large 
amount of data being collected to provide a more comprehensive and representative picture of 
the variables under investigation (Gray, 2014). 
 
 
Research choices 
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Selected time horizon 
For the purpose of this project, cross-sectional timeframe will be utilised for the survey 
strategy for assessing current decision-making approaches of companies and agencies as well 
as case studies for assessing quality decision making with QoDoS. Nevertheless, a 
longitudinal timeframe will also be employed during the case study/action research strategies 
in order to assess quality decision making at different points in time. For example, this 
approach will be used for assessing the reliability of QoDoS, which refers to the extent to 
which the tool measures something in a consistent and reproducible manner (Streiner et al., 
2015), where QoDoS will be applied on two occasions. 
 
Implications for this research 
The formulated research design, based on the approach developed by Saunders and colleagues 
(2009), is illustrated in Figure 2.3, which summarises the philosophy, approach strategy, 
choice and time horizon relevant to this research.  
  
Figure 2.3 The research design process based on the ‘research onion’ approach 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Saunders et al., 2009 
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DATA SOURCES 
Public domain sources 
Bibliographic databases, namely MEDLINE (using PubMed), Web of Knowledge, Google 
Scholar and Open Access theses and dissertations, will be searched for scientific publications, 
books, academic conference proceedings. Gray literature will also be explored using Google 
as well as using country-specific regulatory and HTA agency and pharmaceutical company 
websites. 
 
Sampling techniques 
In statistics, a population includes all members of a defined group being studied from which 
the sample is selected. In this case, the population will comprise individuals from major 
international pharmaceutical companies as defined by their research and development (R&D) 
expenditure; international mature regulatory authorities defined as stringent regulatory 
authorities (SRA) by the World Health Organisation (WHO) (2017) and major HTA agencies 
which are part of the International Network of Agencies for Health Technology Assessment 
(INAHTA, 2018) or European Network for Health Technology Assessment (EUnetHTA, 
2018) to ensure that these various organisations have well established decision-making 
systems. As this research will aim to identify facts and opinions on strategic decision-making 
processes within organisations, senior individuals with at least 5 years experience in a 
managerial position will be selected for the survey techniques, although more junior 
individuals will be included for the various studies with QoDoS. Regarding companies, 
individuals will be recruited from regulatory and health economics and outcomes research 
departments (HEOR), whereas reviewers and decision-making committee members will be 
selected from agencies (Saunders et al., 2009). 
 
Sampling is concerned with the selection of cases from the population for the purpose of the 
study.  The techniques can be broadly divided into two groups, namely probabilistic and non-
probabilistic. Probabilistic sampling is random where each case from the population has an 
equal chance of being selected and the results are therefore less likely to be biased and more 
likely to be generalisable as they reflect the entire population. Conversely, in a non-
probabilistic technique, the probability of selecting an individual is not known and although 
the results are likely to be generalisable, this is usually not possible on statistical grounds 
(Gray, 2014). For the purpose of this research, probability sampling is not suitable as it would 
be impossible to obtain the sample frame, which is the list of all the individuals from the 
specified population. Consequently, a non-probability sampling technique will be used and 
the most relevant types which will be considered are illustrated in Figure 2.4 and discussed 
below (Saunders et al., 2009). 
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Figure 2.4 Non-probability sampling techniques 
Adopted from Saunders et al., 2009 
 
• Quota sampling is based on the idea that the sample will represent the population as 
the variability in the sample for various quota variables is the same as that in the 
population. Quota sampling is therefore a type of stratified sample in which selection 
of cases within strata is non-random.  
• Purposive sampling is a technique where the judgement of the researcher is used to 
select the cases that make up the sample on the basis of the type of case needed to 
meet the research objective. A case can be either critical, extreme, typical or one that 
seeks homogeneity or heterogeneity.  
o Extreme case sampling focuses on unusual or special cases 
o Heterogeneous sampling focuses on obtaining the maximum variation in the 
cases selected 
o Homogeneous sampling focuses on selecting cases from one particular 
subgroup in which all the members are similar 
o Critical case sampling focuses on selecting cases which are important to 
make a particular point or meet an objective 
o Typical case sampling focuses on selecting cases that are illustrative. 
Purposive sampling aims to ensure that the full variety of responses is obtained from 
a range of respondents from the population in order to enable generalisability. 
Nevertheless, the sample is usually considerably smaller compared to quota 
sampling. 
• Snowball sampling is used when there is a challenge in identifying the sample. The 
technique relies on making initial contact with one or two cases in the population and 
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asking those cases to help identify new cases and then carry on with this process until 
the sample is satisfactory. Although this technique is useful for populations that are 
difficult to identify, making the initial contact is difficult and there is also a high 
potential for bias. 
• Self-selection sampling requires people who are interested in the topic, where the 
researcher publicises the research and data is collected from those cases that respond. 
This technique may introduce considerable bias depending on the advertising 
technique selected and it can be relatively costly. 
• Convenience sampling involves selecting cases that are easier to obtain and is used 
when the timescales available for the project are short. Despite the wide use of this 
technique, convenience sampling has a number of limitations, most importunately 
that it is very prone to bias. 
 
Selected sampling method 
The sampling technique, which is deemed the most appropriate based on the research 
objectives, the characteristics of the population as well as resources and access to the 
organisations, is purposive sampling, This will ensure that the data is information-rich and 
allows to explore the research themes in order to gain theoretical insights into quality decision 
making and meet the study objectives. More specifically, heterogeneous sampling will be 
used in order to capture the variance in quality decision-making practices across 
organisations, which will ensure that the roadmap developed will be applicable to a broad 
spectrum of companies and agencies. In order to ensure timeliness and success of the projects, 
the sample will comprise organisations that are members and/or have a working relationship 
with the Centre for Innovation in Regulatory Science (CIRS, 2018). 
 
DATA COLLECTION TECHNIQUES 
The data collection methods were carefully selected in order to meet the research objectives. 
The various qualitative and quantitative data collection techniques are reviewed below based 
on their strengths, weaknesses and applicability. Finally, the most appropriate methods 
selected for the studies are outlined.  
 
Literature Review: systematic and narrative 
In the first place, a literature review will be carried out to identify recent developments in the 
field of quality decision making, both from a broader perspective as well as specific to 
medicines development and regulatory review. Secondly it will also seek to identify from the 
public domain the use of techniques, such as tools, surveys, questionnaires and other studies, 
for measuring the quality of decision-making processes during the lifecycle of medicines. For 
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the purpose of this research, two types of reviews were considered, namely a systematic 
literature review and a narrative literature review, which vary in terms of goals, components 
and value in research as well as in hierarchy of evidence they produce (Cook et al., 1997):  
• A narrative literature review provides a qualitative summary on a topic using 
informal methods to interpret and collect data. The key advantage is that it provides a 
broad and comprehensive overview of a topic, but the conclusions are less likely to be 
based on the summary of the evidence considered.  
• A systematic review provides answers to a specific focused question, with 
components such as pre-specified criteria, a systematic search strategy, independent 
secondary review, assessment of the validity of the findings and interpretation of the 
results. The key advantage is the scientific rigour, which ensures robustness and 
validity of the results and elimination of bias. Nevertheless, such an approach is time 
and resource intensive. 
 
Selected data collection using both a narrative and systematic literature reviews 
For the purpose of this research, both techniques of narrative and systematic review will be 
utilised; the scope and rationale are explained in the following paragraphs. Initially, a 
narrative literature review will be undertaken and summarised in the ‘General Introduction’ 
Chapter 1, where the aim will be to undertake an exploratory search of the recent 
developments in quality decision making during the lifecycle of medicines as well as more 
broadly regarding the art and science of decision making. The review will be undertaken by 
searching bibliographic databases and gray literature. Key search words to be included are: 
decision-making process, quality, decision analysis, medicine development, regulatory 
review, health technology assessment, tools, instruments, frameworks, influences, best 
practices, biases, subjective. In addition, the results of the narrative review will be used to 
refine the research context and objectives. 
 
A systematic literature review will also be undertaken in order to answer a specific question, 
namely to determine the existence and use of techniques (tools, questionnaires, surveys and 
studies) for measuring quality of the decision-making practices across pharmaceutical 
companies, regulatory authorities and HTA agencies. Bibliographic databases will be 
searched for journal articles and Google will be used to search the gray literature. The review 
will be limited to English-language articles and cover a period from 1996 to 2017, which 
reflects the proliferation of publications in this area. Structured search terms will be 
constructed using PubMed guidelines and MESH terms and these will be used in database 
searches against selected criteria: 
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• For inclusion: (1) All articles which identify a technique (tool, instrument, or 
questionnaire) for evaluating quality of decision making applicable to the area of 
medicines development, regulatory, or HTA; (2) Techniques evaluating the decision, 
the decision-making process or key aspect(s) of the process and associated preferences, 
influences and behaviours; (3) Studies that assess the performance of the technique by 
evaluating hypothetical or real (historical) decisions, vignettes, or a reflection of 
individual style or approach. 
• For exclusion (1) General discussions on decision making and quality within the area of 
medicines development, review and HTA; (2) Techniques for measuring quality of 
decision making used specifically in disciplines other than medicines development, 
regulatory review and HTA; (3) Frameworks for structuring and documenting decision-
making processes and for enabling quality to be built into decision making. 
 
To ensure robustness and minimise bias throughout the systematic review, an independent 
secondary review will be carried out in the development of the search strategy and selection 
criteria, as well as article selection and data extraction. In addition, the measurement 
properties of each technique will be assessed and compared to identify the research gaps and 
recommend the way forward. Of interest would be to find a technique that is applicable to all 
three stakeholders, namely companies, regulatory and HTA agencies, in order to have a 
common platform for discussing, sharing and comparing issues in quality decision making 
throughout the lifecycle of medicines. 
 
Survey techniques: questionnaires, interviews and focus groups 
Having selected a survey strategy, three major techniques are considered for collecting data 
directly from the pharmaceutical companies, regulatory and HTA agencies regarding the 
current approaches, measures and challenges to quality decision making. These are namely 
self-administered questionnaires, semi-structured interviews and focus groups. 
• A questionnaire is a technique which uses a series of standardised, structured 
questions to allow a comparison of results within the sample. A self-administered 
questionnaire is a resource and time efficient technique as it can be distributed easily 
and the data can be collected from a large group of people simultaneously in person 
or alternatively via paper format, electronically or via the internet. Nevertheless, 
potential challenges exist such as obtaining a complete response rate, which relies on 
the recipients completing and returning the questionnaires. Moreover, in the case of a 
mail-delivered self-administered questionnaire, there is little opportunity to clarify 
questions as well as to accurately reflect the views of respondents in the case that the 
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choice of answers is restricted (Salant and Dillman, 1994; Needham and Vaske, 
2008). 
• A semi-structured interview, similarly to a questionnaire, is centred around a set of 
questions, generally a set of predetermined open-ended questions or a checklist, with 
other questions emerging from the dialogue between the interviewer and 
interviewees. The difference is that instead of being self-administered, it involves 
direct interactions, either face-to-face, over the phone or a teleconference (Dicicco-
Bloom and Crabtree, 2006). The advantage of carrying out a semi-structured 
interview is the possibility of receiving responses instantaneously and at a high 
response rate. Moreover, respondents are more likely to provide better insights into 
the topics due to the proximity between the interviewer and interviewee as well as an 
enhanced understanding of the questions. Nevertheless, some limitations exist, such 
as having a less controlled environment compared to a questionnaire and potentially 
biased, if questions are leading. Moreover, they are resource intensive and costly to 
carry out as well as to analyse and compare. Semi-structured interview are therefore 
perhaps best suited for generation of ideas and themes (Valenzuela and Shrivastava, 
2005; Needham and Vaske, 2008). 
• A focus group technique can be used to carry out a qualitative exploration of 
opinions, values, knowledge and perceptions of individuals in regard to a particular 
topic, typically involving ten to 12 individuals who have knowledge or experience 
with the topic (Breen, 2006). The discussion is managed by a facilitator and a chair 
who lead the participants through a series of open-ended questions (Glitz, 1997). 
Focus groups are best suited for utilising group dynamics to generate a set of diverse 
qualitative data, to exchange viewpoints and discuss disagreements between 
individuals. Whilst focus groups may be less expensive than interviews, the key 
challenges is that they may become biased due to certain individuals being more 
engaged in the discussions and their views becoming more dominant (Gill et al., 
2008).  Nevertheless, in comparison with other forms of interview, interactions and 
responses are both encouraged and more closely controlled through a chair and 
facilitator to maintain the focus and to help minimise bias. 
 
Selected survey technique 
For the purpose of this research, the techniques of self-administered questionnaires and a 
focus group will be utilised to meet the objectives of this research. For the first part of this 
research, where factual data and responses will be sought regarding quality decision-making 
processes, a questionnaire is best suited in order to collect this data in a structured way and 
ultimately to allow comparisons between the various organisations. Questions will seek to 
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capture the use of frameworks, the prevalence of key influences and perceptions on barriers 
and challenges. The use of a self-administered questionnaire will also minimise the high costs 
and resources involved due to geographic variation in the location of the various companies, 
international agencies as well as the researcher.  
 
In addition to self-administered questionnaires, a focus group technique will be used for the 
purpose of meeting another research objective, namely to explore and identify the practical 
approaches for ensuring the incorporation of the QDMPs, including a checklist, and 
ultimately to provide a roadmap for promoting consistency, transparency and quality during 
decision making. This will ensure that views and opinions are generated and validated across 
a broad range of individuals from companies and agencies (Saunders et al., 2009) 
 
Questionnaire development techniques  
Two techniques were explored for the development of the questionnaires, namely the Delpi 
technique and decision conferencing.  
• Delphi method is a structured technique that involves an iterative process consisting 
of multiple rounds of structured discussions between a group of experts. The 
judgments and opinions are systematically captured through the discussions and are 
analysed in order to build a model which is fed back in a controlled way and the aim 
is then to seek reliable consensus of opinion from the expert group (Skulmoski et al., 
2007). This technique has been used widely in science and healthcare and is a useful 
tool for the development of a questionnaire as it is largely anonymous and seeks to 
capture broad viewpoints and experiences whilst minimising bias and dominance. 
The technique can be a quick, inexpensive and a relatively efficient way of combining 
the knowledge and abilities of an expert group on a particular issue. A limitation is 
that consensus may be difficult to reach and it may result in a dilution of the key 
themes. For the purpose of a questionnaire, the first round involves application of an 
unstructured questionnaire to gain responses from the experts about a broad subject. 
From the summarised findings, subsequent questionnaires are derived and reviewed 
by the panel through multiple iterations in follow-on rounds until consensus is 
reached (Bunag and Savenye, 2013). 
• Decision conferencing is also a technique used to systematically review a group’s 
input. The process begins with an establishment of the objectives of the decision 
conference as well as the key players who will attend (Figure 2.5). A meeting is then 
called where the objectives are reiterated, which will be achieved by the group 
through the creation and review of a model that will capture the key elements that 
must be addressed to resolve an issue. Discussions would involve personal judgments 
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and intuitive opinions in order to improve the model until it reflects the perspectives 
of the group (Phillips, 2006). Decision conferencing during the design of a 
questionnaire is helpful to review the objectives of a questionnaire and generate a 
shared understanding of the questions, but without requiring consensus. 
 
Figure 2.5 A decision conference process 
 
Adopted from Phillips, 2006 
 
Selected questionnaire development technique 
As the purpose of the two questionnaires is exploratory and a body of knowledge has already 
been generated on the issues in quality decision making during the lifecycle of medicines 
based on interviews with key opinion leaders (Donelan et al., 2015), it was decided that the 
Delphi technique and Decision conferencing will not be appropriate due to the resource and 
time required. The questionnaires will therefore be developed based on the outcomes of the 
previous research (Donelan et al., 2015) as well as the literature reviews. A total of four 
questionnaires will be developed, where two questionnaires will capture issues on regulatory 
decision making, one from regulatory authorities and one from pharmaceutical company 
departments, and the other two questionnaires will survey concepts regarding medicines 
reimbursement, one across HTA agencies and one with HEOR company departments. Similar 
questions will be used in the four questionnaires where possible in order to facilitate 
comparisons.  
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Questionnaire validation techniques 
The validity of the questionnaire forms the foundation of accurate measurement of the 
research outcomes. The key technique for ensuring validity is by ensuring content validity, 
which is the extent to which the questions in a questionnaire are well developed, can measure 
what they are intended to measure and possess the appropriate level of emphasis and focus. In 
order to achieve content validity, face validity must also be established. Face validity, defined 
as the appropriateness of the items in relating to the goals of the questionnaire, indicates 
whether, on the face of it, the instrument appears to be assessing the desired qualities based 
on a review of the measure by one or more experts to validate the content, layout, language 
and format (Nunnally and Bernstein, 1994; Streiner et al., 2015). In addition, it is important to 
ensure the internal validity of the study as the conclusions of the questionnaire are frequently 
generalised and extrapolated beyond the original research. The ultimate aim is to achieve 
construct validity, which is the extent to which the instrument accurately measures a 
theoretical construct it is designed to measure. This is typically demonstrated with 
correlations, in this case by comparing the outcomes of the questionnaire with the results from 
other relevant surveys (Streiner et al., 2015) 
 
Selected questionnaire validation technique 
Face validity will be performed by the internal research team during the development of the 
questionnaires. Content validity will be tested through feasibility pilot studies using structured 
feedback questions with at least 10% of the participating pharmaceutical companies, 
regulatory authorities and HTA agencies to determine the appropriateness of the questionnaire 
format; the language clarity; the ease of response and the relevance and accuracy of the 
questions for measuring theoretical construct. Comments from the pilot studies will then be 
incorporated and used to refine the questionnaires. 
 
Research instrument: Quality of decision-making orientation scheme 
In the absence of a validated instrument for measuring quality decision making during the 
lifecycle of medicines, QoDoS was developed (Donelan et al., 2016) and will be used for the 
purpose of this research to evaluate the quality of decision making in companies and agencies. 
It should be noted that QoDoS is a self-administered questionnaire (see Appendix 1).  
 
The QoDoS was developed using a standardised, established approach for the design and 
psychometric evaluation of such measures (Donelan et al., 2015, 2016). The development of 
QoDoS included qualitative research into decision-making approaches and involved 
interviews with 29 key opinion leaders from the pharmaceutical industry (n=10), contract 
research organisations (n=10) and regulatory agencies (n=9), which resulted in the 
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identification of 32 decision-making themes. The key themes included: quality and validity of 
the data; political, financial, competitor and reward influences; analytical and logical 
approach; overconfidence in own judgement; plunging in or procrastinating with decision 
making; impact analysis of decisions; education and awareness of evolving decision-making 
techniques; and SWOT and alternate outcome planning. It was hypothesised that these 
emergent themes could provide insight into a framework for quality decision making. 
Consequently, these themes were distilled into best practices, namely the QDMPs. The 
QoDoS enables measurement against these practices (Donelan et al., 2015). 
 
The QoDoS items generated from the 29 face-to-face semi-structured interviews with key 
opinion leaders yielded a 94-item initial version of the QoDoS with a five-point Likert 
frequency scale response option. Content validity was established using an expert panel to 
confirm that the emphasis and the focus of the QoDoS is fit-for-purpose. The experts rated the 
language clarity, completeness, relevance and scaling of each item on a four-point scale 
(Strongly agree, agree, disagree and strongly disagree) and the agreement among the panel 
members was high with an intra-class correlation coefficient value of 0.89 (95% confidence 
interval = 0.056, 0.99).   
 
Factor analysis was performed on the resulting 76-item instrument and produced a 47-item 
measure (QoDoS) organised into four sections namely, organisational decision-making 
approaches, organisational decision-making culture, individual decision making competencies 
and individual decision-making style.  The 47-item QoDoS showed high internal consistency 
(n = 120, Cronbach’s alpha = 0.89), high reproducibility (n = 20, intra-class correlation = 
0.77) and a mean completion time of ten minutes (Donelan et al., 2016). 
 
Psychometric properties of QoDoS 
The QoDoS instrument developed by Donelan and colleagues (2016) will be further tested to 
ensure it has adequate measurement properties relevant to decision making from the 
perspective of the individual and the organisation. The following validity aspects of QoDoS 
have already been determined by Donelan and colleagues (2016) as defined below (Trochim, 
2006; Streiner et al., 2015): 
• Face validity indicates whether the instrument, on the face of it, assesses the desired 
qualities based on subjective judgment from a review of the measure itself by one or 
more experts; empirical approaches are rarely used. 
• Content validity is established when an instrument includes a representative and 
adequate set of items to uncover the concepts in the research objectives for the 
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intended population. The approach involves an expert panel as well as quantitative 
assessment techniques. 
• Construct validity indicates whether the results obtained from the use of a measure fit 
the theoretical foundations from which it is designed and can be presented using a 
multi-trait-multi-method matrix, which examines convergence (evidence that 
different measurement methods of a construct give similar results) and 
discriminability (ability to differentiate the construct from other related constructs). 
• Internal consistency examines whether the items and the subsets of items in the 
measuring instrument are correlated. The internal consistency, which addresses the 
relatedness/homogeneity of a single test form, may be assessed by correlating 
performance on ‘two halves of a test’, which is termed split-half reliability. 
 
The measurement properties of the tool need to be further evaluated by assessing the 
reliability and sensitivity of the tool, as well as its relevance and practicality in companies, 
regulatory and HTA agencies for evaluating the ten QDMPs, as defined below (Trochim, 
2006; Streiner et al., 2015): 
• Relevance of an instrument would ensure the suitability of the tool which includes the 
respondent burden, resource requirements, the overall clarity and completeness of the 
tool and the scoring. This could be achieved through cognitive debriefing following 
QoDoS studies, a technique of actively testing the tool among representatives of the 
target population (Streiner et al., 2015; Brod et al., 2009). 
• Reliability refers to the extent to which the tool measures something in a consistent 
and reproducible manner. The reliability coefficient expresses the proportion of the 
total variance (degree of error) in the measurement which is due to ‘true’ differences 
between subjects where 0 indicates no reliability and 1 indicates perfect reliability: 
 
Reliability =  
 
A test-retest method will be used by administering QoDoS to the same group on two 
different occasions, with an interval of 7 days, which should help minimise the bias 
due to memory of the respondents’ answers to the items. Intra-class correlations 
(ICC) will be used to assess reliability, which is the ratio of variance of 
measurements of a given target to the variance of all targets. Results will be analysed 
using the Statistical Package for the Social Sciences (SPSS) software and a 
correlation of >0.7 will be sought (Paiva et al., 2014). 
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• Sensitivity is the ability of an instrument to detect change over time. In this case, a 
before and after measurement could be carried out with QoDoS to assess decision 
making of an organisation which has introduced appropriate measures to improve 
their decision making; one test will be applied prior to the intervention and the other 
post-intervention to determine whether the instrument has the sensitivity to identify 
the change. This will not be carried out as part of this research project due to time 
constraints. 
 
In addition, as the development of QoDoS took place in 2013, a systematic review of 
literature will be performed, as outlined above, in order to verify whether other techniques 
have been developed since that time. 
 
Steps in a QoDoS study 
Firstly, the reliability of the instrument and its relevance will be evaluated in the target 
audience in order to further strengthen the psychometric properties of the technique. 
Secondly. QoDoS will be used to evaluate the incorporation of QDMPs in companies, 
regulatory authorities and HTA agencies. Multiple, embedded case studies will be conducted 
within specific groups in each organisation, such as committees and teams. Comparisons will 
be drawn within organisations as well as demographic breakdown using information 
regarding gender and professional experience. The general steps taken in each study have 
been defined as follows: 
1. The participants will be introduced to concepts in decision making as well as QoDoS in 
person or via a teleconference. This approach will aim to ensure consistent baseline 
knowledge of concepts in decision making across the study participants. In the case of 
multiple applications of the QoDoS across the same participant group, such as during 
reliability testing, an introduction session will aim to minimise the ‘learning effect’ that 
might have occurred following the initial administration of QoDoS. Overall, the approach 
will aim to minimise ‘confounding factors’ (i.e. third variables that are not controlled or 
measured) that may negatively affect the internal validity of the study. 
2. The participants will each be given a paper or electronic copy of the QoDoS, to be 
completed on the day. 
3. The participants will be contacted with a gentle reminder by email to complete QoDoS 
4.  Overall results of the study will be circulated to the study leader within a specific 
organisation  
5. A study feedback session will be organised to discuss the results, provide any 
clarifications, as well as to discuss the differences and possible areas of strength and 
weakness.  
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6. If applicable, a cognitive debriefing will be carried out by asking the participants to 
complete a feedback survey to determine the relevance and comprehension of the tool as 
well as the value of the feedback session. 
7. A report will be prepared and sent to the participants containing the QoDoS study results 
and notes from the feedback session discussions.  
 
A summary of the selected data collection techniques 
The selected data collection techniques are outlined in Table 2.2, as well as the corresponding 
objectives and chapters.  
 
Table 2.2 An overview of the planned data collection techniques 
Data collection 
technique 
Study objectives 
Thesis 
Chapter 
Narrative literature 
review 
Exploration of concepts and issues in quality 
decision making particularly in the area of medicines 
development 
Introduction 
 
Systematic literature 
review 
Identification of techniques for evaluating quality 
decision-making practices during medicines 
development, regulatory review and HTA 
Chapter 5 
Self-administered 
questionnaires 
Evaluation of current approaches, measures and 
challenges to quality decision-making process of: 
 
1. Regulatory decision making of agencies and 
relevant company committees 
 
 
 
 
Chapter 3 
 
2.  Reimbursement decision making of HTA agencies 
and relevant company departments 
Chapter 4 
QoDoS instrument 
(self-administered 
questionnaire) 
Validation of the QoDoS instrument in terms of its 
reliability and relevance 
Chapter 6 
Evaluation of practicality of QoDoS in assessing 
quality decision-making practices in pharmaceutical 
companies, regulatory authorities and HTA agencies  
Chapter 7 
Focus group 
Identification of practical approaches for integrating 
quality into decision-making practices in medicines 
development, regulatory review and health 
technology assessment, including the development of 
a checklist 
Chapter 8 
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STUDY PLAN 
The study flow chart is illustrated in Figure 2.6; starting with a literature review and two 
questionnaires in order to meet the objective of identifying current decision-making 
frameworks, processes and techniques for measuring quality decision making, both from the 
point of view of public domain data as well as obtaining information directly from the target 
audience (Studies 1 and 3). The second objective of validation of the QoDoS instrument  and 
evaluation of the level of implementation of the QDMPs will be met through QoDoS case 
studies with companies and agencies as well as a reliability study (Studies 2 and 4). Finally, 
the results from a focus group study (Study 5) aiming to develop practical approaches for 
integrating quality into decision-making processes will be brought together with other key 
study outcomes to develop a checklist. The ultimate aim will be to use all the study results 
and developed methods to build a roadmap for improving the quality of decision-making 
processes to ensure timeliness, transparency, consistency and predictability of decisions. This 
will be described in the General Discussion (Chapter 9). 
 
 Figure 2.6 The study plan 
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DATA PROCESSING AND ANALYSIS 
Data generated through the various studies will be analysed qualitatively and quantitatively. 
Quantitative data will be analysed with descriptive statistics such as medians and the lower 
and upper quartiles (25th and 75th percentile values) using Microsoft Excel. In order to carry 
out the QoDoS reliability studies, statistical tests will be carried out using SPSS, such as the 
ICC and Cronbach alpha. Nevertheless, statistical tests will not be used for questionnaires or 
other exploratory QoDoS studies, which will be hypothesis generating as opposed to 
hypothesis testing.  
 
Qualitative data, such as free text responses and comments from studies and questionnaires, 
will be coded through established methods, including grounded theory (Wertz, 2011) and 
constant comparison method (Boeije, 2012). This will facilitate data reduction and 
conclusions by selecting, focusing, simplifying, abstracting and transforming the data. In 
grounded theory, inductive, systematic analytic strategies will be applied to qualitative data to 
conceptually analyse personal experiences. The constant comparative method involves 
continually comparing and contrasting concepts to inform relationships between phases and 
themes expressed by the study participants. Content analysis will be employed for free text 
responses and comments to identify emerging themes. Ranking will also used where 
applicable. Where consensus is being sought in a study, it will be defined in a variety of ways, 
such as the calculation of percentage levels regarding the agreement of the participants 
(Streiner et al., 2015). 
 
ETHICAL APPROVAL 
This programme of research did not require the national research ethics committee approval. 
However, ethics approval was obtained from the University of Hertfordshire.  
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SUMMARY 
• This chapter describes the rationale for this project as well as outlining the proposed 
studies to be undertaken in order to meet the research aim and objectives 
• The study purpose was defined as mainly exploratory followed by additional 
descripto-explanatory studies where the descriptions gathered from decision-making 
studies will be used as a precursor to the explanation of possible results 
• The research design was based on the ‘research onion approach’, where various 
options were appraised and the following were selected: pragmatic philosophy; 
inductive and deductive approach; experiment, survey, grounded theory, case study 
and action research as the main strategies; mixed-method choice and a cross-sectional 
and longitudinal time horizon 
• Data sources were described for public domain data collection, whereas the selected 
sampling technique was non-probability purposive sampling based on characteristics 
of the population and the objective of the studies 
• Data collection techniques were also appraised to meet the study objectives and the 
following were selected: narrative and systematic literature review; self-administered 
questionnaires (including QoDoS) as well as a focus group approach 
• A detailed outline of questionnaire development and validation techniques were also 
provided as well as general steps in QoDoS studies 
▪ Methodological choices related to data processing and data analyses were also 
described 
▪ A detailed study plan and framework were outlined to demonstrate the relationship 
between the studies, chapters and the objectives of the research programme. 
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CHAPTER 3 
 
 
 
 
 
 
Evaluation of the Quality of Regulatory Decision-
Making Processes in Pharmaceutical Companies and 
Regulatory Authorities 
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INTRODUCTION 
Quality of decision-making processes throughout the lifecycle of medicines is critical for 
ensuring that they become available in a timely and efficient manner, with appropriate 
safeguards to the health of the public. Currently, regulatory authorities and pharmaceutical 
companies focus on the generation of data and the assessment of uncertainty regarding a 
medicine, but it is not always clear how the data is deliberated by individuals and 
organisations to determine whether it has the appropriate safety, efficacy and quality to be 
submitted for regulatory review and thereafter to be given marketing authorisation. The 
various decisions are nevertheless under constant scrutiny by regulatory authorities looking to 
improve their practices for reviewing medicines, pharmaceutical companies seeking to 
enhance the effectiveness of their go/no-go decision making, as well as patients seeking 
increased access to new medicines. Ultimately, quality and transparent decision making is an 
ambition for all stakeholders involved in the development and review of medicines in order to 
provide patients with confidence in the decisions that affect their access to medicines (Liberti 
et al., 2013; Cole et al., 2016). 
 
Pharmaceutical companies and regulatory authorities make many decisions every day with 
regards to new medicines. Faced with an increasingly complex environment, both groups 
have been adopting various tools in order to make their decisions scientifically sound and 
transparent. Examples, as discussed in Chapter 1, include the implementation of various 
benefit-risk assessment methodologies by companies and authorities (Walker et al., 2014; 
Pignatti et al., 2015), introduction of GRevP by authorities (WHO, 2014) as well as specific 
frameworks and guidelines to formalise the decision-making process of various committees 
(EMA, 2007; FDA, 2008). Nevertheless, questions remain that go beyond the review process 
and the assessment of benefits and harms and would seek to understand what decision-making 
practices are built into the various regulatory processes from the point of view of the 
individual and the organisation to enable transparency, consistency and quality. 
 
The science of decision making is well established both from a social and scientific viewpoint 
(Kahneman, 2011). Currently, what is lacking is research and insight into the decision-making 
practices and approaches for individuals and organisations involved in medicines 
development and the regulatory review. This study extends the concepts explored through a 
previous investigation into regulatory decision making, (Donelan et al., 2015) and intends to 
characterise regulatory processes within companies and authorities and to further assess the 
use of decision-making tools and frameworks. As many decisions are made by 
pharmaceutical companies and regulatory authorities every day, this study will focus on 
characterising the final process within a company to determine whether a submission of a new 
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medicine should be made to a regulatory authority; as well as the final process within the 
authority to decide on the approval of the medicine.  
 
The aim of this study was to investigate decision-making behaviours and processes of 
pharmaceutical companies and regulatory authorities during medicines development and 
review.  
 
The objectives were to: 
• Identify current decision-making practices and procedures within their 
organisations  
• Assess the use of different methodologies for measuring the quality of 
decision-making process  
• Investigate views and challenges with regards to the various frameworks they 
are using for decision making. 
 
METHOD 
Design of the assessment tool 
An assessment tool in the form of a questionnaire was designed based on previous research 
outcomes (Donelan et al., 2015) and following a review of the literature, which identified the 
key issues in decision making relating to the use of formal frameworks and techniques for 
structuring and measuring the quality of the decision-making process as well as the 
prevalence of biases and subjective influences, as described in Chapter 1.  
 
Previous research (Leong et al., 2013) suggested that the decision-making process by which 
regulatory authorities and pharmaceutical companies make a decision can be classified into 
two systems, namely quantitative and qualitative (Table 3.1). In addition, free text was 
provided if the system deviated from the definitions, or if it was a combination of the two 
systems.  
 
Definition of a framework 
For the purpose of this study, the definition of a framework was derived from previous 
research in the area of benefit-risk assessment (Ferguson, 2008) and is defined as “a set of 
principles, guidelines and tools which provide a structured systematic approach to guide 
decision makers in selecting, organising, understanding and summarising subjective values 
and judgments that form the basis of a decision, as well as communicating the evidence 
relevant to the decision”. 
  
48 
Table 3.1 Definitions of regulatory decision-making systems 
Adapted from Leong et al., 2013 
 
Quality Decision-Making Practices 
In the absence of other validated criteria for evaluating quality decision making during 
medicines development and the regulatory review, Quality Decision-Making Practices 
(QDMPs) were proposed for evaluating the company and authority frameworks (Table 3.2). 
As previously described, the QDMPs were developed based on key issues in quality decision 
making identified through semi-structured interviews with 29 key opinion leaders from 
authorities and companies (Donelan et al., 2015).  
 
Biases 
The different types of cognitive biases that occur during decision making were also 
investigated. Four main groups of biases adapted from previous research (Lovallo and 
Sibony, 2010) (Table 3.3) were proposed for this study to underpin the evaluation of bias 
perception within companies and authorities. This typology was chosen as it focuses on those 
biases that occur most frequently and that have the largest impact on organisational and 
business decisions. 
 
System Definition (companies) Definition (authorities) 
Qualitative 
Our internal system for the final 
decision to submit a New Drug 
Application (NDA) is purely 
qualitative based on internal experts 
or management making a “gut 
decision”. The final decision will be 
exercised based on Expert Judgment 
and company experience. 
Our internal system for the final 
decision to approve or reject an NDA 
is purely qualitative based on internal 
experts making an intuitive decision 
(“gut decision”). The final decision 
will be exercised based on Expert 
Judgment and agency experience. 
Quantitative 
Our internal system for the final 
decision to submit an NDA is fully 
quantitative which brings together 
various key data for the decision 
(including Clinical ( Benefit-Risk), 
CMC (Manufacturing), Health 
Outcomes and contributing opinions. 
The conclusion is based on the 
cumulative outcome from this single 
system. The final decision will be 
exercised based on Expert Judgment. 
Our internal system for the final 
decision to approve or reject an NDA 
is fully quantitative which brings 
together various key data for the 
decision (including Clinical (Benefit-
Risk), CMC (Manufacturing), Health 
Outcomes and contributing opinions. 
The conclusion is based on the 
cumulative outcome from this single 
system. The final decision will be 
exercised based on Expert Judgment. 
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Table 3.2 Quality Decision-Making Practices (QDMPs) 
1. Have a systematic, structured approach to aid decision making (consistent and 
predictable) 
2. Assign clear roles and responsibilities (decision makers, advisors, contributors) 
3. Consider uncertainty and examine alternative solutions  
4. Assign values and relative importance to decision criteria  
5. Re-evaluate as new information becomes available 
6. Evaluate both internal and external influences/biases 
7. Apply a structured approach to aid transparency and provide a record trail 
8. Perform impact analysis and effectively communicate the basis of the decision 
Adapted from Donelan et al., 2015 
 
Structure and content of the questionnaires 
The assessment tool was finalised into two questionnaires to evaluate the decision-making 
practices of international pharmaceutical companies and regulatory authorities, respectively.  
Since many decisions are made within such organisations on a daily basis, the questionnaires 
focused on the key high-level decisions during medicines development and review, namely 
that to submit a new drug application (NDA) for the company questionnaire and to approve or 
reject an NDA for the regulatory authority questionnaire.   
 
The questionnaires were organised into four sections:  
1. Decision-making process: this section included questions regarding the 
involvement of a committee, different decision-making practices and decision-
making systems 
2.  Decision-making frameworks: this section included questions regarding the use 
of a framework and the practices incorporated 
3. Challenges: this section consisted of questions focusing on biases 
4. Personal perceptions: this section included questions regarding perceived hurdles 
and solutions for making quality decisions and measuring quality of decision 
making 
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Table 3.3 Characteristics and definitions of biases 
Bias type Definition Characteristics 
Action-
oriented 
A bias that drives us to take 
action less thoughtfully 
than we should  
• Excessive optimism 
• Overconfidence 
• Intuition/gut-feeling 
Interest 
A bias that arises in the 
presence of conflicting 
incentives, including 
emotional ones  
• Misaligned individual incentives 
• Inappropriate attachments 
• Misaligned perception of corporate 
goals/hierarchy 
Pattern-
recognition 
A bias that leads us to 
recognise patterns even 
where there are none 
• Confirmation bias to seek out 
information that supports a favoured 
decision 
• Generalising based on examples that are 
recent or memorable 
• Evaluating a plan or proposal based on 
the track record of the person presenting 
it, more than on the facts supporting it 
Stability 
A bias that creates a 
tendency toward inertia in 
the presence of uncertainty 
• Preference for the status quo in the 
absence of pressure to change it 
• The tendency to feel losses more acutely 
than gains of the same amount 
• Rooting oneself to an initial value, 
leading to insufficient adjustments of 
subsequent estimates. 
Adapted from Lovallo and Sibony, 2010 
 
The two questionnaires contained analogous questions where appropriate in order to allow a 
comparison between companies and regulatory authorities. The following issue was unique to 
the company questionnaire: 
• Question 1.1.3 regarding the company departments and disciplines which are part of 
the final decision-making Committee as well as their role (information 
provider/advisor or decision maker) 
The following issue was unique to the regulatory authority questionnaire: 
• Question 1.3 regarding the measures that are in place to help build quality into this 
decision-making process 
The company and regulatory authority questionnaires are shown in Figure 3.1 and Figure 3.2 
respectively.
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          Figure 3.1 The pharmaceutical company regulatory questionnaire 
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Figure 3.2 The regulatory authority questionnaire 
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Study participants 
The study participants were selected based on experience and knowledge using purposive 
sampling, from those holding senior positions and having at least five years of experience in a 
managerial position within major international pharmaceutical companies and regulatory 
authorities. The finalised industry questionnaire was sent to senior management in 24 
international pharmaceutical companies with large research and development (R&D) budget 
(>1bln USD), thereby reflecting their innovativeness and the number of submission decisions 
made (PharmExec, 2014). The 24 companies were selected based on being members of the 
Centre for Innovation in Regulatory Science (CIRS) research programmes to ensure 
timeliness and maximise the response rate (CIRS, 2018).  
 
The finalised authority questionnaire was sent to senior executives within 14 major regulatory 
authorities. The focus was on major authorities, particularly those classified as Stringent 
Regulatory Authorities (SRAs) by the World Health Organisation (WHO) (2017) and which 
have a working relationship with CIRS (2018). To improve the representation of the sample, 
participants from various-sized organisations and geographical locations were invited 
including Australia, Asia, Europe and North America.  
 
The study was designed as a cross-sectional study, aimed at collecting data during a period of 
two months to ensure an objective comparison of results. The study participants were 
contacted via e-mail in May 2015 and were invited to take part in the study and, if agreed, 
they were subsequently asked to complete the questionnaire and return by June 2015. The 
non-responders to the questionnaire were contacted via email, two weeks following the initial 
contact, in order to solicit further responses.  
 
Data processing and analysis 
The responses from each questionnaire were tabulated and analysed using descriptive 
statistics to draw a comparison between these two stakeholders. Data were expressed as 
percentage of number of responders for each question. All free text responses and comments 
were coded using processes guided by established methods, including grounded theory 
(Wertz, 2011) and constant comparison method (Boeije, 2012). In grounded theory, inductive, 
yet systematic analytic strategies are applied to qualitative data to conceptually analyse 
personal experiences. The constant comparative method involves constantly comparing and 
contrasting concepts to inform relationships between phrases and themes expressed by the 
study participants. Content analysis was employed for free text responses and comments to 
identify emerging themes. Ranking was used where applicable. 
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Due to confidentiality reasons, only aggregated results are shown and no data that indentifies 
an individual authority or company are reported. No statistical tests were planned or 
conducted as this study was designed to be exploratory with an aim to provide a qualitative 
assessment of the objectives as well as to generate premises for further research. 
 
RESULTS 
This study focused on the final decision for companies to submit an NDA or for regulatory 
authorities to approve or reject an NDA. The key results are presented in four parts: 
• Part I – Decision-making practices 
• Part II – Decision-making frameworks 
• Part III – Measures for assessing quality of decision making 
• Part IV – Challenges and solutions for making quality decisions. 
 
Characteristics of the study participants 
Seventeen out of 25 companies (68%) responded, namely Abbvie, Actelion, Astellas, 
AstraZeneca, Bayer, Biogen, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, F. Hoffmann-La Roche, 
GlaxoSmithKline, Janssen, NovoNordisk, Pfizer, Sanofi Aventis and Takeda. Out of the 17, 15 
(88%) were in the top 25 companies by R&D expenditure and all 17 had R&D budgets of more 
than 1bln USD (PharmExec, 2014). Ten out of the 14 regulatory authorities (71%) responded, 
with 8 out of the 10 being classified as SRAs and included the European Medicines Agency, 
national authorities from the European member states (Denmark, France, Sweden and UK using 
the national procedure; Netherlands using the centralised procedure), US Food and Drug 
Administration, Therapeutics Goods Administration of Australia, Health Canada and the Health 
Sciences Authority of Singapore. These regulatory authorities and pharmaceutical companies 
formed a diverse group, with representation from a mix of geographical locations and affiliations.  
 
Part I – Decision-making practices 
All of the companies (17) indicated that they have a committee that is involved in decision 
making, but the way that the final decision is made varies. Seven companies reported that 
their decision-making process is through consensus, whereas for six companies an individual 
makes the final decision based on the committee’s recommendations; for five out of six of the 
companies, this individual sits on the committee. Four companies indicated that a different 
practice was used, such as having the decision made by two co-chairs or employing two 
committees.  
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In considering the disciplines that are part of the committee and their role (Figure 3.3), the seven 
companies that made the decision through consensus all indicated that there were multiple 
decision makers on the committee. The most common decision maker disciplines were R&D, 
clinical development, drug/product development, commercial/marketing and regulatory. For the 
six companies in which one individual makes the decision based on the committee’s 
recommendation, the majority of disciplines play the role of an information provider or advisor 
and the most frequent decision maker disciplines were R&D, commercial/marketing, legal, 
finance and clinical development. Ten companies specified a total of 14 other disciplines; for 
example statistics (2) and manufacturing (2) as information providers/advisors and presidents or 
Chief Executive Officer (CEO) (3) as decision makers. 
 
Figure 3.3 The decision-making committee and the disciplines within the 17 companies 
and their role by the type of the decision-making practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
 
 
Similarly, most authorities (nine out of 10) utilised a committee in their decision making. For 
the nine authorities, four used an internal committee to inform all decisions and five used an 
external advisory committee to provide advice on specific questions arising during the review 
and to help inform this decision when requested. For the majority of authorities (six out of 
nine), the decision was made by one individual based on recommendations from the review 
team and advisory committee. Two authorities were found to make the decision through a 
majority vote and one authority indicated that the decision is reached through consensus.  
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Half of the companies (nine out of 17) reported that they were using a quantitative decision-
making system, followed by qualitative system (4) and a combination of both (4). Among the  
authorities, the same number (4) were using a combination or a quantitative, followed by a 
qualitative system (2).  
 
Part II – Decision-making frameworks 
Most companies (11 out of 17) and regulatory authorities (8 out of 10) had a framework in 
place that formed the basis of the decision to submit or to approve or reject an NDA. Seven 
out of the 11 companies indicated that their framework has been formally defined and 
codified and in half of the cases (6) it has been developed internally. Four out of the 11 
companies stated that the framework was informal, by custom and practice. All of the 
authorities that had a framework (8) indicated that it was formally defined and codified. Four 
of these developed their frameworks internally, two externally and two used a mixture of 
internal and external inputs.  
 
Six companies and two authorities stated that they did not have a framework in place. The 
main reasons selected by companies were lack of a validated framework (4), benefits of a 
framework not apparent (4) and lack of knowledge on decision making in general (3). The 
two authorities that did not have a framework indicated that it was because the benefits of a 
framework were not apparent. Out of the six companies that did not have a framework, three 
indicated that they were not sure whether there were plans to adopt a framework in the next 
two years, whereas three companies indicated that there were no plans. Similarly, the two 
authorities without a framework also indicated that there were no plans to adopt one in the 
next two years. 
 
The QDMPs selected by the seven companies and authorities with a formal framework are 
shown in Table 3.4. The practices that were less frequently incorporated by both groups were 
assigning values and relative importance to decision criteria; and performing impact analysis 
and effectively communicating the basis of the decision. The practice of evaluating both 
internal and external influences/biases produced the most disparity between authorities and 
companies, with companies having this practice more frequently incorporated and considered 
more relevant compared to authorities. Only three companies and none of the authorities 
indicated that they had all eight practices incorporated into their framework. Nevertheless, all 
the QDMPs which were not incorporated by the authorities and companies, were still 
considered relevant. 
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Table 3.4 The Quality Decision-Making Practices (QDMPs) incorporated into formal 
regulatory frameworks 
QDMP 
QDMP incorporated into 
organisation’s formal 
framework? 
If QDMP not 
incorporated, is it 
considered relevant? 
Companies 
(n=7) 
Authorities 
(n=8) 
Companies Authorities 
1. Have a systematic, 
structured approach to aid 
decision making (consistent 
and predictable) 
100%  88%  - 100% (n=1) 
2. Assign clear roles and 
responsibilities (decision 
makers, advisors, 
contributors) 
86% 100% 100% (n=1) - 
3. Consider uncertainty and 
examine alternative 
solutions 
100% 100% - - 
4. Assign values and 
relative importance to 
decision criteria 
57% 25% 75% (n=4) 83% (n=6) 
5. Re-evaluate as new 
information becomes 
available 
100% 88% - 100% (n=1) 
6. Evaluate both internal 
and external 
influences/biases 
86% 50% 100% (n=1) 75% (n=4) 
7. Apply a structured 
approach to aid 
transparency and provide a 
record trail 
100% 100% - - 
8. Perform impact analysis 
and effectively 
communicate  the basis of 
the decision 
57% 38% 75% (n=4) 80% (n=5) 
Only companies and authorities that had a formal framework (as opposed to by “custom and 
practice”) are included. 
n = total number of responders 
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Part III – Measures for assessing quality of decision making  
Interestingly, seven of 17 companies, but only two of 10 authorities reported that they had 
formal assessments in place to periodically measure the quality of their decision making. All 
of the companies (7) carried out a re-evaluation based on the outcome; five collected 
feedback from stakeholders and four carried out an audit of the decision making. The majority 
of these assessments (13) were carried out by an internal team while two were carried out by 
an external group. Conversely, of the two authorities that reported having formal assessments, 
both carried out an audit of the decision making and collected feedback from stakeholders and 
one carried out a re-evaluation based on the outcome. The assessments were carried out by a 
mix of external and internal groups, but only four companies and one authority carried out all 
three formal assessment activities. 
 
All companies (17) and seven out of eight authorities (two did not respond) believed that 
there were ways of measuring the quality of decision making even though in general, these 
were not always incorporated. The companies suggested measures which related to both 
evaluating the actual practices but also the outcomes, whereas authorities identified measures 
relating to the practices of decision making only. The most frequent measure suggested by 
companies was assessing the outcomes, such as achieving the label that was expected at 
submission. Authorities quoted most frequently assessing adherence against validated 
standard or guideline for decision making (Table 3.5). 
 
Finally, authorities indicated that they had other measures in place in order to help build 
quality into their decision-making process, such as standard operating procedures (9), internal 
peer review of decisions (8) external independent advisory committees (7), internal quality 
policy (6), as well as a GRevP system (3). Nevertheless, none of the authorities had a 
dedicated quality department.  
 
Part IV – Challenges and solutions for making quality decisions 
Both companies and authorities considered the occurrence of biases within their organisation 
or their influence on the decision making as pertinent. Nevertheless, the perceived frequency 
of their recognition varied for both groups according to the type of bias (Figure 3.4). For 
companies, the action-oriented bias, characterised by overconfidence and intuition, was 
perceived as the most frequently occurring (or influencing the decision making). For 
authorities, the action-oriented bias was considered less relevant and instead the stability bias, 
characterised by the preference for the status quo, was perceived as the most commonly 
occurring bias. 
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Table 3.5 Key measures proposed by companies and regulatory authorities for assessing 
the quality of decision making 
Companies (n=17) Authorities (n=7) 
1. Assess the outcomes such as obtaining a 
first cycle approval, achieving a label decided 
at submission stage, short time to submission 
and approval (n=11) 
1. Assess adherence against validated 
standard or guideline for decision making 
(n=3) 
2. Receive formal feedback from internal and 
external stakeholder (n=6) 
2. Review  the  consistency of the decision-
making practices within an organisation 
(n=2) 
3. Identify signs of bias (n=4) 3. Assess the degree of clarity and 
transparency in decision making (n=2) 
4. Evaluate  adherence to the decision-making 
practices (n=3) 
4. Review that all evidence (positive and 
negative) has been considered (n=2) 
5. Review lessons learned including best 
practices and project insights (n=4) 
5. Formally assess internal stakeholders’ 
evaluation practices (n=1) 
n = number of responders 
 
Figure 3.4 Types of biases and the perceived frequency at which they occur within a 
company or regulatory authority during their decision making 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
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The occurrence or influence of biases also varied depending on the type of the decision- 
making practice within a company, where having one individual make the decision increased 
the perceived frequency of bias compared to consensus decision making (Figure 3.5). 
Similarly, not having a framework or having an informal framework correlated with increased 
reporting of biases, compared to having a formally defined and codified framework (Figure 
3.6). Nevertheless, these differences were not observed for authorities, which may be due to 
the low ‘n’ numbers in the ‘consensus/majority group’ (3) as well as ‘informal framework 
group’ (1). 
 
Interestingly, all companies (17) and most regulatory authorities (nine out of 10; one did not 
respond) believed that the decision making within their organisations could be improved. The 
major hurdle for making quality decisions identified by companies related to the presence of 
action oriented-biases such as excessive optimism and overconfidence. Similarly, the main 
barrier reported by authorities was the presence of internal and external biases, such as the 
stability bias (Table 3.6).  
 
Figure 3.5 The frequency at which biases (all four types consolidated) are perceived to 
occur within a company by the type of the decision-making practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
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Figure 3.6 The frequency at which biases (all four types consolidated) are perceived to 
occur within a company by the type of decision-making framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
 
Table 3.6 Key hurdles for making quality regulatory decisions 
Companies  (n=17) Authorities (n=10) 
1. Action oriented bias; excessive optimism 
and overconfidence (n=11) 
1. Internal and external biases (n=6) 
2. Difficult access to information or 
unavailability of data (n=10) 
2. Inconsistent review or evaluation 
practices/tools (n=5) 
3. Internal misalignment in organisation and 
the presence of competing interests (n=9) 
3. Difficult access to information or 
unavailability of data (n=4) 
4. Lack of a validated framework for decision 
making (n=7) 
4. Time pressure (n=4) 
5. Poor assessment of uncertainty and strength 
of evidence (n=7) 
5. Lack of knowledge with regard to 
decision making concept (n=3) 
6. Time pressure (n=6) 6. Reluctance to discuss uncertainties or 
value judgments (n=3) 
7. Historical bias resulting from previous 
experiences (n=5) 
7. Resource constraints (n=2) 
n = number of responders 
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The majority of the proposed solutions reported by companies related to establishing or 
implementing a structured decision-making framework or methodology that will require 
values, preferences and uncertainty to be made explicit (Table 3.7) as well as to incorporate 
the views from all the relevant stakeholders including patients. Authorities also recommended 
this solution, as well as ensuring transparency and information access. 
 
Table 3.7 Key solutions proposed by companies and authorities for overcoming the 
hurdles for making quality decisions 
Companies (n=17) Authorities (n=10) 
1. Establish or implement a structured 
decision-making framework or method that 
requires values/preferences/uncertainty to be 
made explicit (n=10) 
1. Ensure transparency and information 
access (n=5) 
2. Multi-stakeholder inclusion - incorporate 
the views from all the relevant stakeholders 
including patients (n=10) 
2. Establish or implement a structured 
decision-making framework or method that 
requires values/preferences/uncertainty to be 
made explicit (n=4) 
3. Create an environment that encourages 
dissenting opinions and challenging ideas 
(n=9) 
3. Education on decision-making 
concepts/theory (n=4) 
4. Ensure transparency and information 
access (n=6) 
4. More formal review of the decision-
making practices as well as the decisions 
(both positive and negative) (n=4) 
5. Have a robust system which focuses on 
evidence and facts (n=5) 
5. Create an environment that encourages 
dissenting opinions and challenging ideas 
(n=2) 
6. Education on decision-making 
concepts/theory (n=3) 
6. Have a robust system which focuses on 
evidence and facts (n=2) 
7. More formal review of the decision-
making practices as well as the decisions 
(both positive and negative) (n=2) 
7. Multi-stakeholder inclusion - incorporate 
the views from all the relevant stakeholders 
including patients (n=2) 
n = number of responders 
 
DISCUSSION 
Quality decision making is critical to successful development and the regulatory review to 
ensure patients’ access to innovative medicines. The benefits of making quality choices have 
the potential of influencing all stakeholders and interestingly decision making has recently 
been linked to improving R&D productivity within pharmaceutical companies (Smietana et 
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al., 2014). This study investigated and identified the diversity of current regulatory authority 
and pharmaceutical company practices and perspectives regarding quality decision-making 
processes and measures.  
 
Decision-making systems and committees 
The results revealed that companies and authorities use a mixture of decision-making systems 
and while companies had a preference for a quantitative approach, authorities use a 
quantitative or a combination of methodologies. This finding may relate to the fact that many 
organisations are now moving towards quantitative or semi-quantitative models for other 
decision-making practices such as formalised benefit-risk assessment, (Walker et al., 2014; 
Pignatti et al., 2015) and may therefore suggest a general move towards more structured 
decision making. 
 
All companies and most authorities utilise committees when making decisions. Whilst 
companies and authorities tend to utilise internal committees and external advisory 
committees respectively, these are important vehicles for supporting the decision making and 
ensuring that all stakeholders’ viewpoints are included. Nevertheless, previous studies have 
shown that biases can potentially influence the robustness of decision making in a committee 
setting and these should be countered through structured deployment of de-biasing techniques 
(McIntyre et al., 2012; Marangi et al., 2014; Smietana et al., 2014).  Further research into 
decision making within regulatory authorities and company committees could uncover 
additional insights as well as identifying ways for minimising the impact of biases on decision 
making. 
 
Companies and authorities use different approaches to arrive at the final decision. The 
majority of companies use consensus decision making or have one person make the decision 
based on committee recommendation, whereas most authorities use individual decision-
making approaches. Although each method has advantages, such as speed for individual 
decision making and inclusiveness for group decision making, this study showed that both are 
affected by varying degrees of bias. Indeed, company results showed that individual decision 
making correlated with a higher frequency of perceived bias compared to consensus decision 
making. Although this study only looked at the final decision-making practices to either 
submit or approve an NDA, the process that leads up to this decision is of equal importance. It 
is therefore crucial that a system of checks and balances exists to ensure that the decision 
making is robust and transparent all the way through, whilst accounting for all disciplines and 
helping to minimise the influence of biases on the final decision.  
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Decision-making frameworks and practices 
Although most organisations studied have a decision-making framework in place, the 
majority of companies do not have a formally defined and codified framework, whereas 
authorities do. Nonetheless, most companies and authorities with a formal framework 
incorporated most of the QDMPs including: having a systematic, structured approach to aid 
decision making; assigning clear roles and responsibilities; considering uncertainty and 
examining alternative solutions; re-evaluating as new information becomes available; and 
applying a structured approach to aid transparency and provide a record trail.  
 
The practice of evaluating both internal and external biases was incorporated more widely by 
companies than authorities. However, both authorities and companies listed the influence of 
biases as the biggest hurdle to quality decision making and consequently the wider 
incorporation of this practice through various de-biasing methods could help address this 
issue. Additionally, this study identified that different types of biases are more relevant to 
both groups, with action-oriented biases (characterised by overconfidence) perceived as more 
frequently occurring within companies and stability biases (characterised by the preference 
for status quo) arising most commonly within authorities, suggesting that the authorities are 
perhaps more conservative in their approach to decision making.   
 
The two practices which were incorporated by the lowest number of companies and 
authorities were assigning values and relative importance to decision criteria and performing 
impact analysis and effectively communicating the basis of the decision. Interestingly, 
companies and authorities proposed making decision values, preferences and uncertainty 
more explicit as a top solution for overcoming the hurdles for making quality decisions and 
this solution could be implemented by incorporating the two above practices into the 
organisations’ formal frameworks.  Furthermore, all of the QDMPs which were not 
incorporated by the authorities and companies were generally considered relevant, thereby 
emphasising the appropriateness of the QDMPs as a basis for a framework for both 
authorities and companies. It should be nevertheless noted that although these eight QDMPs 
developed by Donelan and colleagues (2015), were considered fit for purpose, minor changes 
were made to the wording of the QDMPs as a result of the comments and discussions 
following the conduct of this study. This was to ensure the QDMPs are clear and relevant and 
to split QDMPs which contained two items (original QDMP 3 and 8). Changes were also 
made to the order, thereby ensuring the QDMPs are listed in an accurate chronological order 
relative to a decision-making process (Table 3.8). 
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Table 3.8 Modifications made to the wording and order of the Quality Decision-Making 
Practices (QDMPs) 
n = number of responders 
 
By contrast, some companies have informal frameworks and a number of authorities and 
companies do not have a decision-making framework in place at all. Upon closer inspection, 
the companies that had informal frameworks or no framework felt that biases occurred or 
influenced their organisation’s decision making more frequently, compared with those with a 
formal framework. It is important to note that all companies and almost all authorities 
believed that decision making in their organisations could be improved. Both groups 
suggested establishing or implementing a structured decision-making framework as a main 
solution. Consequently, there is a need for a universal framework that will incorporate all of 
the QDMPs in order to enable improved decision making for both the individual and the 
organisation.  
 
It has been recognised that if a group wants to improve their decision making, it needs to 
measure itself internally and also be able to see whether improvements have had an impact on 
the quality of their decision making (Kahneman, 2011). Indeed, some organisations already 
try and measure the quality of their decision making, but these are often based on the outcome 
Original QDMPs Revised QDMP 
1. Have a systematic, structured approach to 
aid decision making (consistent and 
predictable) 
1. Have a systematic, structured approach to aid 
decision making (consistent and predictable and 
timely) 
2. Assign clear roles and responsibilities 
(decision makers, advisors, contributors) 
2. Assign clear roles and responsibilities 
(decision makers, advisors, information 
providers) 
3. Consider uncertainty and examine 
alternative solutions  
5. Examine alternative solutions 
6. Consider uncertainty 
4. Assign values and relative importance to 
decision criteria  
3. Assign values and relative importance to 
decision criteria 
5. Re-evaluate as new information becomes 
available 
7. Re-evaluate as new information becomes 
available  
6. Evaluate both internal and external 
influences/biases 
4. Evaluate both internal and external 
influences/biases 
7. Apply a structured approach to aid 
transparency and provide a record trail 
9. Ensure transparency and provide a record trail 
8. Perform impact analysis and effectively 
communicate  the basis of the decision 
8. Perform impact analysis of the decision 
10. Effectively communicate  the basis of the 
decision 
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rather than the practices, which should be considered separately. There is consequently a need 
to start using suggested techniques and methodologies in order to measure the quality of 
decision making and to determine whether structured decisions are being made, to help 
identify any bias and to improve current practices (Donelan et al., 2015). 
 
Companies and authorities also suggested other solutions for improving decision making 
within organisations, such as the inclusion of views from all stakeholders with an emphasis on 
patients. Change in organisational culture in order to encourage dissenting opinions and 
challenging ideas is also key, although it is then crucial that individuals are also educated and 
trained on the concepts, science and practice of decision making. 
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SUMMARY 
• The science of decision making is well established, but evidence to date showed that 
there is a lack of research into the decision-making process during medicines 
development and the regulatory review 
• The objectives of this study were to determine the current decision-making practices 
and methodologies for structuring and measuring the quality of decision making and 
the hurdles and solutions for making quality decisions within pharmaceutical 
companies and regulatory authorities 
• Two analogous questionnaires were developed for use in this study 
• Fourteen authorities and 25 companies were asked to complete the questionnaire, 
assessing the company decision making for submitting and the regulatory authority 
process for approving a new drug application 
•  The 68% (17 out of 25) and 71% (10 out of 14) response rate from companies and 
authorities, respectively, suggests interest in this topic 
•  From the results it appears that only 41% (seven out of 17) companies and 80% 
(eight out of 10) authorities had a formally defined and codified framework for 
structuring their decision-making processes 
• Only 41% (seven out of 17) companies and 20% (two out of 10) authorities undertake 
formal assessments of decision making quality, but all 17 companies and 90% (nine 
out of 10) authorities believed that this was possible to adopt 
• Moreover, all companies and 90% of the authorities (nine out of 10) believed that 
decision making at their organisations could be improved.  
• The findings of this study support the need to further characterise and assess the 
practices and behaviours of individuals and organisations through medicines 
development and the regulatory review. 
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CHAPTER 4 
 
 
 
 
 
 
 
 
Evaluation of the Quality of Reimbursement 
Decision-Making Processes in Pharmaceutical 
Companies and Health Technology Assessment 
(HTA) Agencies 
 
 
 
 
 
 
 
 
  
72 
INTRODUCTION 
At present, pharmaceutical companies, regulatory authorities and health technology 
assessment (HTA) agencies concentrate on the generation and assessment of evidence 
regarding a medicine to ensure quality outcomes. Nevertheless, another important aspect is 
the process of decision making and, at present, it is not always clear how decisions, which 
require human judgment and interpretation, are made around the data generated or reviewed 
(Cole et al., 2016; Liberti et al., 2017).  
 
An assessment of regulatory authorities and pharmaceutical company departments (Chapter 
3) demonstrated that although both groups considered the Quality Decision-Making Practices 
(QDMPs) as important and relevant, these best practices are not always incorporated into 
organsiational frameworks to support the submission or approval processes for new 
medicines. The study also identified the key challenges as well as potential solutions for 
improving the quality of decision making within those organisations. It is therefore of interest 
to explore these themes regarding the second hurdle following the regulatory approval, 
namely HTA, which is used to recommend the reimbursement of medicines. Such a study 
could focus on the two key stakeholders involved, namely HTA agencies as well as health 
economic and outcomes research (HEOR) company departments. 
 
Health technology assessment is an essential process for ensuring efficient allocation of 
healthcare resources. However, the current global HTA environment is diverse and 
increasingly multidisciplinary. As a result, projects are underway across HTA agencies, most 
recently through the proposal of the European Commission for European cooperation of HTA 
agencies (European Commission, 2018). Other projects focus on aligning the HTA decision 
making in partnership  with pharmaceutical companies as well as regulatory authorities to 
ensure a more timely, efficient and effective development of medicines (Breckenridge et al., 
2010, McAuslane et al., 2016). Indeed, a number of projects have focused on the various 
ways to improve the HTA assessment and appraisal methodologies and practices (Daniels N, 
2000; Wahlster, 2016), to standardise the HTA evidence criteria (EUnetHTA, 2016) and to 
formalise the appraisal processes within the various HTA committees (CADTH, 2012; NICE, 
2015). Some HTA agencies also have been looking to align evidentiary requirements with 
regulatory authorities by carrying out parallel or joint scientific advice as well as to 
synchronise the timing of the assessment process with the regulatory review process in order 
to ensure more timely and aligned decision making between stakeholders (McAuslane et al., 
2016; Wang et al., 2016; Tafuri, 2018). Within companies, frameworks have been developed 
in order to provide better structure around evidence generation during medicines development 
to capture the HTA and payer requirements as well as to try and put systems in place to better 
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align with regulatory requirements (Dunlop et al., 2016; McAuslane et al., 2016). 
Nevertheless, more transparency is needed to understand human judgements and 
interpretations made around the data (Cole et al., 2016).  
 
Researchers in the field of decision making and the psychology of judgment have been 
advocating the use of more structured approaches to decision making as well as the need to 
periodically measure the quality of the decision-making process in order to identify areas for 
improvement (Hammond et al, 1999, Kahneman, 2011). The potential merits of having a 
more structured decision-making process are: higher probability of favourable outcomes, 
improved consistency across decisions, transparency to stakeholders including patients and 
taxpayers, as well as decision accountability and trust (Cole et al., 2016). Consequently, there 
is a need to explicitly evaluate the quality of the deliberative decision-making processes 
within companies and HTA agencies (McAuslane et al., 2014). 
 
The aim of this study was therefore to investigate decision-making behaviours and processes, 
focusing on two key specific processes to support the reimbursement of medicines; firstly, the 
decision-making process for evidence generation by pharmaceutical companies as well as the 
technology appraisal process by HTA agencies of the data submitted by companies.  
 
The objectives were to: 
• Identify current decision-making practices and procedures within the 
organisations  
• Assess the use of different methodologies for measuring the quality of 
decision-making process  
• Investigate views and challenges with regards to the various frameworks used 
for decision making. 
 
METHOD 
Design of the assessment tool 
An assessment tool in the form of a questionnaire was developed for evaluating the decision-
making practices of international pharmaceutical companies and HTA agencies. The 
questions were adapted from the study described in Chapter 3 on regulatory decision making 
of companies and regulatory authorities in order to facilitate comparisons between the two 
studies. The questions were designed based on previous research outcomes (Donelan et al., 
2015) and following a review of the literature, which identified the key issues in decision 
making relating to the use of formal frameworks and techniques for structuring and measuring 
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the quality of the decision-making process as well as the prevalence of biases and subjective 
influences, as described in Chapter 1. Classification of decision-making systems, namely 
qualitative, quantitative as well as mixed (Table 4.1) was derived based on the regulatory 
questionnaire (Chapter 3) and originally adapted from a previous study assessing the need for 
a benefit-risk framework (Leong et al., 2013). 
 
Table 4.1 Definitions of health technology assessment decision-making systems to 
support reimbursement 
Adapted from Leong et al., 2013 
 
System Definition (companies) Definition (agencies) 
Qualitative 
Our internal system regarding the 
decision-making process to support 
the reimbursement of new medicines 
via the relevant HTA agencies is 
purely qualitative based on experts or 
management making a subjective 
decision. The final decision will be 
exercised based on Expert Judgment 
and experience. 
Our internal system for the final 
decision-making process to 
recommend/restrict or not to 
recommend a new medicine for 
reimbursement is purely qualitative 
based on experts making a subjective 
decision. The final recommendation 
decision will be exercised based on 
Expert Judgment and experience. 
Quantitative 
Our internal system regarding the 
decision-making process to support 
the reimbursement of new medicines 
via the relevant HTA agencies is 
quantitative which brings together the 
various key data for the decision 
(such as comparative effectiveness 
data) and contributing opinions. The 
conclusion is based on the 
cumulative outcome from this 
system. 
Our internal system for the final 
decision-making process to 
recommend/ restrict or not to 
recommend a new medicine for 
reimbursement is fully quantitative 
which brings together the various key 
data for the recommendation decision 
(such as comparative effectiveness 
data) and contributing opinions. The 
conclusion is based on the cumulative 
outcome from this system. 
Mixed 
Our internal system regarding the 
decision-making process to support 
the reimbursement of new medicines 
via the relevant HTA agencies is 
mixed, which takes into account 
various quantitative and qualitative 
elements. 
Our internal system for the final 
decision-making process to 
recommend/restrict or not to 
recommend a new medicine for 
reimbursement is mixed, which takes 
into account various quantitative and 
qualitative elements. 
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Definition of a framework 
The definition of a framework was also derived from the regulatory questionnaire (Chapter 3) 
and was initially adapted from previous research in the area of benefit-risk assessment 
(Ferguson, 2008) and was defined as “a set of principles, guidelines and tools which provide a 
structured systematic approach to guide decision makers in selecting, organising, 
understanding and summarising subjective values and judgments that form the basis of a 
decision, as well as communicating the evidence relevant to the decision.” 
 
Quality Decision-Making Practices 
The QDMPs proposed for this study were also utilised in the regulatory study (Chapter 3). 
The QDMPs were developed based on the key issues in quality decision making identified 
through semi-structured interviews with 29 key opinion leaders from authorities and 
companies (Donelan et al., 2015).  
 
Table 4.2 The ten Quality Decision-Making Practices (QDMPs) 
1. Have a systematic, structured approach to aid decision making (consistent, predictable and 
timely) 
2. Assign clear roles and responsibilities (decision makers, advisors, information providers) 
3. Assign values and relative importance to decision criteria 
4. Evaluate both internal and external influences/biases 
5. Examine alternative solutions 
6. Consider uncertainty  
7. Re-evaluate as new information becomes available 
8. Perform impact analysis of the decision 
9. Ensure transparency and provide a record trail 
10. Effectively communicate  the basis of the decision 
Adapted from Donelan et al., 2015 
 
Biases 
The different types of cognitive biases that occur during decision making were also 
investigated. Four main groups of biases adapted from previous research (Lovallo and 
Sibony, 2010) (Table 4.3) were proposed for this study to underpin the evaluation of bias 
perception within companies and agencies. This typology was chosen previously for the 
regulatory study (Chapter 3) as it focuses on those biases that occur most frequently and that 
have the largest impact on organisational and business decisions. 
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Pilot study 
A pilot phase was designed with the aim of content validation of the initial questionnaire. The 
pilot study was conducted with two invited companies and two HTA agencies that agreed to 
complete the questionnaire followed by a short feedback form. The following feedback 
questions were asked: 
1. In general, how did you find the questionnaire?  
2. Is the format of the questionnaire clear? (Yes/No) If no, please comment. 
3. Is the language used in the questionnaire clear? (Yes/No) If no, please list any terms 
or questions which were unclear. 
4. Are there any questions you found difficult to answer? (Yes/No) If yes, please 
provide the question number and comment. 
 
Table 4.3 Characteristics and definitions of biases 
Bias type Definition Characteristics 
Action-
oriented 
A bias that drives us to take 
action less thoughtfully 
than we should  
• Excessive optimism 
• Overconfidence 
• Intuition/gut-feeling 
Interest 
A bias that arises in the 
presence of conflicting 
incentives, including 
emotional ones  
• Misaligned individual incentives 
• Inappropriate attachments 
• Misaligned perception of corporate 
goals/hierarchy 
Pattern-
recognition 
A bias that leads us to 
recognise patterns even 
where there are none 
• Confirmation bias to seek out 
information that supports a favoured 
decision 
• Generalising based on examples that are 
recent or memorable 
• Evaluating a plan or proposal based on 
the track record of the person presenting 
it, more than on the facts supporting it 
Stability 
A bias that creates a 
tendency toward inertia in 
the presence of uncertainty 
• Preference for the status quo in the 
absence of pressure to change it 
• The tendency to feel losses more acutely 
than gains of the same amount 
• Rooting oneself to an initial value, 
leading to insufficient adjustments of 
subsequent estimates. 
Adapted from Lovallo and Sibony, 2010 
 
Structure and content of the questionnaires 
The assessment tool was finalised into two questionnaires to evaluate the decision-making 
practices of international pharmaceutical companies and HTA agencies, respectively. Since 
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many decisions are made within such organisations on a daily basis, these questionnaires 
focused on specific high-level decisions, namely the company process for evidence 
generation to support an HTA dossier for new medicines and the HTA agency appraisal 
decision-making process to recommend reimbursement of new medicines, restrict or reject it. 
 
The questionnaires were organised into four sections:  
1. Decision-making process: this section included questions regarding the 
involvement of a committee, different decision-making practices and decision-
making systems 
2.  Decision-making frameworks: this section included questions regarding the use 
of a framework and the practices incorporated 
3. Challenges: this section consisted of questions focusing on biases 
4. Personal perceptions: this section included questions regarding perceived hurdles 
and solutions for making quality decisions and measuring quality decision 
making 
 
The two questionnaires contained analogous questions where appropriate in order to allow a 
comparison between companies and agencies. The following issues were unique to the 
company questionnaire: 
• Question 1.1.3 regarding the location of the committee  
• Question 1.1.5 examining if the committee is also responsible for the decision-
making process for evidence generation to seek regulatory approval 
• Question 1.1.6 regarding the timing of the decision-making process with regards to 
the filing for regulatory approval 
• Question 1.1.7 pertaining to other decisions made by the Committee  
The following issue was unique to the agency questionnaire: 
• Questions 1.1.4 regarding whether or not the committee is open or closed to external 
stakeholders 
• Question 1.4 regarding whether or not the recommendation is legally binding 
• Question 1.5 pertaining to the decision-making criteria that are defined explicitly by 
the agency’s framework 
• Question 1.6 regarding whether or not there are procedures in place for the 
recommendation decision to be formally challenged 
The company and agency questionnaires are shown in Figure 4.1 and Figure 4.2 respectively.
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Figure 4.1 The pharmaceutical company reimbursement questionnaire 
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      Figure 4.2 The health technology assessment agency questionnaire 
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Study participants 
Similarly to the approach described in the regulatory study in Chapter 3, the study participants 
were selected based on experience and knowledge using purposive sampling, from those 
holding senior positions and having at least five years experience in a managerial position 
within major international pharmaceutical companies and HTA agencies. The finalised 
industry questionnaire was sent to executives within HEOR departments at 24 international 
pharmaceutical companies with large R&D budget (>1bln USD), thereby reflecting their 
innovativeness and the number of decisions made (PharmExec, 2016). The 24 companies were 
selected based on being members of Centre for Innovation in Regulatory Science (CIRS) 
research programme to ensure timeliness and maximise the response rate (CIRS, 2018).  
 
The finalised agency questionnaire was sent to senior executives within 16 major HTA 
agencies. The focus was on major HTA agencies, which are part of the International Network 
of Agencies for Health Technology Assessment (INAHTA, 2018) or European network for 
health technology assessment (EUnetHTA, 2018) and which have a working relationship with 
CIRS (2018). To improve the representation of the sample, participants from various-sized 
organisations and geographical locations were invited including Australia, Asia, Europe and 
North America.  
 
The study was designed as a cross-sectional study and the participants were invited via e-mail 
in January 2017 and were invited to take part in the study and if agreed were subsequently 
asked to complete the questionnaire and return by February 2017. The non-responders to the 
questionnaire were subsequently contacted via email in order to solicit further responses and 
the last response was received in July 2017. 
 
Data processing and analysis 
The responses from each questionnaire were tabulated and analysed using descriptive 
statistics to draw a comparison between the companies and the HTA agencies. Data were 
expressed as percentage of number of responders for each item. All free text responses and 
comments were coded using processes guided by established methods, including grounded 
theory (Wertz, 2011) and constant comparison method (Boeije, 2012). In grounded theory, 
inductive, yet systematic analytic strategies are applied to qualitative data to conceptually 
analyse personal experiences. The constant comparative method involves constantly 
comparing and contrasting concepts to inform relationships between phrases and themes 
expressed by the study participants. Content analysis was employed for free text responses 
and comments to identify emerging themes. Ranking was used where applicable.  
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Due to confidentiality reasons, only aggregated results are shown and no data that indentifies 
an individual agency or company are reported. No statistical tests were planned or conducted 
as this study was designed to be exploratory with an aim to provide a qualitative assessment 
of the objectives as well as to generate premises for further research. 
 
RESULTS 
This study focused on the decision-making practices of pharmaceutical companies for 
evidence generation to support an HTA dossier for new medicines and HTA agencies’ 
appraisal recommendation process. The key results are presented in five parts: 
• Part I – Pilot study results 
• Part II – Decision-making practices 
• Part III – Decision-making frameworks 
• Part IV – Measures for assessing quality of decision making 
• Part V – Challenges and solutions for making quality decisions 
 
Characteristics of the study participants 
Responses were received from 12 out of the 24 executives from company HEOR departments 
recruited into the study (50%), where 1 declined to complete the questionnaire due to the 
inability to meet the deadline. Eleven out of 24 (46%) gave positive responses which were 
used in the analysis, namely Abbvie, Bayer, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, 
Merck, Novartis, Pfizer, Sanofi Aventis and UCB. Nine out of the 11 companies were in the 
top 25 in terms of their R&D expenditure in 2016 and all 11 had R&D budget greater than 
1bln USD (PharmExec, 2016). 
 
As for the agencies, 11 (69%) out of the 16 provided responses, which included the national 
agencies from Australia (Pharmaceutical Benefits Advisory Committee), Belgium 
(Rijksinstituut voor Ziekte- en Invaliditeitsverzekering), Brazil (Comissao Nacional de 
Incorporaca de Technologias), Canada national agency (Canadian Agency for Drugs and 
Technologies in Health), Canada Quebec province (Institut national d’excellence en santé et 
en services sociaux), England (The National Institute for Health and Care Excellence), 
Netherlands (Zorginstituut Nederland), Poland (Agencja Oceny Technologii Medycznych 
i Taryfikacji), Scotland (Scottish Medicines Consortium), Spain Basque region (Servicio de 
Evaluación de Tecnologías Sanitarias) and Sweden (Tandvårds- och 
läkemedelsförmånsverket). The companies and HTA agencies represented a diverse mix of 
geographical locations and affiliations and all belonged to either INAHTA (2018) or 
EUnetHTA (2018), demonstrating that these agencies have established HTA systems in place. 
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Part I – Pilot study results 
The questionnaire was piloted among two companies and two agencies. The two agencies 
judged the questionnaire as ‘straightforward’, ‘thorough’ and ‘detailed’. Both agencies 
considered the format and language used as clear and did not think that any questions should 
be removed as a result of being irrelevant or repetitive. One question was considered as 
unclear by one agency, which resulted in a word revision from ‘In your opinion what are the 
top three hurdles for making a quality decision’ to ‘In your opinion what are the top three 
barriers for making a quality decision’.  Two questions were added as a result of a suggestion 
from one agency, namely ‘Is the recommendation made by the HTA agency legally binding 
for adoption by payer bodies?’ and ‘Which of the following criteria apply in order to make 
the recommendation decision as defined explicitly by the agency’s framework?’. 
 
The two companies rated the language used as clear, but one company found the format 
unclear in terms of separation between questions and answers, which resulted in the question 
text made bold. Questions regarding ‘committee’ were found difficult to answer which lead to 
a definition added, namely ‘a formal or informal decision-making group’. In addition, the 
wording of one question was found unclear by a company and was subsequently changed 
from ‘How are the decisions made by this Committee relating to evidence generation to seek 
reimbursement of new medicines’ to ‘In general, how are decisions made for evidence 
generation to support the reimbursement of new medicines via the relevant HTA agencies?’. 
None of the companies thought that questions should be removed as a result of being 
irrelevant or repetitive and no further questions were suggested. 
 
Part II – Decision-making practices 
A comparison of committees and systems  
Almost all of the companies (10 out of 11) and HTA agencies (10 out of 11) reported that 
they have a committee that is involved in the decision-making processes for the generation of 
evidence to support the reimbursement of medicines. The number of company committee 
members ranged from six to 20 and this number also varied within a company for example 
depending on the product. The mean for the agency committee members was 20, with a range 
from nine to 31 members. Both groups adopted mixed decision-making systems. For 
companies, an individual made the ultimate decision based on the respective committee’s 
recommendation (4), the decision was made by consensus (4) or a different process was 
adopted (2). None of the companies used a majority vote system. Agencies utilised a majority 
vote (5; where three used open voting and two used a secret ballot), consensus (4; where two 
used a majority vote if consensus could not be reached) or an individual makes the decision 
(1). Almost all the companies (8) and agencies (9) utilised a mixed internal decision-making 
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system (which takes into account various quantitative and qualitative elements), as opposed to 
a purely qualitative or quantitative system. 
 
Regarding the disciplines that were represented in the committee, the majority of companies 
had representatives from research and development, clinical development/medical affairs, 
drug/product development, commercial/marketing, health economics/outcomes, market 
access/pricing, regulatory, pharmacovigilance/drug safety, senior management and regional 
representatives (Figure 4.3). Overall, the most common decision makers were clinical 
development/medical affairs, commercial/marketing and market access/pricing and only 
minor differences were observed by type of decision-making practice (i.e. whether the 
decision is made by an individual, consensus or other). The group was split as to whether or 
not an individual member of the committee could veto the decision, with four stating this 
could be done, usually by the chair and the other four reported that it was not done. Other 
decisions made by the committee included label/indication for reimbursement (9), target 
population for (8) and price setting (4). 
 
Figure 4.3 The decision-making committee and the disciplines within the ten companies 
and their role by the type of the decision-making practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
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For agencies, other than technical members, a number of stakeholders attended appraisal 
committee meetings, namely the industry, payers, patient/patient interest groups and lay 
representatives/public members. For committees where a decision is made through majority, 
the most common decision-making group (other than technical members) were payers, 
whereas for consensus-style committees, it was the lay representatives/public members 
(Figure 4.4). An individual in the committee could veto the decision in only one agency, but 
in most cases (10) the decision could be challenged by external stakeholders, primarily 
through legal procedures. 
 
Company-specific characteristics 
The majority of companies (8) reported that the committees were based centrally in the head 
office. In addition, companies were mixed as to the process timing with regards to the filing 
for regulatory approval, where, in most cases, the HTA committee process occurred either 
immediately ahead of process to file for regulatory approval (5) or as an iterative process 
before, during and post filing (4) or at the same time (1). For half of the companies (5), this 
committee was also responsible for generating evidence for seeking regulatory approval. For 
the companies where this was not the case (5), the majority (3) stated that the committees 
interacted by ensuring that there was an overlap of members on both committees.  
 
Figure 4.4 Stakeholders in the committee (other than the technical agency members) 
within the ten agencies and their role by the type of the decision-making practice  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
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Agency-specific characteristics 
In terms of the criteria used by each committee to make the recommendation decision as 
defined explicitly by the agency’s framework: all agencies (11) utilised cost-effectiveness 
threshold/range and almost all used comparative effectiveness (10) and budget impact (8), 
whereas 8 specified other criteria, including burden of disease and unmet need. For the 
majority of the agencies (7) the committee recommendation was non-binding, for three 
agencies it was binding and in 1 case it would only be binding if it was a negative 
recommendation. 
 
Part III – Decision-making frameworks 
The majority of companies (9) had a framework that formed the basis of the decision-making 
process for evidence generation to support the reimbursement of medicines, where 6 were 
formally defined and codified and three were informal by “custom and practice”; that is, the 
framework had never been clearly agreed but over time had become the practice. The 
majority of companies (6) developed the framework internally and 2 used mixed internal and 
external input (1 did not respond). For the companies that did not have a framework (2), the 
reasons for this were mixed, including the time factor relating to the maturity of the 
organisation, organisational structure or size of the company, the lack of a validated 
framework and the fact that the benefits of a framework were not apparent. One company 
indicated that it had plans to adopt a framework in the next two years whereas one indicated 
that there were no plans.  
 
All 11 agencies had a framework, where seven were formally defined and codified and 4 had 
an informal framework by “custom and practice”. The majority of agencies (6) developed the 
framework using mixed internal and external input, whereas for two, development was 
internal (3 did not respond). 
 
The incorporation of the ten QDMPs into company and agency formal frameworks is shown 
in Table 4.4. In general, the majority of the ten QDMPs were incorporated into the company 
and agency formal frameworks. QDMP 3 (assign values and relative importance to decision 
criteria) and QDMP 4 (evaluate both internal and external influences/biases) were least 
incorporated by the two groups. QDMP 5 (examine alternative solutions) was incorporated by 
all the companies, but only four out of seven agencies, whereas QDMP 8 (perform impact 
analysis of the decision) was incorporated by the majority of agencies, but only one out of the 
six companies. Only two agencies and none of the companies indicated that they had all ten 
QDMPs incorporated into their framework. Nevertheless, all the QDMPs that were least 
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incorporated into agency and company frameworks were generally considered as relevant by 
both groups. 
 
Table 4.4 The Quality Decision-Making Practices (QDMPs) incorporated into 
organisations’ formal frameworks 
Quality decision-making 
practices (QDMPs) 
QDMP incorporated into 
organisation’s formal 
framework? 
If QDMP not 
incorporated, is it 
considered relevant? 
Companies 
(n=6) 
Agencies 
(n=7) 
Companies Agencies 
1. Have a systematic, 
structured approach to aid 
decision making (consistent, 
predictable and timely) 
67% 100% 100% (n=2) - 
2. Assign clear roles and 
responsibilities (decision 
makers, advisors, information 
providers) 
100% 100% - - 
3. Assign values and relative 
importance to decision criteria 
50% 43% 100% (n=3) 75% (n=4) 
4. Evaluate both internal and 
external influences/biases 
33% 43% 100% (n=4) 100% (n=4) 
5. Examine alternative 
solutions 
100% 57%  67% (n=3) 
6. Consider uncertainty  100% 71% - 100% (n=2) 
7. Re-evaluate as new 
information becomes available 
100% 86% - 100% (n=1) 
8. Perform impact analysis of 
the decision 
17% 86% 80% (n=5) 100% (n=1) 
9. Ensure transparency and 
provide a record trail 
83% 86% 100% (n=1) 100% (n=1) 
10. Effectively communicate  
the basis of the decision 
67% 86% 100% (n=2) 100% (n=1) 
* Only companies and agencies that had a formal framework (as opposed to by “custom and 
practice”) are included. 
n = total number of responders. 
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Part IV - Measures for assessing quality of decision making 
The majority of companies and agencies did not have formal assessments in place to measure 
the quality of decision making. For the 4 companies and 6 agencies that had formal 
assessments, most obtained formal feedback from internal and external stakeholders, followed 
by examining the actual outcome compared with expected outcome, but only two companies 
and three agencies reported that they audited their decision-making process. The assessments 
were generally carried out on a systematic basis, by internal groups for companies and a mix 
of internal and external groups for agencies. Interestingly, most companies (9 out of 11) and 
agencies (7 out of 11) believed that there were ways of measuring the quality of decision-
making process. Moreover, companies and agencies primarily suggested measures for 
assessing the process, although currently the majority of organisations only assess outcomes 
(Table 4.5).  
 
Table 4.5 Key measures proposed by pharmaceutical companies and health technology 
assessment agencies for assessing the quality of decision making 
Companies (n=7) Agencies (n=6) 
1.Formal assessment of the internal decision-
making process including decision 
transparency and communication (n=3) 
1. External benchmarking of decision-
making processes and outcomes compared 
to other jurisdictions (n=4) 
2. Incorporation of milestones and indicators 
into process to verify if key factors at each 
stage are addressed by internal stakeholders 
(n=2) 
2. Internal assessment of the decision-
making process (structure; use of 
committees and frameworks) (n=3) 
3. Evaluation of HTA success compared to the 
evidence generated (n=2) 
3. Degree of participation and engagement 
with stakeholders (n=2) 
4. Analysis of the actual decision and its 
foundation including the evidence considered 
and other influencing factors (n=2) 
4. Formal feedback from internal and 
external stakeholders regarding decision 
making (n=2) 
n = number of responders 
 
Part V - Challenges and solutions for making quality decisions 
In general, both agencies and particularly companies considered the occurrence of biases 
within their organisation or their influence on the decision making as pertinent. Nevertheless, 
the perceived frequency of their recognition varied for both groups according to the type of 
bias (Figure 4.5). In general, action-oriented bias (for example, overconfidence or intuition 
leading individuals to take action less thoughtfully) was perceived as most influential and 
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interest bias; that is, bias arising in the presence of conflicting incentives was perceived as the 
least pertinent for agencies, whereas for companies it was mixed. 
 
Figure 4.5 Types of biases and the perceived frequency at which they occur within 
pharmaceutical companies or health technology assessment agencies during their 
decision making 
 
 
 
 
 
 
 
 
 
 
 
n = number of responders 
 
Almost all the companies (9 out of 11; 2 did not respond) and agencies (9 out of 11) believed 
that decision making within their organisations could be improved. Both groups identified 
barriers (Table 4.6) and possible solutions (Table 4.7) for making a quality decision. For 
agencies, the major barrier was regarding poor quality of evidence submitted as well as high 
uncertainty around the information. It was suggested that this could be addressed through the 
use of improved methodologies for clinical study design, economic modelling and price 
setting, as well as increased reliance on real world evidence/data. Nevertheless, agencies also 
highlighted lack of knowledge and frameworks for decision making as well as the presence of 
biases and time pressures. This in turn could be addressed by defining an internationally 
agreed decision-making framework and providing training on the topic of quality decision 
making, as suggested by the agencies. Companies reported challenges due to misalignment 
and competing interests, particularly externally, relating to divergent HTA agency decision-
making processes, requirements and standards, as well as internal conflicts within companies, 
namely between HTA and regulatory functions and requirements (focus primarily on 
registration). Respondents suggested that this could be addressed by incentivising internal 
systems to align as well as encouraging external engagement with stakeholders. Resource and 
time constraints as well as lack of knowledge and experience with regard to HTA and 
reimbursement decision making were also highlighted as a key barrier.  Companies suggested 
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that improvements could be made by increasing awareness of decision-making concepts 
within companies and by carrying out a more formal review of their decision-making 
processes and respective outcomes. 
 
Table 4.6 Key barriers identified by pharmaceutical companies and health technology 
assessment agencies for quality decision making 
Companies (n=9) Agencies (n=10) 
1. Lack of alignment relating to decision-
making processes, requirements and HTA 
standards (e.g. local vs. global; HTA vs. 
regulatory) (n=10) 
1. Poor quality of evidence submitted by 
companies (n=10) 
 
2. Resource and time constraints – need to 
decide quickly and reluctance to start early 
(n=6) 
2. Limited data and high levels of uncertainty 
around the information (n=6) 
 
3. Internal decision-making misalignment 
between HTA and regulatory functions and 
requirements for evidence generation (n=5) 
3. Lack of knowledge and frameworks with 
regard to decision making (n=4) 
 
4. Lack of in-house knowledge and 
experience with regard to HTA and 
reimbursement decision making (n=4) 
4. Internal and external biases, trust issues 
and political pressures (n=3) 
 
5. No feedback loop in identifying the impact 
of decisions made (n=2) 
5. Time available to make the decision (n=2) 
n = number of responders 
 
Table 4.7 Key solutions proposed by companies and health technology assessment 
agencies for overcoming the barriers for making quality decisions 
Companies (n=9) Agencies (n=10) 
1. Incentivise internal systems to align and 
facilitate cross-functional collaborations 
(HTA-regulatory) early in the process  (n=7) 
1. Improved methodologies for clinical study 
design, economic modelling and price setting 
(n=8) 
2. Education, capacity building and 
international engagement with external 
stakeholders (regulatory and HTA)  (n=7) 
2. Increased reliance on real world 
evidence/data during decision making  (n=6) 
3. More formal review of decision-making 
process, outcomes and feedback from 
stakeholders (n=4) 
3. Education, capacity building and 
international engagement (n=5) 
 
4. Lobby for a more predictable and 
harmonised HTA environment (n=4) 
4. Define an international framework to 
enable more structured decision making 
(n=3) 
n = number of responders 
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DISCUSSION 
Having a structured decision-making processes in place with appropriate frameworks and 
incorporating all ten QDMPs is imperative to ensuring transparency and increasing the 
probability of favourable outcomes regarding the reimbursement of new medicines. This 
study aimed to evaluate the decision-making processes within pharmaceutical company 
HEOR departments during medicines development for evidence generation to support an 
HTA dossier for new medicines and the HTA agency appraisal decision-making process to 
recommend reimbursement restriction or rejection of new medicines. The results provide a 
unique insight into the organisational practices within companies and agencies, their views of 
the occurrence of biases and the potential barriers and solutions for quality decision-making 
processes.  
 
As this analysis has already been carried out for regulatory authorities and pharmaceutical 
companies regarding the decision-making processes for regulatory submission and review 
(Chapter 3), the results of the two studies are discussed to identify the areas of common 
strength as well as divergence. Such a comparison aims to promote future improvement and 
alignment of best practices for building quality into decision-making practices during 
medicines development, regulatory review and HTA. Indeed, ensuring the quality of decision-
making practices for all organisations involved throughout the lifecycle of medicines is key to 
increase the probability of better outcomes. 
 
Other initiatives have been carried out to characterise jurisdictional regulatory and HTA 
decision-making systems (Franken et al., 2012; Allen et al., 2013) and practices (Wang et al., 
2015; Oortwijn et al., 2017), as well as to compare the evidentiary requirements from 
regulatory authorities and HTA agencies. Nevertheless, these studies do not take into account 
the various approaches organisations have been implementing to ensure a quality decision-
making process. Nor do the studies attempt to clarify how decisions, which require human 
judgment and interpretation, are made around the data by the various committees in 
companies and agencies. Consequently, this study has moved beyond simply characterising 
the stepwise processes within organisations and aimed to determine the use of frameworks for 
decision making, the incorporation of best practices into those frameworks and the use of 
tools for evaluating the quality of decision making within those organisations. 
 
Decision-making systems and committees  
This study evaluated firstly the process characteristics across companies and HTA agencies, 
namely the use of committees; types of decision-making processes (consensus; majority vote 
or one individual makes the decision based on committee recommendation) and types of 
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decision-making systems (qualitative, which is based on expert or management opinion; 
quantitative primarily based on data and computing or mixed). 
 
Some similarities exist between the decision-making processes of pharmaceutical companies 
and HTA agencies, such as the use of committees and having a primarily internal decision-
making system. Nevertheless, the results also indicate that different organisations use diverse 
processes to arrive at the final decision, where companies primarily make decisions via one 
individual or consensus whereas agencies also use a majority vote system. This may be due to 
the difference in the purpose of the decision made by an agency as opposed to a company, as 
well as to other factors such as differences in scope, political pressures or cultural differences 
between the various organisations.  
 
Divergences in HTA decision-making processes, as well as internal decision-making systems, 
are consistent with the findings from the study with regulatory authorities and pharmaceutical 
companies (Chapter 3). It should be noted that differences in processes are not generally an 
issue and each method has its advantages, such as speed for individual decision making and 
inclusiveness as well as objectivity for group (majority or consensus) decision making. These 
differences nevertheless pose potential challenges faced by regulatory authorities and HTA 
agencies in trying to align practices and certain evidentiary requirements during the 
regulatory review and HTA recommendation processes. However, if attained, such alignment, 
both within and across regulatory authorities and HTA agencies, could increase decision 
consistency as well as enable potential reliance by one agency on the assessment of data by 
another (McAuslane et al., 2016).  
 
Decision-making frameworks and practices 
Secondly, the study evaluated the use of frameworks to structure the decision-making 
processes within companies and agencies. It was revealed that the majority of HTA agencies 
and companies have a framework that forms the basis of their decision making, but that is not 
always formally defined and codified, particularly within companies. Nevertheless, most 
agencies and companies with formal frameworks have incorporated the majority of the ten 
QDMPs. This is consistent with the results from the regulatory questionnaire (Chapter 3).  
 
The QDMP that was least incorporated into company and HTA agency frameworks were 
QDMPs 3 (assign values and relative importance to decision criteria) and 4 (evaluate both 
internal and external influences/biases). This is also in line with the results of the previously 
reported regulatory study (Chapter 3).  
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Regarding QDMP 3 (assign values and relative importance to decision criteria), this has been 
emphasised through other research on HTA agency decision making, which uncovered that 
the role and implementation of decision criteria during HTA decision making is not always 
clear and should therefore be better defined (Franken et al., 2012). In addition, companies 
need to be more explicit in the criteria used for evidence generation to support their HTA 
dossier, as well as the timing of this process with respect to regulatory-evidence generation, 
where the two processes should be better aligned to increase the probability of favourable 
outcomes. The lack of incorporation of QDMP 4 (evaluate both internal and external 
influences/biases) is consistent with the perception that biases systematically affect decision-
making processes within companies and agencies alike; this will be discussed in more detail 
in the next section. 
 
Finally, QDMP 5 (examine alternative solutions) and QDMP 8 (perform impact analysis of 
the decision) was specifically not incorporated by HTA agencies only, which was also the 
case for the regulatory questionnaire but in this case this was for both the companies and 
regulatory authorities alike. This may be due to the perceived narrow frame of the decision 
where, despite its importance, generation of alternatives and impact analysis may not be 
considered as essential steps when the decision appears to be a yes/no. Nevertheless, those 
QDMPs which were least incorporated into company, regulatory and HTA agency 
frameworks were generally considered relevant and should therefore be implemented by such 
organisations to maximise decision quality.  
 
Biases, challenges and solutions 
Any decision with an element of risk is subject to universal human biases such as over-
optimism and loss aversion (tendency to prefer avoiding losses to acquiring equivalent gain). 
Key, strategic decisions are also susceptible to biases, particularly when the incentives of 
certain individuals are not aligned with the rest of the organisation. Consequently, the 
different types of cognitive biases that occur during decision making were also investigated. 
Indeed, almost all the companies and HTA agencies perceived that decision making within 
their organisation was influenced by biases. The type of bias, nevertheless, varied according 
to organisation type.  
 
For companies, the results were mixed, but in general, companies perceived a higher 
influence of biases on their decision making compared to agencies, which again was similar 
to regulatory department results (Chapter 3). Action-oriented bias (e.g., overconfidence or 
intuition leading individuals to take action less thoughtfully) was seen as most influential for 
HTA agencies, compared to stability bias (creating a tendency towards inertia in the presence 
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of uncertainty) within regulatory authorities (Chapter 3). In general, interest bias (arising in 
the presence of conflicting incentives) was perceived as the least influential by both HTA and 
also regulatory authorities (Chapter 3), which may be due to strict conflict of interest rules 
within the various committees at both organisations.  
 
Companies and agencies identified challenges and potential solutions to quality decision 
making. Firstly, pharmaceutical companies highlighted the misalignment of international 
HTA requirements.  Company respondents also emphasised the need for internal alignment, 
where HTA company functions are not always fully integrated with regulatory functions in 
the evidence-generation processes and are therefore not consistently involved in decision 
making during medicines development, as described previously by McAuslane and colleagues 
(2016). As a result, the company submission may not incorporate the necessary evidence to 
support an HTA dossier in addition to regulatory approval.  Potential solutions to these 
challenges would be to incentivise the alignment of internal systems within companies during 
medicines development through improved methodologies for decision making and to promote 
external harmonisation of the HTA environment through various international initiatives, such 
as early scientific advice (EUnetHTA, 2017). 
 
In addition, barriers for decision making identified by HTA agencies centred on the 
assessment of data rather than on decision making per se, highlighting the current focus on 
the generation of good-quality information rather than on how decisions should be made 
around that information (Cole et al., 2016). Here, focused education, training and capacity 
building (such as through creation of teams focusing on decision quality) were highlighted by 
companies and HTA agencies to develop internal decision-making capabilities.  
 
Decision-making assessments 
The only way organisations can learn how to make better decisions is by first evaluating the 
quality of their decision making (Kahneman, 2011). Consequently, companies and agencies 
were asked whether and how decision making should be measured. The majority of company 
departments and HTA agencies believe that the quality of decision-making processes can and 
should be measured and this was also the case regarding the perceptions of company 
regulatory departments and regulatory authorities (Chapter 3).  Respondents suggested 
internal assessments of decision transparency and structure, as well as external benchmarking 
as possible areas of assessment in their decision making. 
 
Nevertheless, despite this belief that measuring decision making is key, the majority of 
organisations do not currently perform such assessments and if they do perform them, it is 
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primarily to assess outcomes rather than process. Consequently, more effort is needed to 
increase the awareness of assessing and improving the quality of the process to increase the 
probability of good outcomes. 
 
Currently it seems that organisations involved in the HTA of medicines focus mainly on the 
data and uncertainty when making decisions but insufficient attention is paid to the 
deliberative decision-making process itself when appraising the information. Although most 
participants recognised the occurrence of biases within their organisation as well as the need 
to improve the quality of their decision-making process, the majority do not currently perform 
any such formal assessments, but believe that it can and should be done. The findings of this 
study demonstrate the relevance of the ten QDMPs for ensuring quality decision making by 
companies, regulatory authorities and HTA agencies. Furthermore, they support the need to 
implement formal decision-making frameworks within organisations and to evaluate the 
practical implementation of the QDMPs throughout medicines development, regulatory 
review and health technology assessment. This could be achieved by formally evaluating the 
quality decision-making process within companies and regulatory and HTA agencies using 
the appropriate available techniques, as discussed in the next chapter. Such research could 
help increase awareness of the importance of quality decision making as well as uncover 
areas for improvement within companies and agencies in order to promote consistency and 
transparency to be built into the critical decisions during the lifecycle of medicines. Finally, 
such research would aim to improve internal as well as external decision-making 
accountability to ultimately ensure that the public understand and trust the decisions made by 
companies and agencies. 
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SUMMARY 
• Currently, pharmaceutical companies and health technology assessment (HTA) 
agencies concentrate on evidence, but studies have shown that it is not always clear 
how decisions, which require human judgment and interpretation, are made around 
the data to support the reimbursement of new medicines 
• The aims of this study were to determine the current decision-making practices and 
methodologies for structuring and measuring the quality of decision making and the 
barriers and solutions for making quality decisions within pharmaceutical companies 
and HTA agencies 
• Two analogous questionnaires were developed for use in this study 
• Sixteen agencies and 24 companies were asked to complete the questionnaire, 
assessing the company decision making for evidence generation to support an HTA 
dossier for new medicines and the HTA agency appraisal decision-making process to 
recommend, restrict or reject the reimbursement of new medicines 
• Responses were obtained from 11 companies (50% response rate) and 11 HTA 
agencies (69%) 
• Some similarities were identified between the decision-making processes of 
companies and agencies, such as the use of committees, having a primarily mixed 
(qualitative/quantitative) internal decision-making system, as well as the lack of 
systematic assessments of quality decision making and the relatively infrequent use of 
formal decision-making frameworks 
• Nevertheless, the results indicate differences as companies and agencies use diverse 
processes to arrive at the final decision either through consensus, majority vote or an 
individual making the decision 
• The majority of companies and agencies believe that the quality of decision making 
can and should be measured; moreover, organisations considered the occurrence of 
biases within their organisation as pertinent 
• Finally, almost all the participants felt that there was room for improvement for their 
organisation’s quality of decision making 
• These findings are consistent with a published study on regulatory processes and 
support the need for more consistent and predictable decision-making processes 
during the lifecycle of medicines 
• This could be achieved through capacity building, systematically evaluating the 
quality of decision-making and encouraging utilisation of formal decision-making 
frameworks within companies and agencies. 
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CHAPTER 5 
 
 
 
 
 
 
 
 
Systematic Review of Techniques for Evaluating the 
Ten Quality Decision-Making Practices (QDMPs) 
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INTRODUCTION 
The literature on decision making stretches back over several centuries and encompasses a 
wide range of academic disciplines—from philosophy and history to mathematics (Buchanan 
and O'Connell, 2006). More recently, the science and art of decision making have been 
established regarding the psychology of judgment, decision-making styles, as well as 
behavioural economics to enable quality decision making (Thaler and Sustein, 2009; Lovallo 
and Sibony, 2010; Kahneman, 2011).  
 
However, research on decision making to enable a quality process during medicines 
development, regulatory review and health technology assessment (HTA) is less well-
articulated and it is not certain how it is being applied by organisations and individuals in 
companies and agencies. This may be because there is limited awareness regarding the 
science of decision making in this area, as well as limited training and education (Chapters 3 
and 4). In addition, the current frameworks utilised by pharmaceutical companies, regulatory 
authorities and HTA agencies do not often account for the subjective elements, such as 
behaviours and influences that affect the process with which individuals and organisations 
arrive at the final decision. 
 
In order to address this gap, a previous review of recent research on decision making has 
resulted in the development of ten QDMPs to enable quality decision making. These QDMPs 
were considered as relevant best practices by pharmaceutical companies, regulatory 
authorities and HTA agencies for incorporation into decision-making frameworks (Chapter 3 
and 4). Moreover, the key frameworks used during medicines development, particularly in the 
area of benefit-risk assessment (Leong et al., 2015), as well as the science of decision making 
(Matheson and Matheson, 1998; Hammond et al., 1999; Blenko et al., 2010; SDG, 2011) are 
underpinned by this set of holistic practices.  
 
Routine assessment of the quality of the decision-making processes (as opposed to just 
measuring outcomes) has been recognised as key for identifying areas of strength and 
weakness across the best practices in order to provide a basis for improvement to ultimately 
increase the productivity in decision making (Kahneman, 2011). This literature review aims 
to identify current techniques, including tools, questionnaires, surveys as well as studies that 
measure the quality of the decision-making process within regulatory authorities, HTA 
agencies and pharmaceutical companies.  
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The objectives were to  
• Compare the existing techniques 
• Assess their measurement properties 
• Identify research gaps and recommend the way forward 
Of interest would be to identify a technique that is applicable to all three stakeholders in order 
to have a common platform for discussing, sharing and comparing issues in quality decision 
making throughout the lifecycle of medicines. 
 
METHOD 
A systematic review of the literature was undertaken to identify current approaches for 
assessing quality decision making in medicines development, regulatory review and HTA. 
 
Data Sources 
The following databases were searched: MEDLINE (using PubMed), Web of Knowledge, 
Google Scholar and Open Access theses and dissertations. Gray literature was also searched 
using Google. This review was limited to English-language articles and covered the period 
from 1996 to 2017, which reflects the proliferation of publications in this area. 
 
Search Terms 
Initially, an exploratory search was undertaken using basic terms as key words including 
quality, decision making, techniques, instruments, tools, measurement, regulatory review, 
medicines development and HTA. These were also used to search gray literature. The 
following structured search terms were constructed using PubMed guidelines and Medical 
Subject Headings (MeSH) terms and these were used in database searches (Decision* OR 
“decision mak*” OR preference*) AND (“health technology” OR HTA OR reimbursement 
OR coverage OR regulat* OR R&D OR “research and development” OR development OR 
medicine*) AND (agency OR committee OR assessor* OR reviewer* “pharmaceutical 
compan*” OR industry) AND (measur* or metric* OR evaluat* OR assess* OR apprais* OR 
analys*) AND (technique OR checklist OR tool OR scale OR feedback OR survey OR 
questionnaire OR instrument). 
 
Selection Procedure 
The titles and abstracts resulting from this search were screened for relevance and 
duplication. The full text studies were obtained for all titles/abstracts that appeared to meet 
the inclusion/exclusion criteria or where there was any uncertainty. The full text articles were 
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then screened and literature was also obtained by checking the references of the included 
articles as well as by searching the gray literature. 
 
Selection Criteria 
Included were: (1) All articles which identified a technique (tool, instrument, or 
questionnaire) for evaluating quality of decision making applicable to the area of medicines 
development, regulatory, or HTA including generic tools (e.g. where sample or audience were 
unspecified); (2) Techniques evaluating the decision, the decision-making process or key 
aspect(s) of the process and associated preferences, influences and behaviours; (3) Studies 
that assess the performance of the technique by evaluating hypothetical or real (historical) 
decisions, vignettes, or a reflection of individual style or approach. 
 
Excluded were (1) General discussions on decision making and quality within the area of 
medicines development, review and HTA; (2) Techniques for measuring quality of decision 
making used specifically in disciplines other than medicines development, regulatory review 
and HTA (such as other industries including unrelated health organisations); (3) Frameworks 
for structuring and documenting decision-making processes and for enabling quality to be 
built into decision making. 
 
Data Extraction and Synthesis 
The following extracted information was recorded: title of the technique, decision area (e.g., 
regulatory advisory committee or medicines R&D), study subject (e.g., regulatory authority, 
HTA agency or industry), subject type (organisations or individuals) and method. 
 
Assessment of the Techniques 
In the absence of an alternative evaluation criteria system that captures issues relevant to the 
areas of medicines development, review and HTA assessment, the ten QDMPs were used to 
evaluate the techniques identified in this review to ensure that each technique is evaluating all 
key aspects of quality decision making. The ten QDMPs were developed based on results 
from semi-structured interview with 29 key opinion leaders from regulatory authorities and 
pharmaceutical companies to investigate and identify the important issues that influence 
decision making (Donelan et al., 2015). In addition, the key decision-making frameworks 
(Hammond et al., 1999; Blenko et al., 2010; SDG, 2011) as well as benefit-risk assessment 
methodologies (Leong et al., 2015; Pignatti et al., 2015) are also underpinned by these 
practices. In a subsequent review, these QDMPs were presented to major pharmaceutical 
companies, regulatory authorities and HTA agencies were considered as relevant (Chapters 3 
and 4). 
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In addition, the measurement properties of each technique were assessed in terms of: 
• Theoretical underpinning (development of a technique was based on a well-described 
methodological framework); 
• Psychometric properties (content validity, internal consistency was demonstrated); 
• Psychometric evaluations (reliability, relevance and sensitivity of the tool was 
demonstrated); 
• Demonstrated practicality (the technique was applied to target population through pilot 
studies); 
• Generalisability (the technique can be used across industry, regulatory and HTA); and 
• Applicability (the technique is applicable to evaluating individuals and organisations), 
which were considered as the key properties that need to be considered when evaluating 
such instruments (McDowell, 2006; Streiner et al., 2015). 
 
Secondary Review 
An independent secondary reviewer was involved in the development of the search strategy 
and selection criteria, as well as article selection and data extraction. Secondary screening was 
carried out as follows: Magda Bujar (MB) selected at random 25% of the full text papers (10 
out of 38), which were re-assessed for inclusion/exclusion by the secondary reviewer against 
the criteria. Disagreements were resolved through discussion, where MB and secondary 
reviewer disagreed regarding the inclusion of one paper. This was resolved by refining the 
inclusion criteria to make them more specific. Following this modification, 100% 
concordance was reached regarding the included papers. Secondary reviewer also 
independently carried out data extraction and a small number of disagreements were resolved 
through discussions until full agreement was reached. 
 
RESULTS 
For the purpose of clarity, the key results are presented in three parts: 
• Part I: Selected articles for review 
• Part II: Identified techniques for evaluating quality of decision making 
• Part III: Measurement properties of the techniques. 
 
Part I: Selected Articles for Review 
Of 4,782 records, 785 were removed as duplicates and 3,959 were excluded following 
screening of titles and abstracts. Out of the 38 full text articles identified, 29 articles were 
excluded and an additional four articles were identified from references or gray literature 
(Figure 5.1). A total of 13 articles met the inclusion/exclusion criteria, each describing a 
technique for evaluating quality of decision making and assessing a total sample of 
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approximately 2,500 subjects (individuals, organisations, or medicines). These are 
summarised in Table 5.1 and described in greater detail below. 
 
Figure 5.1 Flow diagram of article selection 
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Table 5.1 Summary characteristics of the 13 techniques for assessing quality decision making listed in descending order of total Quality Decision-
Making Practices (QDMPs) evaluated by the technique 
No. Ref. Title 
Decision 
Area 
Study subject 
Subject 
type 
Method 
QDMPs evaluated 
1 2 3 4 5 6 7 8 9 10 
1 
Matheson D 
& Matheson 
J, 1998 
Organisational IQ test Corporate 
Industry 
(including 
pharm.) 
Org. 
45-item questionnaire assessing nine principles 
for strategic decision making in an organisation 
(N = 100s) 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
2 
Donelan et 
al., 2016 
Quality of Decision Making 
Orientation Scheme (QoDoS) 
instrument 
Medicines 
R&D/Reg. 
Review 
Regulatory 
authority + 
pharm. 
industry 
Org. + Ind. 
Questionnaire with 47 items assessing 
organisational decision making culture and 
approach, as well as individual competence and 
style (N = 76) 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
3 
Mindtools, 
2013 
‘How Good Are Your 
Decision-Making Skills?' 
Questionnaire 
General ND Ind. 
Questionnaire, 'How Good Are Your Decision-
Making Skills?' containing 18 items (N = ND) 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
 
4 
Garbuio et 
al., 2015 
Survey on strategic decision 
making 
Corporate 
Industry 
(including 
pharm.) 
Org. 
Survey (28 items) assessing relationship 
between robustness of analysis, dialogue and 
decision-making effectiveness (N = 634) 
✓ ✓ ✓ ✓ ✓ ✓ 
 
✓ 
 
✓ 
5 
Open 
University, 
2013 
Decision making 
Questionnaire 
General ND Org. + Ind. 
Questionnaire containing 12 items in three areas: 
decision-making process, psychological 
perspective and the role of social influences (N 
= ND) 
✓ 
 
✓ ✓ ✓ ✓ ✓ ✓ 
  
6 
Fischer et al., 
2011 
A structured tool to analyse 
coverage decision making 
HTA HTA agencies Med. 
Ten indicators for a structured empirical 
comparison of coverage decisions with 
corresponding ordinal rankings (N = 6) 
✓ ✓ ✓ 
    
✓ ✓ ✓ 
7 Wood, 2012 
Study exploring individual 
differences in decision-
making styles as predictors of 
good decision making 
General 
University 
students 
Ind. 
Three-part study: 1. General Decision-Making 
Style measure (25 items)  
2. The BFI personality test (50 items) 3. Peer 
ratings of decision-making quality (26 items) (N 
= 315) 
✓ 
 
✓ ✓ ✓ ✓ ✓ 
   
8 
Blenko et al., 
2010 
Decision and organisational 
scorecard 
General ND Org. 
Two web-based questionnaires, with 4 and 10 
items respectively assessing decision 
effectiveness and organisational drivers (N = 
1,065) 
✓ ✓ 
       
✓ 
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(continued) Table 5.1 Summary characteristics of the 13 techniques for assessing quality decision making listed in descending order of total Quality 
Decision-Making Practices (QDMPs) evaluated by the technique 
No. Ref. Title 
Decision 
Area 
Study subject 
Subject 
type 
Method 
QDMPs evaluated 
1 2 3 4 5 6 7 8 9 10 
9 
Cowlrick et 
al., 2011 
Questionnaire for assessing 
perception of risk through 
phases of medicine R&D 
Medicines 
R&D 
Pharm. 
industry 
Ind. 
Questionnaire with 5 sets of judgment 
statements to assess case studies for 4 medicines 
(N = 52) 
   
✓ 
 
✓ ✓ 
   
10 
McIntyre et 
al., 2012 
Questionnaire for assessing 
how US FDA Advisory 
Committee Members prepare 
and what influences them 
Regulatory 
Advisory 
Committee 
Regulatory 
authority (US 
FDA) 
Ind. 
26-item questionnaire assessing US FDA 
committees' preparatory practices, influencers 
and preferences (N =101) 
   
✓ ✓ 
 
✓ 
   
11 
Marangi et 
al., 2014 
Survey of the Italian 
Medicines Agency (AIFA) 
2013 
Regulatory 
Advisory 
Committee 
Regulatory 
authority 
(AIFA) 
Ind. 
Questionnaire, 'Survey AIFA 2013' consisting of 
17 questions, 4 regarding participant information 
and 13 assessing influences on AIFA 
committees (N = 72) 
   
✓ ✓ 
 
✓ 
   
12 
Beyer et al., 
2015 
A field study using the 
Domain Specific Risk Taking 
(DOSPERT) scale and the 
Big Five Jackson Inventory 
(BFI) scale 
Reg. review 
Regulatory 
authority (EU) 
Ind. 
Three-part questionnaire:  
1. Demographic data and DOSPERT scale; 2. 
Medicine case Study;  
3. The BFI personality test consisting of 44 
items to assess risk perceptions of assessors (N = 
75) 
   
✓ 
 
✓ 
    
13 
Salek et al. 
2012 
Scorecards to assess the 
quality of a regulatory 
submission and its review 
Reg. 
submission 
and review 
Reg. 
authorities + 
pharm. 
industry 
Med. 
Two scorecards containing 50 items grouped into 
7 domains: application format, content of the 
dossier, labelling, scientific advice, conduct of the 
review, communication and overall assessment (N 
= 4) 
✓ 
         
Where: US FDA = Food and Drug Administration, HTA = health technology assessment; ind.=individual; med. = medicine; N = sample subject size used in testing; ND = not defined; 
org.=organisation; pharm.= pharmaceutical; QDMP = quality decision-making practice; reg. = regulatory; R&D = research and development;  ✓ = QDMP evaluated by the technique; the 
QDMPs are: 1=Have a systematic, structured approach to aid decision making (consistent, predictable and timely); 2=Assign clear roles and responsibilities (decision makers, advisors, 
contributors); 3=Assign values and relative importance to decision criteria; 4=Evaluate both internal and external influences/biases; 5=Examine alternative solutions; 6=Consider uncertainty; 
7=Re-evaluate as new information becomes available; 8=Perform impact analysis of decision; 9=Ensure transparency and provide a record trail; 10=Effectively communicate the basis of the 
decision
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Part II: Identified Techniques for Evaluating Quality of Decision Making 
Out of the 13 techniques identified in this review, seven were developed specifically to assess 
decision making in the area of medicines development, regulatory review or HTA; two 
examined corporate decision making and four were regarding general decision making. An 
examination of subject type demonstrated that the largest proportion of the techniques (6, 
46%) assessed decision making of individuals, followed by the perception of individuals 
regarding the decision making of the organisation (3, 23%) and then the decision making 
regarding the medicine itself (2, 15%). Only two techniques (15%) evaluated both the 
decision making of individuals and organisations. 
 
Regarding the ability for each technique to evaluate the ten QDMPs, the 13 techniques 
assessed a median of six QDMPs, with a mode of three QDMPs and only two techniques 
accounted for all ten QDMPs. An examination of the two most commonly assessed practices 
indicated that ten techniques assessed QDMP 4 (Evaluate both internal and external 
influences/biases), whereas nine techniques evaluated QDMP 1 (Have a systematic, 
structured approach to aid decision making). The two practices that were least evaluated were 
QDMP 9 (Ensure transparency and provide a record trail) and QDMP 10 (Effectively 
communicate the basis of the decision), with four and five approaches, respectively. 
 
The 13 techniques are listed in Table 5.1 in descending order of total number of QDMPs 
evaluated by the technique, followed by the year of publication. They are then described in 
more detail based on published information. 
 
1. Organisational IQ Test (Matheson and Matheson, 1998) 
This test measures an R&D organisation's adherence to the nine principles of a smart 
organisation: value creation culture, creative alternatives, continual learning, embracing 
uncertainty, outside-in strategic perspective, systems thinking, open information flow, 
alignment and empowerment as well as disciplined decision making. The aim of this test is to 
benchmark “organisational intelligence” (i.e., the strategic decision-making abilities of an 
organisation), identify barriers to decision quality and prioritise the principles an organisation 
must focus on to increase its performance (Matheson and Matheson, 1998). 
 
The nine principles were developed based on previous studies of decision quality and best 
practices, which were conducted in five well-described phases, namely: brief survey to 
identify organisations that exemplified high quality R&D decision making; in depth 
interviews with 22 companies to identify 45 best practices; questionnaire to create statistical 
benchmarks for practices; validation through conformational studies with other companies; 
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and extension of results to develop the principles. Subsequently, the test was developed and it 
consists of 45 questions, with five questions on each of the nine principles (Matheson and 
Matheson, 1998) These 45 questions can be used to evaluate all ten QDMPs from the point of 
view of an organisation. 
 
The tool has now been used to assess approximately a hundred corporations from the point of 
view of thousands of individuals regarding their organisation's decision making and the 
results show that a strong IQ profile correlates positively with the financial performance of 
organisations, thereby demonstrating the applicability of the tool (Matheson and Matheson, 
2011). The sensitivity or reproducibility of the tool has not been described. Although the tool 
evaluates the full spectrum of organisational-level QDMPs, the practices of an individual are 
not evaluated. Furthermore, the test is specific to R&D organisations and possesses 
generalisability to be applied within different departments in companies including the 
pharmaceutical industry, but its design did not involve input from regulatory authorities or 
HTA agencies and consequently, it does not assess the issues specific to those stakeholders. 
 
In summary, the Organisational IQ, which was developed through studies with a range of 
R&D organisations, is a 45-item test that measures corporate decision making across all ten 
QDMPs from an organisational point of view only; it has been assessed in over a hundred 
companies, but it has not been developed or validated within agencies. 
 
2. Quality of Decision Making Orientation Scheme (QoDoS; Donelan et al., 2016) 
QoDoS (see Appendix 1) is a generic instrument for assessing the quality of decision making. 
Its aim is to evaluate the quality of decision making of individuals and organisations in order 
to promote awareness of best practices and biases in decision making. This should facilitate a 
clearer understanding of strengths and areas for improvement and ultimately encourage a 
better decision-making process for both companies and agencies (Donelan et al., 2016). 
 
The tool was developed and validated using a standardised approach with both qualitative and 
quantitative techniques. The qualitative phase involved semi-structured interviews with 29 
key opinion leaders from the pharmaceutical industry (10), regulatory authorities (9) and 
contract research organisations (10) (Donelan et al., 2015). This was followed by content 
validity testing, using a panel of experts for language clarity, completeness, relevance and 
scaling, resulting in a favourable agreement by panel members with an intra-class correlation 
coefficient value of 0.89 (95% confidence interval = 0.56, 0.99). The quantitative phase of 
factor analysis produced a 47-item tool with four domains: Part I = Organisational—
Decision-Making Approach and Decision-Making Culture; Part II = Individual—Decision-
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Making Competence and Decision-Making Style. QoDoS showed high internal consistency 
(n = 120, Cronbach's alpha = 0.89), high reproducibility (n = 20, intra-class correlation = 
0.77) and a mean completion time of ten min (Donelan et al., 2016). Most importantly, 
QoDoS items can be mapped to assess the full spectrum of the ten QDMPs across different 
decision points from both the perspective of an organisation and an individual. 
 
The applicability of the tool in a regulatory authority and pharmaceutical company setting 
was confirmed through a study with 76 participants (50% from regulatory authorities and 
50% from pharmaceutical companies). The findings of this pilot study demonstrate that 
QoDoS has the practicality to identify differences in decision making between individuals and 
their organisation as well as between companies and regulatory authorities across all ten 
QDMPs (Bujar et al., 2016). Moreover, QoDoS possesses strong psychometric properties, is 
easy to understand and can be completed in a short time frame. Nevertheless, the tool needs to 
be further tested in terms of its reliability and relevance (Chapter 6) and sensitivity (outside 
the scope of this study). Moreover, although the initial practicality of QoDoS has been 
demonstrated, it would be of value to carry out in depth studies to further demonstrate the 
practicality of the instrument for assessing QDMPs in specific teams and departments within 
pharmaceutical companies, regulatory authorities and HTA agencies (Chapter 7). 
 
To summarise, the QoDoS is a 47-item test that measures quality decision making across all 
ten QDMPs from an organisational and individual point of view. It was developed through 
studies with the population it was intended for (i.e., both the pharmaceutical industry and 
regulatory authorities); its applicability has been assessed with 76 participants with more 
testing planned in the future. 
 
3.“How Good Are Your Decision-Making Skills?” Questionnaire (Mindtools, 2013) 
The aim of this generic web-based questionnaire was to assess individual decision-making 
skills and practices. It is composed of 18 questions that relate to six essential steps in any 
decision-making process: establishing a positive decision-making environment, generating 
potential solutions, evaluating the solutions, deciding, checking the decision and 
communicating and implementing (Mindtools, 2013). 
 
The method used in the development or validation was not published, nor any results that 
were collected from participants. Overall, this questionnaire assesses nine QDMPs from the 
point of view of an individual, but nevertheless does not assess QDMP 10 regarding 
communication of the decision and it does not assess the personal perceptions regarding 
organisational decision making. This tool possesses generalisability to other decision areas 
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and subjects, but it lacks published data on its method used in development or validity testing 
to determine its practicality and robustness. 
 
In summary, this questionnaire is a generic 18-item test that measures decision making across 
nine QDMPs from an individual point of view only; its origin and testing were not described. 
 
4. Survey on Strategic Decision Making (Garbuio et al., 2015) 
The aim of this survey was to assess strategic decision making amongst international 
companies, including the pharmaceutical industry. It was used in a study to test three 
hypotheses regarding the effect of two dimensions, namely the analysis performed on the 
decision and strategic conversations about the decision (coined “disinterested dialogue”) on 
decision-making effectiveness (Garbuio et al., 2015). 
 
The development of the survey was based on a literature review, previous scholarly works in 
this area (Dean and Sharfman, 1996) and interviews with 29 executives from large 
corporations. The survey assesses an individual's perception of decision making and contains 
a total of 28 questions focusing on a key strategic decision made in the past five years: eight 
on demographic characteristics of the respondents, six variables measuring robustness of 
analysis performed, six on disinterested dialogue, four on strategic decision effectiveness and 
four control variables. The Cronbach's alpha coefficient for strategic decision effectiveness, 
robustness of analysis and disinterested dialogue were 0.886, 0.793 and 0.716, respectively, 
which indicates the survey was appropriately formulated and suitable for the analysis 
(Garbuio et al., 2015). These survey items can be mapped to eight  out of the ten QDMPs 
from the point of view of an individual, mainly regarding “Structure and Approach” (QDMP 
1, 2), “Evaluation” (QDMPs 3, 4, 5 and 6), “Impact” (QDMP 8) as well as communication of 
the decision (QDMP 10). It nevertheless does not assess QDMP 7 regarding re-evaluating the 
decision with new information, as well as QDMPs 9 regarding ensuring transparency and 
providing a record trail. 
 
The survey was completed by 634 executives from a global range of industries, regions and 
functional specialties. The response rate was 45%, which may be due to the lengthy method 
used in the study. Exploratory and confirmatory factor analysis was used to test the 
hypotheses (Garbuio et al., 2015). Overall, this survey provided a good overview of some of 
the perceptions of organisational-level QDMPs in companies. Nevertheless, the survey does 
not evaluate two of the QDMPs and it does not assess the individual level decision-making 
practices, which could have provided further key insights regarding decision making in 
companies. The survey possesses generalisability to be used in various teams and departments 
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in pharmaceutical companies, but would need to be validated further in terms of its sensitivity 
and reproducibility. Nevertheless, it is not appropriate for use in regulatory authorities and 
HTA agencies due to the specific nature of the technique. 
 
To summarise, this technique is a 28-item survey that assesses corporate strategic decision 
making from the point of view of an organisation. Consequently, it was developed through 
studies with companies only (some of which were pharmaceutical) and subsequently tested 
with 634 subjects across eight QDMPs; it is not relevant to agencies. 
 
5. Open University Decision-Making Questionnaire (Open University, 2013) 
This test was administered as part of a postgraduate course in Business at the Open 
University, UK. The aim of the questionnaire was to help an individual develop greater 
insight into their personal decision-making processes (Open University, 2013).  
 
The development or testing of the tool was not published. The questionnaire is composed of 
12 questions assessing decision making in a recent major decision concentrating on three 
areas: formal rational decision-making process; psychological perspective and focus on the 
tendency to rely on “heuristics” (i.e., subjective judgments); and the role of social influences 
on decision making. The 12 questions can be mapped to seven out of the ten QDMPs from the 
point of view of an individual (though a small number of questions are applicable to 
organisations too), excluding QDMP 2 regarding roles and responsibilities and QDMPs 9 and 
10 regarding transparency and communication. 
 
In summary, this technique is a 12-item questionnaire that assesses decision making from the 
point of view of an individual or an organisation. Due to its generic nature, it may be 
applicable to companies and agencies alike, though this would require practicality testing and 
validation. Nevertheless, the development and testing of the tool were not described and the 
questionnaire assessed seven out of ten QDMPs. 
 
6. A Structured Tool to Analyse Coverage Decisions (Fischer et al., 2011) 
This study presents a structured tool that aims to analyse coverage decision-making processes 
and drivers. Its purpose was to compare country-specific reimbursement systems to inform a 
number of stakeholder including HTA agencies, manufacturers, policy-makers, patients and 
the public (Fischer et al., 2011).  
 
The tool was developed based on the published conceptual framework of Rogowski et al. 
(2008) that identified seven key components in deciding on the reimbursement of a new 
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technology. Fifteen semi-structured interviews were conducted to apply this framework to 
specific case studies in the area of cancer prevention with participants from decision-making 
institutions from Austria, Sweden and Lithuania; data were further validated with publicly 
available documentation. From the case studies, the structured scheme describing the 
components of reimbursement decision processes and a proposal of ordinal rankings were 
deduced and validated through consultations with experts. The developed scheme contains 
eight reimbursement decision-making steps namely: trigger; participation, publication, 
assessment, appraisal, reimbursement, management and impact (Fischer et al., 2011). Overall, 
the tool evaluates six of the QDMPs covering all practices relating to “Structure and 
approach,” “Impact,” and “Transparency and Communication,” but only one QDMP 
regarding “Evaluation,” namely QDMP 3 (assign values and relative importance to decision 
criteria). 
 
This method was applied to case scenarios with six medicines and it generated a scheme for 
structured and consistent comparison of a large variety of procedural aspects of 
reimbursement decision processes. The study met its purpose and a robust method was used 
to develop the scheme. Nevertheless, the semi-structured phone interviews were considered 
time consuming and the scope for interpretation of questions during interviews was wide. 
Further validation of the structured scheme and indicators as well as development of a web-
based tool for more efficient large-scale empirical studies is still needed (Fischer et al., 2011). 
Moreover, the scheme does not explicitly assess QDMPs relating to evaluation, which if 
incorporated, would perhaps give more rationale for some of the heterogeneity seen in the 
decision outcomes. 
 
In summary, this technique, which was designed based on a conceptual framework, is a 
structured tool to analyse coverage decision making of medicines using ten indicators across 
six QDMPs. Nevertheless, the tool is specific to evaluating certain decisions regarding 
technologies in HTA agencies and was not designed to assess general organisational or 
individual practices or decision making within companies and regulatory authorities. 
 
7. Study Exploring Individual Differences in Decision-Making Styles as Predictors of Good 
Decision Making (Wood, 2012) 
The aim of this study was to examine the relationship between decision-making styles and 
subjective self- and peer-ratings of decision quality. The second purpose of the study was to 
evaluate the incremental validity of decision styles and personality traits for predicting 
decision quality (Wood, 2012). 
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The method involved three phases. Decision style was measured using Scott and Bruce 
(1995) General Decision-Making Style measure; the Big Five Jackson Inventory (BFI) 
personality test (50 items) was conducted using the International Personality Item Pool short 
scales (Goldberg, 1999; Goldberg et al., 2006) and peer ratings of decision-making quality 
were collected using a scale where peers were asked to evaluate their friends' decision making 
by rating their habits in four sections. The first two measures were developed and validated 
previously; the third was created for the purpose of this study through factor analysis and 
psychometric tests for internal consistency. Overall, this technique can be used to assess six 
out of ten QDMPs, including all five QDMPs relating to evaluation, as well as QDMP 1 
regarding having a structured approach. The technique can be used to assess the decision 
making of individuals only, but uniquely, the assessment can be conducted from the point of 
view of the participants as well as the perception of peers regarding the ratees' decision-
making habits. 
 
Three hundred and fifteen target participants from undergraduate courses at a public 
university in the Midwestern United States took part in phases 1 and 2 of the study, using an 
online survey administration and data collection system. In addition, 168 peer raters 
completed phase 3 of the study regarding decision-making habits of the target participants. 
However, the completion time was not specified and there are limitations to the use of the 
peer rating system, as indicated by a relatively low response rate (53% of phase 1 and 2 
participants participated in phase 3). Furthermore, this technique does not assess 
organisational-level QDMPs or individual practices regarding roles and responsibilities, 
decision impact, transparency and communication, as specified by QDMPs 2, 8, 9 and 10, 
respectively. 
 
To summarise, this three-part study, which aimed to assess differences in decision-making 
styles, was designed to be global in nature and consequently it may be applicable to any 
decision areas as well as be used by any subjects. Nevertheless, it assessed only six QDMPs 
and the method would require testing and validation in pharmaceutical companies, regulatory 
authorities and HTA agencies. 
 
8. Decision Effectiveness and Organisational Scorecards (Blenko et al., 2010) 
The aims of the scorecards were to give a high-level assessment of decision making within 
organisations, help identify the most pertinent issues and guide prioritisation of actions on 
specific decisions and broader organisation enablers. The two scorecards represent step 1, 
namely “Score your organisation,” with a sequence of five steps to improve decision making 
(Blenko et al., 2010). 
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The method used in the development of the two scorecards was not published. The decision 
effectiveness scorecard is composed of four items assessing quality, speed, yield and effort of 
the decision making-process. The organisational scorecard has ten items and it is used to 
assess drivers of decision effectiveness in an organisation, namely context, alignment, 
accountability, structure, process, information, tools, skills and capabilities, leadership and 
culture. Overall, the two scorecards look beyond decision making as a marker of an effective 
organisation and consequently assess three out of ten organisational-level QDMPs, namely 
QDMP 1 (structure), 2 (roles and responsibilities) and ten (communication of the decision). 
The scorecards were used to assess 1,065 organisations including large multinational 
corporations, entrepreneurial ventures, research universities and non-profit institutions, 
thereby highlighting the generalisability of this method (Blenko et al., 2010). 
 
To summarise, this two-part scorecard is generic in nature and can be used to assess decision 
making of organisations. Nevertheless, the approach used in the development and validation 
of the scorecards was not described and none of the individual-level QDMPs and only three 
organisational-level practices can be assessed. 
 
9. Questionnaire for Assessing Perception of Risk through Phases of Medicine R&D 
(Cowlrick et al., 2011) 
This questionnaire was designed to assess risk perceptions in the pharmaceutical industry and 
allied healthcare sectors and is analogous to the Beyer regulatory authority study (Beyer et al., 
2015) described later in this chapter. The aim is to investigate go/no-go judgments in 
discovery and medicine development in order to evaluate the influence of personality, 
experience as well as demographic traits on decision making (Cowlrick et al., 2011). 
 
The method consists of a web-based questionnaire where respondents were asked to make 
five sets of judgment within case studies regarding four medicines derived from real 
scenarios. These five judgments were derived from 18 non-discrete steps relating to the 
regulatory requirements as set by the European Medicines Agency (EMA) and the US Food 
and Drug Administration (US FDA) and were related to major key disciplines in medicines 
R&D, namely target selection/ pharmacology; toxicology; biopharmacy and galenics; and 
clinical development/market introduction. In addition, the study assessed to what extent the 
individual judgments given by the respondents were influenced by demographics, experience, 
or their perceived entrepreneurial character. Paradigms of entrepreneurial behaviour were 
selected based on previous research, although the exact process for question design was not 
described (Cowlrick et al., 2011). The completion of the questionnaire takes ~10 min. 
Overall, the tool assesses only three of the ten QDMPs relating to evaluation, namely QDMP 
  
117 
4 (evaluate internal/external influences/biases), 6 (consider uncertainty) and 7 (re-evaluate as 
new information becomes available). Due to the stepwise nature of the cases, this tool offers 
the potential to understand whether individuals re-evaluated their decision making with new 
information, which was not possible in the single step decision study by Beyer et al. (2015). 
 
The questionnaire was completed by 52 participants, a response rate of 62%, which indicated 
moderate acceptability (Cowlrick et al., 2011). The authors did not describe how the method 
used was developed, compared with the Beyer et al. (2015) study in which validated tools 
were used, but nevertheless, this technique was less time intensive. 
 
In summary, this questionnaire was used to assess decision making during medicines R&D 
across three QDMPs from the point of view of an individual only. The design of the 
questionnaire is unknown. Furthermore, the questions are generalisable to other stakeholders, 
whereas the case studies are specific to the pharmaceutical industry and would require major 
modifications and further validation if to be used in regulatory authorities and HTA agencies. 
 
10. Questionnaire for Assessing How US FDA Advisory Committee Members Prepare and 
What Influences Them (McIntyre et al., 2012) 
This qualitative study was carried out to understand preparatory practices, influencers and 
preferences of US FDA advisory committees regarding materials provided by the sponsor and 
the FDA, advisory committee presentations and question and answer (Q&A) sessions. The 
goal was to understand what advisory committee members want from sponsors to enable their 
informed participation in the meetings (McIntyre et al., 2012). 
 
It consisted of a web-based survey composed of 26 questions, with a target completion time 
of ten min. The method used in the design and validation of the questions was not described. 
This survey assesses a limited set of decision-making practices, namely QDMP 4, 5 and 7 
regarding evaluation of influences/biases, examination of alternatives and re-evaluation with 
new information respectively from the point of view of an individual only. 
 
The qualitative questionnaire was administered to 101 current or former members of one of 
the US FDA public biomedical advisory committees. The advantages are a short completion 
time and that the questionnaire captured the relevant individual practices and influences 
regarding evaluation of material for committee meetings (McIntyre et al., 2012). Moreover, 
the survey does not evaluate seven out of the ten individual practices, or what the individuals 
think about the practices of the organisation (in this case, the committee). This is likely due to 
the fact that this was outside the scope of this study. 
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In summary, this 26-item questionnaire was used to assess decision making by the US FDA 
Advisory Committee across three QDMPs from the point of view of an individual only. 
Nevertheless, the development and validation of the questions were not published. Although 
this questionnaire could be adopted for other regulatory bodies, the questions are specific to 
committee decision making and have limited transferability to other regulatory areas as well 
as stakeholders such as industry and HTA agencies. 
 
11. Survey of the Italian Medicines Agency (AIFA) 2013 (Marangi et al., 2014) 
A questionnaire that was analogous to US FDA's was undertaken by AIFA in 2013 to assess 
the influences on agency committees and secretariats' opinions and decisions. This study was 
part of an initiative to enhance a transparency-oriented policy and improve information 
exchange as well as decision making with stakeholders (Marangi et al., 2014). 
 
The study was a web-based questionnaire with a completion time of seven min and a total of 
17 questions assessing the demographics, professional qualifications and committee 
experiences, followed by questions regarding internal and external influences on committees 
and secretariat member opinions. The method used in the design of the questions was not 
described. Similar to the US FDA study, the questions are specific to AIFA advisory 
committee meetings and the survey assesses a narrow set of individual QDMPs relating to 
decision-making evaluation practices only (QDMP 4, 5 and 7). A total of 72 participants from 
AIFA committees, secretariats and subcommission members took part in the study (Marangi 
et al., 2014). This qualitative survey can be completed in a short timeframe, but the 
development of the questions was not described. 
 
To summarise, this 17-item questionnaire was used to assess decision making by the AIFA 
Advisory Committee across three QDMPs from the point of view of an individual only. 
Moreover, the origin of the questionnaire has not been published. Although the questionnaire 
meets its objectives, it is not transferable outside the regulatory advisory committee setting to 
industry and HTA agencies. 
 
12. A Field Study Using the Domain-Specific Risk Taking (DOSPERT) Scale and the Big Five 
Jackson Inventory (BFI) Scale (Beyer et al., 2015) 
This set of tests aimed to assess the influence of risk attitudes and personality traits on clinical 
decision making of expert regulators. The two main objectives of the study were to describe 
the distribution of risk attitudes among medical assessors within EMA and to measure their 
personality traits and cross-domain risk attitudes (Beyer et al., 2015). 
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This study was implemented as a web-based questionnaire and was composed of three well-
defined phases using validated tests; phase 1: demographic data and 30-item DOSPERT scale 
to measure risk appetite; phase 2: medicine case study using mock “clinical dossiers” for 
three medicines and eight rating scales on benefit-risk dimensions; and phase 3: The BFI 44-
item personality test. Ordinal regression models were used to evaluate the relationships 
between the variables regarding risk taking, personality as well as the assessment of benefit 
and risk of a medicine (Beyer et al., 2015). Although the study evaluates the relationship 
between perception of uncertainty and personal influences as defined by QDMP 4 and 6, it 
does not evaluate any of the practices relating to decision making “structure and approach,” 
“impact,” or “transparency and communication” of decision making. Indeed, other individual 
as well as organisational decision-making practices should be explored in order to understand 
the broader context of these findings. 
 
This technique was used to assess 75 assessors from European regulatory authorities. It 
utilises validated methods and it meets its purpose of assessing risk attitudes in medical 
assessors (Beyer et al., 2015). It generalisable to other agencies, but would need to be adapted 
for companies and HTA agencies with some modifications to phase 2 (medicine case study). 
A major drawback of this technique is that it is resource and time intensive for both the 
assessors and researchers. 
 
To summarise, this three-part questionnaire was used to assess decision making of regulatory 
assessors. The development of the study was well-described, but it can only be used to assess 
two out of ten QDMPs and it does not evaluate the perceptions of the individuals regarding 
their organisation. 
 
13. Scorecards to Assess the Quality of a Regulatory Submission and Its Review (Salek et al., 
2012) 
Two scorecards were developed to enable companies to assess the quality of the regulatory 
review and for regulatory authorities to assess the quality of submission relating to a specific 
product. This allows for a unique comparison of the quality of the submission compared to 
review, as well as inter-product, company, or agency cross-evaluations (Salek et al., 2012). 
 
The scorecards were developed through a structured and well-described process of 
conceptualisation (expert discussions; bibliography review), item generation (literature 
review; expert input) and reduction (qualitative reduction; content validation). Each scorecard 
includes more than 50 items that are grouped into seven domains (application format, content, 
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labelling, scientific advice, conduct of the review, communication and overall assessment). 
The two scorecards enable a quantitative assessment of the quality of the information and 
communication specific to dossiers and go beyond just decision making as a marker of quality 
(Salek et al., 2012). As a consequence they evaluate whether a structured approach was taken 
(QDMP 1), but do not evaluate the roles and responsibilities of an individual/organisation 
(QDMP 2) or the quality of individual and organisational decision making as outlined in 
QDMP 3, 4, 5, 6 and 7, which are related to the evaluation practices as well as preferences, or 
QDMP 8, 9 and 10 which assess decision-making transparency and decision communication. 
 
The scorecards were tested by three major regulatory authorities and four international 
pharmaceutical companies based on the same four products. The majority of respondents 
agreed that the scorecards covered all critical factors that affect the quality of the dossier and 
the review. A number of modifications were made following a pilot study, particularly the 
inclusion of definitions for each rating response option, which further added to the robustness 
of the scorecards (Salek et al., 2012). 
 
The high response rate as well as positive feedback indicated their practicality, clarity and 
applicability, whilst the method used was well-described. The scorecards can be used for 
different regulatory procedures and across different teams and can be therefore applied to 
optimise the regulatory authority and company processes. Importantly, this technique 
encourages open internal and external dialogue. Although the scorecards meet their purpose 
of assessing the quality of review and submission, it can be argued that aspects specific to 
decision making, other than having a structured approach (QDMP 1), need to also be 
addressed to ensure that companies and agencies are not only embedding good review and 
submission practices, but are also making quality decisions (Liberti et al., 2013). 
 
In summary, the scorecards can be used to assess the quality of regulatory submission and 
review and were developed using a well-defined framework using input from regulatory 
authorities and companies. Nevertheless, they only assess one QDMP and are outside the 
scope of HTA agencies; a separate set of scorecards would need to be developed and 
validated for this purpose. 
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Part III: Measurement Properties of the Techniques for Evaluating Quality of Decision 
Making 
The 13 techniques were evaluated in terms of their measurement properties, according to six 
key criteria (McDowell, 2006; Streiner et al., 2015), namely theoretical underpinning 
(development technique was based on a well-described methodological framework); 
psychometric properties (development of technique involved psychometric tests, content 
validity and internal consistency); psychometric evaluations (reliability, relevance and 
sensitivity of the tool was demonstrated); demonstrated practicality (the technique was 
applied to target population through pilot studies); generalisability (the technique can be used 
across industry, regulatory and HTA); and applicability (the technique is applicable to 
evaluating individuals and organisations). The techniques were listed in a descending order by 
total number of criteria met, followed by year of publication (Table 5.2). Only five properties 
are shown in Table 5.2, as none of the techniques underwent psychometric evaluations. 
 
Out of the 13 articles, only one met all criteria described in Table 5.2. Eleven (85%) of the 
techniques met at least two criteria, namely demonstrated practicality, followed by theoretical 
underpinning (8, 62%). On the other hand, the criteria that were met by the minority of the 
techniques were generalisability of study subjects (5, 38%); psychometric properties (3, 
23%); and applicability to both assessing individuals and organisations (2, 15%). None of the 
13 techniques met the criteria of psychometric evaluations regarding the demonstration of 
sensitivity/responsiveness (detecting change over time), reliability (producing similar results 
under consistent conditions) and relevance (being practical to the target audience) and were 
consequently not illustrated in Table 5.2. 
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Table 5.2 Measurement properties of the 13 techniques for assessing quality decision making in descending order of total properties met, 
followed by year of publication 
No. Ref. Title 
Theoretical 
underpinning 
Psychometric 
properties 
Demonstrated 
practicality 
Generalisability Applicability 
Development 
technique was based 
on a well described 
methodological 
framework 
Content validity, 
internal consistency 
was demonstrated 
The technique was 
applied to target 
population through 
pilot studies 
The technique can 
be used across 
industry, 
regulatory and 
HTA  
The technique is 
applicable to 
evaluating 
individuals and 
organisations 
1 
Donelan et al., 
2016 
Quality of Decision Making 
Orientation Scheme 
(QoDoS) instrument 
✓ ✓ ✓ ✓ ✓ 
2 Wood, 2012 
Study exploring individual 
differences in decision-
making styles as predictors 
of good decision making 
✓ ✓ ✓ ✓ 
 
3 
Garbuio et al., 
2015 
Survey on strategic decision 
making 
✓ ✓ ✓ 
  
4 
Matheson D & 
Matheson J, 1998 
Organisational IQ test ✓ 
 
✓ 
  
5 
Blenko et al., 
2010 
Decision and Organisational 
Scorecard   
✓ ✓ 
 
6 
Fischer et al., 
2011 
A structured tool to analyse 
coverage decision making 
✓ 
 
✓ 
  
7 
Cowlrick et al., 
2011 
Questionnaire for assessing 
perception of risk through 
phases of medicine R&D 
✓ 
 
✓ 
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(continued) Table 5.2 Measurement properties of the 13 techniques for assessing quality decision making in descending order of total 
properties met, followed by year of publication 
No. Ref. Title 
Theoretical 
underpinning 
Psychometric 
properties 
Demonstrated 
practicality 
Generalisability Applicability 
Development 
technique was based 
on a well described 
methodological 
framework 
Content validity, 
internal consistency 
was demonstrated 
The technique was 
applied to target 
population through 
pilot studies 
The technique can 
be used across 
industry, 
regulatory and 
HTA  
The technique is 
applicable to 
evaluating 
individuals and 
organisations 
8 Salek et al. 2012 
Scorecards to assess the 
quality of a regulatory 
submission and its review 
✓ 
 
✓ 
  
9 
Open University, 
2013 
Decision making 
Questionnaire    
✓ ✓ 
10 Beyer et al., 2015 
A field study using the 
Domain Specific Risk 
Taking (DOSPERT) scale 
and the Big Five Jackson 
Inventory (BFI) scale 
✓ 
 
✓ 
  
11 
McIntyre et al., 
2012 
Questionnaire for assessing 
how US FDA Advisory 
Committee Members 
Prepare and What 
Influences Them 
  
✓ 
  
12 Mindtools, 2013 
‘How Good Are Your 
Decision-Making Skills?' 
Questionnaire 
   
✓ 
 
13 
Marangi et al., 
2014 
Survey of the Italian 
Medicines Agency (AIFA) 
2013 
  
✓ 
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DISCUSSION 
This is the first literature review that has identified techniques for evaluating the quality of the 
decision-making process in medicines development, regulatory review and HTA. The 
objectives were to compare the existing techniques, assess their properties, identify research 
gaps and recommend the next steps. This literature review has demonstrated that the area of 
quality decision making has been explored to a certain extent during the medicines research 
and development, but in a fragmented way, where studies have been independent, few have 
been replicated and there is no overarching mutually agreed framework for quality decision 
making. 
 
This is consistent with previous research which has identified that the majority of 
pharmaceutical companies,  regulatory authorities and HTA agencies do not have formal 
assessments in place to periodically measure the quality of their decision making (Chapter 3 
and 4) and this could be partially explained by the fact that very few appropriate techniques 
exist to enable this to be done. Nevertheless, both of these stakeholders believe that such 
measurements of quality decision making would be possible and would improve practices for 
individuals and organisations, which could be achieved by utilising the best techniques 
currently available (Chapter 3 and 4). Consequently, there is a need to identify a technique 
that is relevant, robust and can be applied to pharmaceutical companies, regulatory authorities 
and HTA agencies. 
 
It should be noted that most of the techniques are suitably robust to be used in the area they 
were created for and therefore should be utilised for their specific purposes despite not having 
the applicability across all three stakeholders. Nevertheless, an advantage of having a tool 
valid across all three stakeholders would be the ability to discuss, share and compare 
challenges in decision making using a common terminology. Already companies, regulatory 
and HTA agencies have been collaborating regarding topics such as parallel scientific advice 
(EMA, 2016), real world evidence generation as well as parallel regulatory and HTA reviews 
(McAuslane et al., 2016) and it would be of interest to align best practices in decision making 
across the three groups. 
 
Key Trends and Features of Existing Techniques 
This review identified 13 techniques for evaluating the quality of decision-making process in 
medicines development, regulatory review and HTA. This is a relatively low number, 
considering the increasing pressure on pharmaceutical companies, regulatory authorities and 
HTA agencies to make the best-quality decisions (Liberti et al., 2013). Moreover, routine 
assessment of the quality of the decision-making process (as opposed to just measuring 
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outcomes) has been recognised as key for improving the productivity of any organisation 
(Kahneman, 2011). 
 
Out of the 13 techniques, 1, the Organisational IQ, was developed in 1998 and 12 were 
published from 2010 onward. This indicates that although some initial work was done early 
on and stands ahead of its time, it is only in more recent years that measuring decision making 
or understanding decision-making styles and approaches has become of interest in this arena. 
The 13 techniques have unique aims as well as strengths and weaknesses based on their origin 
and the methods that were used in their development and testing. Furthermore, they can be 
classified into three groups described below. 
 
Group 1: Seven Specific Research Techniques for Assessing the Quality of the Decision 
Making-Process in Medicines Development, Regulatory Review, or HTA 
An examination of the seven techniques developed specifically to assess decision making in 
the area of medicines development, regulatory review, or HTA demonstrated that a number of 
were developed to meet the needs of a particular organisation, for example to increase 
transparency of regulatory advisory committee meetings within AIFA and US FDA (McIntyre 
et al., 2012; Marangi et al., 2014). Nevertheless, although these two surveys are practical for 
their purpose and are characterised by low resource intensity, their design was not described 
and their latitude for generalisability and measurement against the QDMPs is limited due to 
their specific scope. 
 
Other techniques, as exemplified by the work of Beyer et al. (2015) and Cowlrick et al. 
(2011) were developed as research tools to measure the effect of risk attitudes and personality 
traits on decision making regarding medicines development and review. These studies 
developed and tested a number of interesting hypotheses, but are resource intensive and are 
limited to the specific decision area as well as to the subjects they were designed to assess. 
Finally, a number of techniques evaluate more than just decision making as a marker of 
quality, such as the “Scorecards to Assess the Quality of Regulatory Submission and Review” 
(Salek et al., 2012) and the “Structural tool to analyse coverage decision making” (Fischer et 
al., 2011) and may represent promising techniques to study the general area of quality to 
assess the effectiveness of an organisation or an outcome (Fischer et al., 2011; Salek et al., 
2012). 
 
The last technique in this group “Survey on strategic decision making” (Garbuio et al., 2015) 
looked specifically at corporate decision making, which is applicable to pharmaceutical 
companies (i.e., medicines development). Although the tool was developed based on a well-
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designed methodological framework and demonstrated practicality in companies, it is 
resource intensive and does not possess the generalisability to allow its application to other 
subjects such as regulatory authorities or HTA agencies or to individuals (as opposed to just 
organisations) due to the specific nature of the questions. It is important to note that, all seven 
of these techniques were used primarily for research or as one-off studies, but they have not 
been systematically adopted for use by companies, regulatory authorities or HTA agencies. 
Overall, none of these seven techniques are appropriate to measure decision making quality 
due to low generalisability as well as an inability to measure all ten QDMPs. 
 
Group 2: Four Educational or Consulting Techniques for Assessing the Quality of the 
Decision-Making Process 
Four of the techniques were either developed for educational purposes or by consulting 
groups to assess decision making in general (Blenko et al., 2010; Wood, 2012; Mindtools, 
2013; Open University, 2013). Consequently, although all four possess good generalisability 
to be applied to industry, regulatory authorities and HTA agencies, only one of the techniques 
has published information regarding its design and psychometric properties (Wood, 2012), 
while only two have demonstrated practicality through pilot studies (Blenko et al., 
2010; Wood, 2012). As well as that, only one of the techniques has the applicability to 
measure decision making in both individuals and organisations (Open University, 2013). 
Consequently, these may be useful generic tools for informal assessments of decision making, 
but due to lack of published data regarding their design and measurement properties, as well 
as a lack of applicability to individuals and organisations across the ten QDMPS, these 
techniques lack robustness to formally evaluate quality decision making in companies, 
regulatory authorities and HTA agencies. 
 
Group 3: The Two Most Promising Techniques for Assessing the Quality of the 
Decision-Making Process 
Only two of the 13 techniques evaluated the full spectrum of the ten QDMPs, namely the 
Organisational IQ (Matheson and Matheson, 1998) and QoDoS (see Appendix 1; Donelan et 
al., 2016). Incidentally, the two instruments possess a similar number of items (45 for 
Organisational IQ and 47 for QoDoS) and can therefore be completed in a short timeframe. 
Both techniques were designed based on a well-hypothesised conceptual and well-described 
methodological framework and demonstrated practicality in the target populations, but only 
QoDoS underwent psychometric testing during its design, namely content validity and 
internal consistency. It is nevertheless interesting and significant that these two most 
promising techniques for quality decision making were developed independently, with a 20-
year time gap between them and both resulted in similar key features. 
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The second area of disparity is that the Organisational IQ test, unlike QoDoS, does not assess 
the practices of both individuals and organisations, but just the latter. Although it could be 
argued that this is sufficient as individuals make up an organisation, assessing individuals is 
also key as people tend to score themselves more favourably but be more critical of an 
organisation (Bujar et al., 2016). While this could be a potential sign of bias, areas of 
disparity between the individuals and organisations could also indicate deficiencies in 
practices within companies, agencies and committees, as changes in individuals could 
translate into better organisational practices. Consequently, assessment with QoDoS gives a 
unique perspective of both groups which helps to identify areas for improvement. 
 
In the third area of divergence between the two techniques, the development of the 
Organisational IQ test was based on research among R&D organisations and consequently the 
factors in decision making specific to regulatory authorities and HTA agencies were not 
incorporated into the instrument. Nevertheless, the Organisational IQ test represents a 
practical approach and possibly a gold standard for measuring decision making of 
pharmaceutical and other companies. In contrast, QoDoS was developed specifically to look 
at decision making in the area of medicines development and regulatory review, based on 
interviews with key opinion leaders from agencies and companies. It is therefore a more 
appropriate tool compared with the Organisational IQ test to measure quality decision making 
in pharmaceutical companies, regulatory authorities and HTA agencies and moreover it can 
be applied to identify commonalities and differences between the various stakeholders as well 
as strengths and areas for improvement (Chapters 3 and 4). Most importantly, it can increase 
an awareness of the biases and influences that need to be considered when making decisions, 
as well as the best practices that should be incorporated into a decision-making framework. 
Although the psychometric evaluation of QoDoS has been partially established, further 
testing would seek to demonstrate its practicality through in depth case studies, as described 
in Chapter 7, as well as to assess its reliability and relevance (Chapter 6) and sensitivity 
(outside the scope of this research programme). 
 
Emerging Research Themes 
A secondary outcome of this review has been the identification of research themes and 
hypotheses regarding decision-making preferences and influences. These have been derived 
from the pilot studies conducted using the identified techniques and instruments. A selection 
of the findings is described below. 
 
The research themes identified through the work of Beyer et al. (2015) as well as Cowlrick et 
al. (2011) relate to the impact of personality traits, functional role, education and gender on 
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decision making of individuals within pharmaceutical companies and regulatory authorities. 
Both studies demonstrate that these factors can explain the variability in judgments and 
decision-making techniques within organisations. Moreover, the study by Beyer et al. 
(2015) demonstrated that “conscientiousness” (being thorough and careful) predicted an 
increase in the perception of a medicine's benefits; whereas extraverted disposition was 
predictive of seeing fewer risks and interestingly, male assessors gave higher scores for a 
medicine's benefit ratings than did female assessors. Importantly, these research findings are 
in line with general research on decision making and risk taking (Thaler and Sustein, 
2009; Lovallo and Sibony, 2010; Kahneman, 2011; SDG, 2011) and emphasise that despite 
sound scientific knowledge and experience, individuals within agencies and companies are 
equally prone to biases and reliance on emotional judgments when compared with lay people. 
Moreover, individuals are likely to rate their performance as superior to their organisation 
(Bujar et al., 2016). This has already been emphasised in a number of recent studies, which 
have discussed the role of informal factors in decision making, relating to biases and 
behaviours, which influence the decision-making processes during the delivery of dossiers for 
regulatory submissions as well as during the medicine evaluation process (Tafuri, 2013; Cook 
et al., 2014; Donelan et al., 2015). Furthermore, the occurrence of biases within organisations 
or their influence on decision making was perceived by regulatory authorities and 
pharmaceutical companies as one of the major barriers to ensuring quality decision making. 
This emphasises the importance of implementing a decision-making framework and 
incorporating the ten QDMPs, particularly making decision values, preferences and 
uncertainty more explicit, as suggested by pharmaceutical companies, regulatory authorities 
and HTA agencies in order to ensure that quality decisions are made throughout the life cycle 
of medicines (Chapters 3 and 4). 
 
The two surveys described by McIntyre et al. (2012) and Marangi et al. (2014), which studied 
the decision making of the US FDA and the Italian AIFA Advisory Committees regarding 
how the members prepare for meetings and what influences their decision-making, 
interestingly both concluded a number of similar findings. Those included a diverse range of 
practices utilised by the members as well as potential biases that influence the decision 
making that may subsequently need closer monitoring. Both studies identified that a large 
proportion of individuals attend committee meetings having already decided how to vote. As 
well as that, the members are seldom influenced by external stakeholders such as healthcare 
professionals, patients and sponsors, despite finding their input important. On the other hand, 
the members are frequently influenced by internal committee members, particularly 
colleagues or the committee chair. Both studies suggest that in addition to already minimising 
biases due to conflicts of interest, the agencies should consider measuring the impact of the 
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so-called intellectual bias on decision making during meetings, which may lead the committee 
members believing information which appears more favourable or familiar. Moreover, better 
practices could be achieved by implementing the ten QDMPs into agency processes that 
promote having a structured approach to decision making (QDMP 1), assigning values to 
decision criteria (QDMP 3), evaluating different alternatives (QDMP 5) and new information 
(QDMP 7) and more importantly, evaluating different influences and biases (QDMP 4) to 
ensure that structured decisions are made during the review of medicines. It would be of 
interest to widen the scope of such studies to other regulatory authorities, as well as HTA 
committees in order to address the uncertainty surrounding the process for appraising whether 
or not medicines should be recommended for reimbursement (Calnan et al., 2017). 
 
Finally, the research by Garbuio et al. (2015) assessed decision making amongst international 
companies through a study of 634 outcomes made by executives across multiple industries, 
including the pharmaceutical industry. This study demonstrated first of all that strategic 
decision making is important for decision effectiveness. Secondly, the study found that robust 
analysis of data and strategic conversations and communication during decision making 
around the data (“disinterested dialogue”) have a significant positive relationship with 
decision-making effectiveness. Moreover, the findings demonstrated that the strategic 
conversations have in fact more impact on decision effectiveness than analysis of data. This is 
consistent with previous research in this area, such as that by Westley (1990) where managers 
were interviewed regarding challenges on strategic making; for example the difficulties in not 
being included in strategic meetings but being given lengthy reports instead, as expressed by 
one of the interviewees: “just looking at the numbers doesn't give me the insights. It does not 
give me to total picture. I don't know how they (executives) are interpreting those numbers.” 
 
This emphasises the importance of QDMP 10 regarding communication during decision 
making, as well as QDMP 9 to ensure transparency and provide a record trail of the process 
through which the decision was made. Despite its apparent importance, QDMPs 9 and 10 
were the least assessed practices by the 13 decision-making techniques identified in this 
review. Consequently, these practices may require closer evaluation and better incorporation 
into the decision-making practices of individuals and organisations to ensure decision 
effectiveness. 
 
This systematic literature review identified a general paucity of research in the area of 
decision making in medicines development and review, but particularly in the area of HTA 
regarding the development as well as the systematic application of techniques for evaluating 
quality decision making and lack of consensus around a gold standard. 
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This review found 13 techniques that can be used to assess the quality of decision making by 
pharmaceutical companies, regulatory authorities and HTA agencies in order to ultimately 
enable a more consistent and transparent process. Although some of these techniques are 
scientifically sound and have been developed and tested using robust methodologies, the 
majority do not possess generalisability to be applied across companies, regulatory authorities 
and HTA agencies, whereas only a proportion have demonstrated practicality and 
applicability to measure decision making in individuals and organisations against all ten 
QDMPs. Indeed, assessing the quality of decision making using a common technique can 
provide a basis for clear dialogue of issues in decision making within the three stakeholders 
and ultimately build trust and understanding of what issues are common and which are 
specific to the three stakeholders. There is also a need to develop more transparency around 
how some of the existing techniques and instruments were developed, as well as more testing 
and routine application for the most promising techniques. Furthermore, such measurements 
of quality will enable trust, consistency, transparency and timeliness to be built into critical 
decisions in medicines development, regulatory review and HTA. 
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SUMMARY 
• Routine assessment of the quality of the decision-making process (as opposed to just 
measuring outcomes) has been recognised as key for improving the productivity of 
any organisation 
• This systematic review of literature aimed to identify current techniques, including 
tools, questionnaires, surveys as well as studies that measure the quality of the 
decision-making process within regulatory authorities, HTA agencies and 
pharmaceutical companies 
• Major databases were searched in addition to gray literature covering the period from 
1996 to 2017 
• A systematic approach was used using search terms, defined selection procedure and 
criteria and well as extraction of data and a secondary review was carried out to 
validate this 
• Each technique was evaluated according to its ability to assess quality of decision 
making according to the ten QDMPs; the measurement properties of each technique 
were also assessed  
• This systematic literature review identified a general paucity of research in the area of 
decision making in medicines development, regulatory review and HTA 
• Out of the 13 techniques reviewed, two, Organisational IQ and QoDoS, have been 
identified as the most promising, as they assess all ten QDMPs 
• Nevertheless, the Organisational IQ can only be applied to the pharmaceutical 
industry from an organisational point of view, whereas QoDoS has the potential to 
capture the issues of companies and agencies alike, as well as evaluating both 
individuals and their perception of their organisations 
• This could render QoDoS as the most appropriate measure relative to the other 
techniques identified 
• The next steps would be to test the relevance and reliability (Chapter 6) as well as 
sensitivity of QoDoS (not undertaken as part of this research project) and to further 
demonstrate its practicality across the relevant stakeholders (Chapter 7) 
• The review also identified a number of interesting themes, such as the roles of 
personality traits, gender in decision making, as well as the importance of bias 
awareness and dialogue during the decision-making process 
• The overall benefit of systematically assessing the quality of decision making with 
QoDoS is to enable an increased awareness of biases and best practices but also 
provide the ability to measure change over time in order to determine the impact of 
improvement initiative. 
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of the Reliability and Relevance of the 
Quality of Decision-Making Orientation Scheme 
(QoDoS) 
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INTRODUCTION 
In the absence of a validated instrument for measuring quality of the decision-making processes 
throughout the lifecycle of medicines, the Quality of Decision-Making Orientation Scheme 
(QoDoS) was developed using a standardised, established approach for the design and 
evaluation of such measures. QoDoS already possesses certain psychometric properties including 
validity, which refers to the fact that a tool measures what it purports to measure. A number of 
validity aspects of QoDoS have already been demonstrated by Donelan and colleagues (2016), 
namely face validity (instrument assesses desired qualities), content validity (instrument includes a 
representative set of items) and construct validity (the results obtained from the use of a measure 
fit the theoretical foundations from which it is designed) (Trochim, 2006; Streiner et al., 2015). 
In addition, QoDoS is easy to understand and can be completed in a short time frame (Donelan et 
al., 2015; 2016).  The practicality of the tool in a regulatory authority and pharmaceutical 
company setting was confirmed through a study with 76 participants (50% from regulatory 
authorities and 50% from pharmaceutical companies). The findings of this pilot study as well as 
the results of a recent literature review (Chapter 5) demonstrate that QoDoS is the most promising 
instrument for evaluating quality of the decision-making process during medicines research, 
development and assessment, identifying differences between stakeholders and raising awareness 
of the issues in quality decision making across individuals and within organisations. The challenge 
is how to ensure that QoDoS, in addition to the above described capabilities, produces reliable 
results. 
 
The relevance of the instrument can be evaluated by applying cognitive debriefing, a technique of 
actively testing the tool among representatives of the target population. The aim will be to 
determine the perception of the participants regarding the relevance, language clarity and 
completeness of the QoDoS items (Brod et al., 2009; Streiner et al., 2015). Reliability, on the 
other hand, reflects the scale’s ability to differentiate among participants, despite measurement 
error. It can be demonstrated in two ways, firstly through internal consistency, based on a single 
administration of the measure, which represents the average of the correlations among all the 
items in the measure (Streiner et al., 2015). Cronbach’s alpha determinations were already used to 
measure this by Donelan and colleagues (2016) and QoDoS showed high internal consistency (n 
= 120, Cronbach’s alpha = 0.89), which will be re-examined through this study. Secondly, 
where an assessment instrument is used over time, reliability can be determined by the 
reproducibility of the scores on different occasions. This can be demonstrated with test-retest 
reliability by evaluating whether an instrument yields the same scores over time with multiple 
administrations, assuming subject stability (Streiner et al., 2015), namely that the decision-
making practices of the individuals and the perception of their organisation has not changed 
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The aim of this study was to further test the psychometric properties of the QoDoS tool with 
the target audience, namely pharmaceutical companies, regulatory authorities and health 
technology assessment (HTA) agencies. The objectives across the three stakeholders were to: 
• Confirm the internal consistency of the scores for QoDoS individual and 
organisational parts of the scale; and the overall scale score 
• Assess the test-retest reliability of QoDoS items; the scores for the QoDoS individual 
and organisational parts of the scale; and the overall scale score 
• Apply cognitive debriefing to evaluate the relevance, language clarity and 
completeness of QoDoS items; the clarity of the scaling as well as spontaneity 
responding to the questionnaire. 
 
METHOD 
Design of the study 
This study was designed as a longitudinal study with participants assessed on two different 
occasions, firstly at baseline (‘test 1’) and then seven days after initial application (‘test 2’). A 
period of seven days has been recommended to ensure that participants do not remember their 
responses following the first administration of such a test. The aim is therefore to minimise 
‘confounding factors’ (i.e. third variables) that may impact the retest, yet on the other hand, to 
ensure that the condition of the participants should have remained stable (Paiva et al., 2014). 
In addition, internal consistency of the scores was determined for both ‘test 1’ and ‘test 2’ and 
relevance of the questionnaire was evaluated for ‘test 1’. 
 
Assessment tool 
This study utilised the Quality of Decision-Making Orientation Scheme (QoDoS) (See 
Appendix 1). The 47-item QoDoS has two parts, where ‘Part 1’ relates to the ‘Organisation’, 
which has two domains (‘Approach’, items 1-12; and ‘Culture’, items 13-23) and ‘Part 2’ 
relates to the ‘Individual’ with two domains (‘Competence’, items 24-37; and ‘Style’, items 
38-47). As many decisions are made by individuals every day, the participants were asked to 
complete the instrument relating to their views on their personal and their organisation's 
decision-making processes for major strategic choices within their organisation. 
 
The 47 QoDoS items were rated as either favourable or unfavourable using an expert panel 
(Table 6.1); for example, item 2 ‘My organisation’s decision making is transparent’ 
represents a favourable practice, whereas item 13 ‘My organisation has suffered a negative 
outcome due to slow decision making’ represents unfavourable practice. Based on this, the 
Likert scale response options were quantified by assigning scores to each of the response 
  
135 
scale. For QoDoS items considered as favourable practice, the following scores were assigned 
where ‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For 
QoDoS items considered as unfavourable practice, the reverse scores were assigned where 
‘Not at all’ = 4, ‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0 (Table 6.1). In 
addition, four background questions were used to collect data on gender, job title, 
professional experience and organisation type. 
  
In addition, respondents for ‘test 1’ were asked to complete five questions to assess the 
following properties: relevance, where each item should reflect an aspect of importance 
regarding decision making to the target population; language clarity, where sentences should 
be clear, understandable, straightforward and simple; scaling, where the format of the 
categories must be clear and fit with the items and the construct; comprehensiveness to ensure 
that no items are believed to be missing or as seen as repetitive and spontaneity to ensure that 
QoDoS can be completed efficiently without prompting or rethink, thereby maximising 
response rate and minimising errors or undesirable response behaviour. The following 
questions were developed for the purpose of this study (Brod et al., 2009; Streiner et al., 2015): 
o Question 1: Did you find the QoDoS items relevant? (yes/no) If no please 
specify item number. 
o Question 2: Did you find the QoDoS items easy to understand? (yes/no) If no 
please specify item number. 
o Question 3: Did you find the response options easy to understand? (yes/no) If 
no please specify. 
o Question 4: Were you able to respond to the QoDoS spontaneously? (yes/no)  
o Question 5: Any items that you believe should be deleted or added (yes/no) If 
yes please specify. 
 
Table 6.1 Quality of Decision-Making Orientation Scheme (QoDoS) items assigned as 
either favourable or unfavourable practice 
Assignment QoDoS item number 
Favourable 
practice 
1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 
34, 35, 37 
Unfavourable 
practice 
5, 13, 14, 15, 16, 17, 18, 19, 20, 21, 36, 38, 39, 40, 41, 42, 43, 45, 46, 47 
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Study participants 
The focus groups were organised as part of an international workshop on quality decision 
making (CIRS, 2017). The study participants were recruited based on experience using 
purposive sampling, from those holding senior positions having at least five years of 
experience in a managerial position within major international pharmaceutical companies, 
regulatory authorities, HTA agencies as well as relevant academic institutions. A sample size 
of at least 30 individuals for ‘test 1’ and ‘test 2’ was required (Paiva et al., 2014).  
 
Study procedure 
Participants were invited in May 2017, with the study planned to take place in June 2017. 
Prior to the ‘test 1’, participants were subject to a one-day training course on quality decision 
making in order to ensure that their baseline knowledge of decision making is the same and to 
minimise ‘learning effect’ occurring between the initial and second completion of the 
questionnaire.  As a result, it was assumed that the decision-making practices of the 
individuals and the perception of their organisation has not changed and therefore that the 
participants’ circumstances are stable. Following completion of the first assessment, 
participants received a second copy of the QoDoS with a unique identification number, 
contact information and a note with the completion date indicated (seven days from the initial 
assessment). They were also informed that they would receive a reminder for the follow-up 
questionnaire. On the sixth day following their initial assessment the participants were sent a 
reminder email regarding the completion of the retest the following day; on the seventh day, 
they were sent an electronic copy of the QoDoS for completion. All the respondents who 
completed ‘tests 1 and 2’ within a seven- and eight-day interval were included in the analysis.  
 
Data processing and analysis 
Information was gathered manually into an Excel database for the completed questionnaires 
and subsequently cleaned and coded. The questionnaires were paired based on the unique 
identification numbers assigned to each copy of the instrument. The analysis was carried out 
on the 47 QoDoS items using Excel and Statistical Package for the Social Sciences (SPSS) 
version 23. Initially, the responses were plotted as a ‘box-and-whisker’ graph, which indicates 
the 25th and 75th percentile (box), the 5th and 95th percentile (whiskers) as well as the median 
(diamond) in order to explore variance within each item as well as when comparing ‘test 1’ 
with ‘test 2’ (Figure 6.1). Internal consistency of QoDoS was assessed using the Cronbach 
alpha coefficient for the inter-item correlation, where a value of 0.7-0.9 was required based on 
the number of items in the instrument. A value that is too low signifies that some items are 
not representative whereas a value that is too high may reflect redundancy amongst items 
(Streiner et al., 2015). Test-retest reliability was assessed using the Intraclass Correlation 
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Coefficient (ICC), which shows absolute agreement between two scores where a value of 
>0.7 was required. The ICC also accounts for systematic error and it is based on analysis of 
variance in scores (Paiva et al., 2014; Streiner et al., 2015). For the purpose of this study 
where the rater is the same (intra-rater reliability) a ‘two-way mixed effects’ model was 
chosen and the definition of relationship was considered as ‘absolute agreement’ (Koo and Li, 
2016). Responses to the five questions regarding the relevance were analysed using Excel and 
the comments were codified and combined where applicable. Due to confidentiality reasons, 
only aggregated results are shown and no data that indentifies an individual or a specific 
organisation were reported. 
 
Figure 6.1 Guide to interpreting a ‘box-and-whisker’ plot 
 
 
 
 
 
 
 
 
 
RESULTS 
This study focussed on relevance and reliability testing (internal consistency and test-re-test 
reliability) of the QoDoS instrument in the target population, namely individuals involved 
throughout medicines development, regulatory review and reimbursement of medicines. For 
the purpose of clarity, the key results are presented in three parts: 
• Part I – Internal consistency testing 
• Part II – Test-retest reliability 
• Part II – Relevance testing 
 
Characteristics of the study participants 
The initial ‘test 1’ was completed by 44 individuals from 55 contacted (80% response rate), 
where 24 (55%) were from pharmaceutical companies, 12 (27%) from regulatory authorities, 
three (7%) from HTA agencies and five (11%) from a range of relevant academic institutions. 
In terms of gender, 20 (45%) were male, 22 (50%) female and two individuals did not specify 
(5%). The individuals had a median of 21 years of work experience, with a range of five to 38 
years and titles ranging from manager to organisational head and professor in the case of 
Whiskers 
Box 
95th percentile 
5th percentile 
75th percentile 
25th percentile 
50th percentile 
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academia (Table 6.2). The re-test (‘test 2’) was completed by 32 out of the 44 individuals who 
had completed ‘test 1’, resulting in a 73% response rate. In this case, 13 individuals were 
from companies (41%), 11 from regulatory authorities (34%), three (9%) from HTA agencies, 
five (16%) from academia. In terms of gender, 15 were male (47%) and 17 female (53%) with 
a median of 18 years of professional experience ranging from seven to 38 years and titles 
varying from manager to organisational head and professor in the case of academia (Table 
6.2).  
 
Part I – Internal consistency testing 
Variance in QoDoS scores 
Initially, the variance within each item for ‘test 1’ and ‘test 2’ was illustrated with a ‘box-and 
whisker’ plot for the organisational and individual QoDoS parts (Figure 6.2) across all the 
responders. The variance was reported in terms of 5th, 25th, 50th, 75th and 95th percentiles. 
Overall, each item had a considerable variance around the median, generally a difference of 
two points in the 25th and 75th percentile box. 
 
Table 6.2 Demographic characteristics of the study participants for tests 1 and 2 
Test 
Total 
number of 
respondents 
Number of respondents by organisation 
Number of 
respondents by gender 
Pharmaceutical 
companies 
Regulatory 
authorities 
HTA 
agencies 
Academia Male Female 
Not 
specified 
1 44 24 12 3 5 20 22 2 
2 32 13 11 3 5 15 17 0 
 
For ‘test 1’, the organisational items with smallest variance in terms of the length of the 25th 
and 75th percentile box were items 14 (‘My organisation’s culture has resulted in its inability 
to make a decision’), 16 (‘My organisation’s decision making results in making the same 
mistake as in the past’) and 17 (‘My organisation’s decision making is influenced by the 
vested interest of individuals (e.g. conflict of interest)’). The items with the biggest variance 
were 4 (‘My organisation uses a structured approach in its decision making) and 22 (‘My 
organisation effectively communicates the decisions it makes’) according to the largest 
difference between the 5th and 95th percentiles (whiskers). The ‘test 1’ individual items with 
the smallest variance were items 31 (‘I understand the importance of the decisions I make’), 
38 (‘Emotion is part of my decision making’), 40 (‘I have experienced a negative outcome by 
a decision not being made’) and 42 (‘Recent or dramatic events greatly impact my decision 
making’), whereas the largest variance was for item 33 (‘I assign qualitative values to its 
decision-making criteria’). In general, these differences were also reflected in ‘test 2’, 
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although the variance was somehow smaller for a number of items in ‘test 2’ compared to 
‘test 1’ due to smaller sample size. 
 
Figure 6.2 Quality of Decision-Making Orientation Scheme (QoDoS) scores; where whiskers 
indicate 95th and 5th percentile, the 75th and 25th percentile and the white diamond is the 
median 
 
a) Test 1; n = 44 
i) ‘Organisational’ items 1-23 (‘Approach’, items 1-12; and ‘Culture’, items 13-23) 
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ii) Individual’ items 24-47 (‘Competence’, items 24-37; and ‘Style’, items 38-47) 
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(continued) Figure 6.2 Quality of Decision-Making Orientation Scheme scores (QoDoS); 
where whiskers indicate 95th and 5th percentile, the 75th and 25th percentile and the white 
diamond is the median 
 
b) Test 2; n = 32 
i) ‘Organisational’ items 1-23 (‘Approach’, items 1-12; and ‘Culture’, items 13-23) 
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ii) Individual’ items 24-47 (‘Competence’, items 24-37; and ‘Style’, items 38-47) 
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Cronbach Alpha Coefficient 
Internal consistency of the QoDoS scores was assessed in terms of the Cronbach alpha 
coefficient both for the ‘test 1’ and ‘test 2’ across the pooled sample (Table 6.3). The 
assessment was carried out for each of the four QoDoS domains, namely organisational 
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decision-making approach and culture as well as individual decision-making competence and 
style. Cronbach alpha coefficient was greater than 0.7 across all the QoDoS domains for ‘test 
1’ and ‘test 2’, ranging from 0.713 to 0.792., indicating ‘good’ consistency (Streiner et al., 
2015). For the overall score across all 47 items, the coefficient was 0.805 for ‘test 1’ and 
0.861 for ‘test 2’ which is considered as ‘very good’ (Streiner et al., 2015).  
 
Table 6.3 Internal consistency Cronbach’s alpha coefficient for Quality of Decision-
Making Orientation Scheme (QoDoS) domains 
QoDoS domain Test 1 (n=44) Test 2 (n=32) 
Organisational decision-
making approach  (12 items) 
.767 .792 
Organisational decision-
making culture  (11 items) 
.715 .787 
Individual decision-making 
competence (14 items) 
.757 .848 
Individual decision-making 
style (10 items) 
.713 .703 
Overall (47 items) .805 .861 
 
Part II: Test-retest reliability 
The external consistency (reproducibility) of the QoDoS scores for two completions was 
assessed. For ‘Test 2’, 32 individuals returned their responses out of the 44 included in ‘test 
1’ (73%). Interestingly, from the 12 individuals who did not provide responses to the re-test, 
11 were from pharmaceutical companies. ICC estimates and their 95% confident intervals 
were calculated based on absolute agreement, 2-way mixed-effects model. The four QoDoS 
domains showed moderate to strong reproducibility (ICC range 0.626-0.857). The ICC was 
lower for the two individual domains (0.626 for competence and 0.721 for style) compared to 
the two organisational domains (0.857 for approach and 0.821 for culture). The QoDoS had 
an overall ICC of 0.871 (Table 6.4). 
 
Part III: Relevance testing 
Cognitive debriefing was applied to test the relevance of the QoDoS questionnaire. The five 
feedback questions included in ‘test 1’ of the study were completed by 43 out of the 44 
participants, where one individual from a pharmaceutical company did not provide responses 
(Figure 6.3). Overall, 41 out of 43 (95%) of the participants considered the QoDoS items 
relevant, easy to understand and spontaneous to answer based on responses to questions 1, 2 
and 4 respectively. For question 3 regarding the response options, 91% of individuals agreed 
that the response options are easy to understand, whereas 86% of the participants believed 
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QoDoS tool to be complete and that that no additional items should be added or deleted. The 
comments provided by the diverging individuals are summarised in Table 6.5.  
 
Table 6.4 Test-retest reliability of Quality of Decision-Making Orientation Scheme 
(QoDoS) domains with 32 participants 
QoDoS domain ICC 
95% CI 
Significance 
Lower 
Bound 
Upper 
Bound 
Organisational decision-making approach  
(12 items) 
.857 .724 .928 .0001 
Organisational decision-making culture  
(11 items) 
.820 .665 .908 .0001 
Individual decision-making competence 
(14 items) 
.721 .504 .853 .0001 
Individual decision-making style (10 
items) 
.626 .359 .798 .0001 
Overall (47 items) .871 .753 .935 .0001 
 
Figure 6.3 Responses to the five ‘cognitive debriefing’ questions to establish the Quality of 
Decision-Making Orientations Scheme (QoDoS) relevance 
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1. Did you find the 
QoDoS items 
relevant?
2. Did you find the 
QoDoS items easy to 
understand?
3. Did you find the 
response options easy 
to understand
4. Were you able to 
respond to the QoDoS 
spontaneously
5. Any items that you 
believe should be 
deleted or added
 
n=number of participants 
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Table 6.5 Comments from participants regarding ‘cognitive debriefing’ to establish 
Quality of Decision-Making Orientation Scheme (QoDoS) relevance 
Question Comment 
1. Did you find the QoDoS 
items relevant (yes/no)? If no 
please specify item number. 
• Don't think all the items should be equally weighed 
(n=1) 
• Many questions were repetitive (n=3) 
2.  Did you find the QoDoS 
items easy to understand? 
(yes/no) If no please specify 
item number. 
• Need to clarify context further (i.e. development 
process) (n=1) 
• Unclear whether to respond as an individual versus for 
the organisation (n=1) 
• Item 6: my organisation assigns qualitative values to 
its decision-making criteria (n=1) 
3. Did you find the response 
options easy to understand? 
(yes/no) If no please specify. 
• Need to differentiate between frequently/often (n=3) 
• Could benefit from yes/no instead of current answers 
(n=2) 
5. Any items that you believe 
should be deleted or added? 
(yes/no) If yes please specify. 
• Availability of tools to support decision making (n=1) 
• Instructions why tool is required (n=1) 
n=number of participants 
 
DISCUSSION 
A recent literature review has demonstrated that QoDoS is the most promising available 
technique for assessing decision making in the lifecycle of medicines (Chapter 5). The overall 
benefit of systematically assessing the quality of decision making with QoDoS is to enable an 
increased awareness of biases and best practices but also provide the ability to measure 
change over time in order to determine the impact of improvement initiatives. One of the 
literature review recommendations was therefore to further test the reliability of the QoDoS, 
this being a fundamental property of any subjective measure of such type, in order to ensure 
that the results produced are precise, reliable and reproducible over time, which is particularly 
important when using QoDoS in longitudinal studies.  Consequently, this study aimed to 
demonstrate the relevance and reliability (internal consistency and test-retest reliability) of the 
QoDoS instrument and thereby provide confidence of its robustness in evaluating quality of 
decision making during the research and development of medicines.  
 
The variance around the QoDoS scores, particularly for ‘test 1’ and also for ‘test 2’, was 
considerable, which reflects the ability of the tool to differentiate between participants 
regarding their perception of their own decision making as well as that of their organisation. 
The items with the smallest variance, such as 16 (‘My organisation’s culture has resulted in 
its inability to make a decision’) or 40 (I have experienced a negative outcome by a decision 
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not being made’), should also be further evaluated in future QoDoS studies. Perhaps for these 
two items, both referring to timeliness, the scores might have been narrow and generally 
positive due to the fact that companies and agencies have to make key decisions within a 
specified time limit (either legislated timelines by regulatory authorities/HTA agencies or 
business decisions dictated by companies). The rationale and differences in the items with the 
largest variance should also be explored in future studies with organisations. 
 
The reliability of the QoDoS was assessed for the total scale as well as the four domains 
(organisational decision-making approach; organisational decision-making culture; individual 
decision-making competence and individual decision-making style). The results confirmed 
acceptable internal consistency according to Cronbach’s alpha for the overall instrument and 
the domains, as compared to the internal consistency of QoDoS evaluated by Donelan and 
colleagues (2016). This demonstrates that the domains and the overall instrument are well 
defined and homogenous in terms of tapping into the appropriate aspects of the same 
construct (quality decision-making). 
 
The reproducibility of the QoDoS was also established using test-retest reliability with a 7 
days period between the two assessments. Interestingly, almost all the participants who 
completed ‘test 1’ but not ‘test 2’ where from pharmaceutical companies, which suggests that 
individuals from industry may not recognise the importance of such an exercise or that they 
are less accustomed to being engaged in these kinds of studies compared to agencies and 
academia. The results from the test-retest demonstrate a strong level of agreement between 
the initial and second assessment across the four domains and for the overall QoDoS score. 
Interestingly, the ICC was lower for the two individual domains of QoDoS compared to those 
of the organisation. This may be due to the fact that the opinion of an individual regarding 
their own decision making is less stable as an individual’s perception of their own abilities 
may be subject to mood changes or personal circumstances at the time of completion, as 
opposed to being more objective regarding their assessment of their organisation. Another 
explanation may be that individuals might have adjusted their decision making during the 
seven days following the training session received on the day of the ‘test 1’ completion. 
Nevertheless, the overall ICC score was more than 0.8 for the instrument indicating that 
QoDoS generates results that are precise and objective despite the subjective nature of the 
topic the scale assesses. 
 
This study also demonstrated the relevance of QoDoS in target participants, where the 
feedback from the respondents confirmed the relevance, language clarity and completeness of 
the QoDoS items; the clarity of the scaling as well as spontaneity to the response process. The 
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comments received by the individuals have also been reviewed. Regarding question 1 
(relevance of items), individuals commented that items should be equally weighed and that 
questions were repetitive. Nevertheless, it should be noted that QoDoS items have already 
been reduced using factor analysis to enable mean completion time of 10 minutes, whereas 
item deletion may result in loss of information regarding certain key areas of the construct. 
Secondly, although the 47 items are equally weighted, the items can be assigned to ten 
QDMPs, where each QDMP, according to its relative importance, has a different number of 
QoDoS items, thereby resulting in partial weighting of results (Donelan et al., 2016).  
 
Regarding the clarity of the items (question 2), individuals provided comments regarding the 
need to clarify the decision context beyond just stating ‘key strategic decisions’. Nevertheless, 
this was not possible for the purpose of this study due to the wide range of participants and 
therefore decisions they make, but will be taken into account in future studies with similar 
organisations or individuals. In addition, item 6 was highlighted as unclear (‘my organisation 
assigns qualitative values to its decision-making criteria’) and this should be explored further, 
though noting that only one respondent highlighted this issue. Finally, the lack of clarity 
regarding the distinction between organisational and individual level questions was noted and 
this could be addressed by making the difference between the QoDoS tables for ‘part 1’ and 
‘part 2’ more apparent (see Appendix). 
 
For the response options (question 3), individuals reflected that they do not see the difference 
between ‘frequently’ and ‘often’. Nevertheless, the weighing of the response options has been 
clearly defined in the instrument, i.e. “Assume that Not at all = 0% of time; Sometimes = 25% 
of time; Frequently = 50% of time; Often = 75% of time; Always = 100% of time” and 
perhaps this sentence should be further highlighted in the questionnaire or the percentages 
should be noted in the actual table containing the 47 questions. In addition, two individuals 
recommended changing the options to ‘yes’ and ‘no’, but this may result in loss of 
information, where intermediate options may be required by respondents. 
 
Finally, in question 5 regarding completeness of the tool, participants highlighted that an item 
could be added regarding ‘availability of tools to support decision making as well as adding 
‘instructions why tool is required’. This could be addressed by creating a supplementary 
‘Questions and Answers’ document for future QoDoS studies. For the former comment, 
QoDoS already provides insight into the aspects of tool availability to support decision 
making through item 27 regarding the use of Strengths-Weaknesses-Opportunities-Threats 
(SWOT) analysis. This could be addressed further by revising item 27 (‘I generate a 
Strengths-Weaknesses-Opportunities-Threats (SWOT) analysis in my decision making’) to (‘I 
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utilise decision making tools such as Strengths-Weaknesses-Opportunities-Threats (SWOT) 
analysis in my decision making’). 
 
The feedback received will be taken into account during future QoDoS studies in order to 
further ensure the objectiveness and precision of the results obtained. Future studies would 
also concentrate on establishing the differences between the reliability of QoDoS across the 
three groups, pharmaceutical companies, regulatory authorities and HTA agencies, which 
would require a larger sample. In conclusion, the results of this study provide a strong support 
for the relevance and reliability of QoDoS for longitudinal and cross-sectional application of 
the instrument when evaluating quality of decision making across participants involved in the 
R&D of medicines.  
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SUMMARY 
• This study aimed to evaluate reliability (internal consistency and test-re-test 
reliability) and relevance (using cognitive debriefing) of the QoDoS instrument in the 
target population 
• Participants included individuals from pharmaceutical companies, regulatory 
authorities, HTA agencies and academia 
• The initial ‘test 1’ was completed by 44 individuals from 55 contacted (80% response 
rate) and the re-test (‘test 2’) was completed by 32 out of the 44 individuals who 
completed ‘test 1’, resulting in a 73% response rate  
• Variance within each QoDoS item for ‘test 1’ and ‘test 2’ was evaluated with a ‘box-
and whisker’ plot for the organisational and individual QoDoS parts across all the 
responders; the variance was reported in terms of 5th, 25th, 50th, 75th and 95th 
percentiles. 
• The internal consistency was assessed with Cronbach’s alpha and the test-retest was 
evaluated using the ICC for the four QoDoS domains (organisational decision-
making approach; organisational decision-making culture; individual decision-
making competence and individual decision-making style) 
• Cronbach alpha coefficient was greater than 0.7 across all the domains for ‘test 1’ and 
‘test 2’, ranging from 0.713 to 0.792., indicating ‘good’ consistency (Streiner et al., 
2015) 
• For the overall score across all 47 items, the Cronbach alpha coefficient was .805 for 
‘test 1’ and .861 for ‘test 2’ which is ‘very good’ (Streiner et al., 2015) 
• ICC estimates and their 95% confidence intervals were calculated based on absolute 
agreement, 2 way mixed-effects model.  
• The four QoDoS domains showed moderate to strong reproducibility (ICC range 
0.626-0.857) with an overall ICC of 0.871 
• The relevance of QoDoS was evaluated by applying cognitive debriefing using five 
short feedback questions following ‘test 1’ 
• The feedback from the 43 respondents (98% response rate) confirmed the relevance 
(95% agreement), language clarity (95%) and completeness of items (86%); the 
clarity of the scaling (91%) as well as spontaneity to the response process (95%) 
• The results of this study provide a strong support for the relevance and reliability of 
QoDoS, which are key properties for future for longitudinal and cross-sectional 
application of the instrument when evaluating quality of decision making across 
participants involved in the lifecycle of medicines. 
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CHAPTER 7 
 
 
 
 
 
Assessment of the Ten Quality Decision-Making 
Practices (QDMPs) in a Pharmaceutical Company, a 
Regulatory Authority and a Health Technology 
Assessment (HTA) Agencies Agency with the Quality 
of Decision-Making Orientation Scheme (QoDoS) 
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INTRODUCTION 
In order for organisations to determine their status quo regarding the incorporation of the ten 
Quality Decision-Making Practices (QDMPs) into key decision-making processes, the 
Quality of Decision-Making Orientation Scheme (QoDoS) was developed (Donelan et al., 
2015, Donelan et al., 2016) and was deemed as the most promising available technique for such 
assessments (Chapter 5). A pilot study with a mixed group of participants from pharmaceutical 
companies and regulatory authorities demonstrated the initial practicality of QoDoS in assessing 
the strengths and weaknesses as well as similarities and differences in decision-making practices 
across the individuals, as well as their perception of the organisation (Bujar et al., 2016). 
Furthermore, Chapter 6 demonstrated the reliability and relevance of QoDoS in pharmaceutical 
companies, regulatory authorities and health technology assessment (HTA) agencies. These two 
properties are crucial for any future applications of the instrument, particularly longitudinal studies 
in order to ensure that a potential change in decision-making practices is a result of modified 
organisational processes, as opposed to being due to measurement error (Streiner et al., 2015).  
 
The next step is to apply QoDoS in pharmaceutical companies, regulatory authorities and HTA 
agencies, in order to determine whether the instrument has the ability to assess the level of 
implementation of the ten QDMPs within the three distinct stakeholder groups. This could be 
achieved by carrying out in-depth studies with participants from specific teams, committees or 
departments from across the three types of organisations. Such studies could be used to determine 
the factors that influence decision making within organisations, including favourable practices and 
those that may require improvement, as well as to identify common themes in quality decision 
making across the organisations, such as decision-making preferences as a result of gender, as 
initially discussed in Chapter 5. This chapter will consequently describe an initial set of such 
case studies with organisations, which will be used to illustrate the above properties. 
 
Importantly, the data obtained from QoDoS studies could provide a basis for internal dialogue 
(within an organisation) and, where applicable, external discussions (across organisations) to 
explore the rationale for the responses and increase the awareness of the QDMPs and other key 
considerations during decision making across the individuals (McAuslane et al., 2011). 
Organisations could also utilise the data and the discussion points gathered through such a 
study to promote best practices across their organisation to ensure consistency, as well as to 
address the least favourable practices by incorporating them  more effectively into decision-
making frameworks. This could ultimately improve the R&D productivity of pharmaceutical 
companies (Smietana et al., 2014) and ensure that regulatory authorities and HTA agencies 
are not only undertaking good-quality assessments, but are also making quality decisions 
(McAuslane et al., 2011).  
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The aim of this study was to evaluate the practicality of QoDoS in identifying the 
incorporation of the ten QDMPs in three types of organisations through illustrative case 
studies, with a pharmaceutical company, a regulatory authority and an HTA agency. The 
objectives were to: 
• Evaluate the quality of the decision-making practices of the individuals and their 
perception of their organisation’s decision making 
• Identify favourable and unfavourable practices across the ten QDMPs  
• Assess consistency of the QDMPs within each organisation according to pre-
specified sub-groups as well as pertaining to the group demographics (work 
experience and gender) 
• Evaluate the feasibility and the perceived benefits of the study method based on 
feedback discussions as well as lessons learned. 
 
METHOD 
Design of the study 
This study was designed in the form of three case studies, with a pharmaceutical company, a 
regulatory authority and an HTA agency, where participants were asked to complete the 
QoDoS instrument (see Appendix 1). Each study was planned as a cross-sectional assessment, 
where the data was collected at one point in time. The purpose of each study was to examine 
the organisation as a whole and, where possible to assess a number of logical sub-units, such 
as departments, within each organisation. 
 
Assessment technique 
This study utilised QoDoS (see Appendix 1) with 47-item and two parts, where ‘Part 1’ 
relating to the ‘Organisation’ has two domains (‘Approach’, items 1-12;  and ‘Culture’, items 
13-23) and ‘Part 2’ relates to the ‘Individual’ with two domains (‘Competence’, items 24-37; 
and ‘Style’, items 38-47).  In addition four background questions were used to collect data on 
gender, job title, professional experience and organisation type. The 47 QoDoS individual and 
organisational items can be grouped according to the ten QDMPs based on each QoDoS item 
representing either favourable or unfavourable practice (Table 7.1). The QoDoS Likert scale 
response options were also quantified by assigning scores to each of the response scale, 
according to whether a QoDoS item describes favourable or unfavourable practice, as shown 
in Table 7.1. For QoDoS items corresponding to ‘favourable practice’, the following scores 
were assigned where ‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, 
‘Always’ = 4. For QoDoS items categorised as ‘unfavourable’, the reverse scores were 
assigned where ‘Not at all’ = 4, ‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0.  
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Table 7.1 Quality of Decision-Making Orientation Scheme (QoDoS) items mapped to the 
ten Quality Decision-Making Practices (QDMPs) 
Ten Quality Decision-Making 
Practices  
QDMP short 
name 
24 QoDoS 
individual 
items  
23 QoDoS 
organisational 
items   
1. Have a systematic, structured 
approach to aid decision making 
(consistent, predictable and timely)  
Structure 
24, 25, 27, 30, 
32, 35, 36, 39, 
40, 43   
3, 4, 11,  13, 14  
2. Assign clear roles and 
responsibilities (decision makers, 
advisors, contributors)  
Roles 37 15, 23  
3. Assign values and relative 
importance to decision criteria  
Criteria 33, 34, 44  6, 7  
4. Evaluate both internal and external 
influences/biases  
Bias 38,  42  5, 17, 20, 21  
5. Examine alternative solutions  Alternatives 28 8, 9  
6. Consider uncertainty   Uncertainty 26,  45  10,  18  
7. Re-evaluate as new information 
becomes available  
New 
information 
46 12, 19  
8. Perform impact analysis of the 
decision  
Impact 31, 47  1 
9. Ensure transparency and provide a 
record trail  
Transparency 29, 41  2, 16  
10. Effectively communicate the basis 
of the decision  
Communication    22 
Underlined items indicate those that correspond to ‘unfavourable practice’, whereas non-
underlined items indicate those which represent ‘favourable practice’. 
 
Study participants 
Selection process 
Four pharmaceutical companies, four regulatory authorities and four HTA agencies were 
initially invited to take part in this study with the aim of identifying one from each type of 
organisation. The 12 organisations were selected using purposive sampling from across the 
members of the Centre for Innovation in Regulatory Science (CIRS) research programmes or 
from those organisations which have a working relationship with CIRS to help ensure the 
timeliness of the study completion and to maximise the response rate (CIRS, 2018). This 
sampling process was considered appropriate as the aim was to produce illustrative pilot case 
studies as opposed to generating company, regulatory authority or HTA agency aggregated 
trends.  
 
The selected companies had large R&D expenditure (>1bln USD) (PharmExec, 2017) thereby 
reflecting their innovativeness and the number of decisions made. The four regulatory 
authorities were all classified as Stringent Regulatory Authority (SRA) as defined by the 
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WHO (2017). Lastly, the four HTA agencies were selected based on size and maturity from 
those organisations which are part of the INAHTA (2018) or EUnetHTA (2018). This was to 
ensure that the organisations involved in the studies have well established decision-making 
systems in place in order to be able to complete the QoDoS. 
 
Senior executives from the 12 organisations were selected based on their past involvement in 
other studies as part of this research programme (Chapters 3 and 4) as well as perceived 
interest, which was estimated from the questionnaires as well as personal interactions. A 
detailed study protocol was sent to the potential study participants by email, which outlined 
the purpose and objectives of the study, the proposed method and project timeliness. The 
relevance of this study was also highlighted by sharing a copy of research and development 
Briefing (Bujar et al., 2017; see Appendix 2) covering the outcomes of the other research 
studies undertaken as part of this programme.  
 
Positive responses were obtained from two pharmaceutical companies, two regulatory 
authorities and one HTA agency. Teleconferences were subsequently organised with each 
organisation to further investigate their willingness and suitability to participate.  The criteria 
for selection for the study were: availability of resources in terms of staff and time as well as 
cohort size, where a larger group with sub-groups was preferred. This would enable 
calculation of the response variance as well as sub-group analysis on the dataset to identify 
differences and similarities and the consistency of implementation of the ten QDMPs. 
 
Out of the two companies and two regulatory authorities which provided positive responses, 
all were appropriate in terms of resource and willingness to participate; but only one was 
selected from each to take part in the study based superior group size. More specifically, for 
the company, one organisation proposed 12 individuals from one group, compared to the 
selected company where 31 participants across 4 groups were proposed to take part in the 
study. One of the regulatory authorities proposed a study with nine individuals from one 
group compared with the selected regulatory authority which suggested involving 47 
individuals from across two groups. The HTA agency which agreed to participate proposed a 
group with a cohort size of 28. 
 
Selected study participants 
The pharmaceutical company cohort consisted of 31 individuals from across the leadership 
team (LT), which focuses on ensuring regulatory, quality and safety aspects of medicines for 
the purpose of submission of the dossier to a regulatory authority; as well as three sub-teams 
(STs) which develop the data for the leadership committee, where two STs focus on 
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regulatory affairs’ aspects and one ST focuses on medicines’ safety aspects. For the selected 
agency, the 47 participants were all assessors who review the regulatory dossier prior to the 
issuance of the marketing authorisation of a medicine (pre-market assessors) as well as 
assessors who re-evaluate the marketing authorisation status of a medicine based on new 
information to determine whether or not to modify the marketing authorisation (post-market 
assessors). The HTA agency participants were members of the agency’s appraisal committee 
which recommends whether or not a new medicine should be reimbursed under the national 
health system. The members were all external experts not directly employed by the agency. 
 
Decision-making process 
As many decisions are made on a daily basis, each organisation selected a key strategic 
decision-making process of interest to them (Table 7.2) and this was described in the QoDoS 
questionnaire. It should be noted that for the pharmaceutical company, the RA LT was asked 
to assess their decision making relating to submitting a new drug application (NDA) to a 
regulatory authority, whereas the three STs assessed both their perception of their own 
decision making as well as how they believe the RA LT makes decisions, thereby facilitating 
comparisons. For the regulatory authority and the HTA agency, the decision-making 
processes focussed on the review and appraisal of new medicines respectively, assessing both 
how the individuals believe they make decisions as well as how they believe their 
organisation (the regulatory authority and the HTA agency) makes decisions. 
 
Study procedure 
Once the participants and the decision point were selected, the steps and timelines for each of 
the studies were agreed. Each study followed the same format as described below to ensure 
process consistency. 
1. Initially, the participants were given a 60 min presentation on the study background 
and the importance of decision making, as well as being provided with a study 
protocol that included the study aim, objectives and method as described in this 
chapter. 
2. Following the introduction session, the participants were given a copy of the QoDoS 
questionnaire and were asked to complete this immediately following the 
presentation. The three studies were completed by February 2018. 
3. The responses were analysed within a month and a report of the results was shared 
with the participants. 
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4. Initial feedback discussions were organised with the cohort leaders in order to discuss 
the relevance and clarity of the results as well as initial perception of the study 
method feasibility and benefits. 
5. Formal feedback discussions have been planned for the second part of 2018 with each 
group in order to:  
• Discuss the suitability of the method used in each study 
• Discuss the rationale for the results obtained particularly where there was 
variance or identification of an unfavourable practice 
• Establish the benefits of completing QoDoS as well as having feedback 
discussions 
• Establish areas of best practice and consider the lessons learned and any next 
steps, particularly where areas for improvement were identified.  
 
Table 7.2 Decision-making processes assessed with the Quality of Decision-Making 
Orientation Scheme (QoDoS) across the three case studies 
Study Subject 
Decision-making process specified  
for completing QoDoS 
Part 1 (organisation) Part 2 (individual) 
Pharmaceutical 
company 
Leadership team 
(LT) 
LT process to submit a New Drug Application to a 
regulatory authority 
Sub-teams (STs): 
two regulatory and 
one safety 
LT’s decision making 
to submit a New Drug 
Application to a 
regulatory authority 
ST process to present an 
emerging risk to a 
regulatory authority 
Regulatory 
authority 
Pre-market 
assessors 
Pre-market process to approve or reject a New Drug 
Application 
Post-market 
assessors 
Post-market process to modify (or not) the marketing 
authorisation of a new medicine based on new 
information 
HTA agency 
Appraisal 
committee 
members 
Committee’s process to recommend/restrict or not to 
recommend reimbursement of a new medicine, 
focusing on single technology assessment of 
pharmaceutical products. 
 
Data processing and analysis 
Information was processed manually into an Excel database for the completed questionnaires 
and subsequently cleaned and coded. The scores for the individual QoDoS items were 
codified based on the categorisation in Table 7.1. This was then used to calculate the overall 
score for each QDMP by taking a median across the relevant QoDoS item scores. Due to 
confidentiality reasons, only aggregated results were shown and no data that indentifies an 
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individual or a specific organisation was reported. No statistical tests were planned or 
conducted as this study was designed to be illustrative, with an aim of providing a qualitative 
assessment of the objectives as well as to generate premises for further research. 
 
The data were analysed using descriptive statistics, including calculation of median (50th 
percentile) and variance (25th and 75th percentiles). The results relating to the ten QDMPs 
(individual and organisation) were plotted in the form of box plots as well as spider diagrams 
using Excel. The box plots were used to illustrate the 25th and 75th percentiles for the QDMP 
scores as well as the median (diamond), whereas the spider diagrams showed the median for 
each QDMP. The following traffic light colour coding was utilised according to the overall 
QDMP score, where 
• score <1 = ‘unfavourable practice’ = red;  
• score >1 and <3 = ‘needs improvement’ = yellow 
• score >3 = ‘favourable practice’ = green. 
 
An analysis of the items which are the same for Part 1 and Part 2 within the QoDoS was also 
carried for the regulatory authority and the HTA agency (as the decision-making processes 
were the same for Part 1 and Part 2; Table 7.2) for the following ten item pairs: 
• 3 and 25 - Consistent decision making  
• 4 and 32- Apply a structured approach to decision making  
• 11 and 35 - Provide/receive training in decision making 
• 6 and 33 - Assign qualitative values to decision-making criteria  
• 7 and 34 - Assign quantitative values to decision-making criteria  
• 10 and 26 - Consider uncertainty in decision making  
• 18 and 45 - Underestimate problems that adversely impact decision making 
• 19 and 46 - Continue with projects/products which should be terminated earlier 
• 2 and 29 - Transparent decision making 
• 16 and 41 - Make the same mistake as in the past 
 
RESULTS 
This study focussed on the assessment of the implementation of the ten QDMPs using QoDoS 
through three cross-sectional case studies with a pharmaceutical company, a regulatory 
authority and an HTA agency. For the purpose of clarity, the results are presented in five 
parts: 
• Part I – Pharmaceutical company  
• Part II – Regulatory authority  
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• Part III – HTA agency 
• Part IV – Demographic breakdown 
• Part V – Initial feedback  
 
Characteristics of the study participants 
The three QoDoS studies were completed by a total of 31 individuals from across the four 
teams from the company, 40 individuals from the regulatory authority and 25 from the HTA 
agency. The response rate was 100% for the company (31 individuals), for the regulatory 
authority it was 78% for the pre-market assessors (25 out of 32 individuals contacted) and 
100% for the post-market assessors (15 individuals) and for the HTA agency it was 89% (25 
out of 28 individuals). Both studies were generally balanced in terms of gender, whereas the 
median work experience was 20 years for the combined data set for the company, 15 years for 
the regulatory authority and 24 years for the HTA agency as shown in Table 7.3. 
 
Table 7.3 Demographic characteristics of the study participants 
Cohort Subject 
Total 
number of 
respondents 
Number of respondents 
by gender 
Work experience 
Male Female 
Not 
specified 
Median Max Min 
Pharma-
ceutical 
company 
Leadership 
team 
5 2 3 0 20 36 13 
Sub-team 1 
(regulatory) 
6 1 3 2 25 37 14 
Sub-team 2 
(regulatory) 
11 6 3 2 20 32 8 
Sub-team 3 
(safety) 
9 3 6 0 20 33 11 
Combined 
company 
31 12 15 4 20 37 8 
Regulatory 
authority 
Pre-market 
assessors  
25 11  11  3 20  32  2  
Post-market 
assessors  
15  5  9  1 6  37  1  
Combined 
authority  
40  16  20  4 15  37  1  
HTA 
agency 
Appraisal 
Committee 
members 
25  15  6  4  24  35  2.5  
Combined 
(all cohorts) 
All subjects 96 43 41 12 21 37 1 
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Part I – Pharmaceutical company 
Assessment of individual practices 
This study demonstrated that overall, the individual-level QDMPs of the company 
participants are generally favourable, namely regarding how the individuals within the three 
sub-teams perceive their decision-making process for presenting an emerging risk to a 
regulatory authority as well as how the individuals within the leadership team perceive their 
process for submitting an NDA to a regulatory authority (Figure 7.1).   
 
Interestingly, an analysis of the QDMP median scores for the three STs uncovered that the 
individual practices were identical and generally favourable for ST1 and ST 2, thereby 
suggesting more consistency across the two regulatory sub-teams compared to the safety sub-
team (ST 3) where there were some differences that should be explored with the participants. 
One practice that was not favourable for ST 1 and 2 was QDMP 3 (assign values and relative 
importance to decision criteria), which received a median score of two.  The practices for the 
safety group (ST 3) were also generally favourable and differed from ST1 and ST2 regarding 
QDMP 3 (criteria) and 6 (consider uncertainty) with higher scores for ST3 compared to ST 1 
and ST 2, whereas QDMP 9 (ensure transparency and provide a record trail) received a lower 
score for the safety group compared to the two regulatory STs.  
 
The main differences between the practices of the three STs and the LT were QDMP 2 
(assign clear roles and responsibilities), where the practices of the leadership team were less 
favourable by one point; similarly QDMP 5 (examine alternative solutions), where the LT 
scored in the area of ‘needing improvement’ and finally QDMP 9 (transparency) was also less 
favourable for the LT compared to the three STs.  
 
The variance in the scores was also explored (Figure 7.2) and demonstrated that despite some 
differences in medians, the overlap between the scores was considerable, for example for 
QDMP 2 (roles) where the median score was between 3 and 4 for the three STs, whereas the 
25th-75th median range was also between 3 and 4, demonstrating that generally the individual 
practices are relatively consistent and favourable. On the other hand, some differences in 
variance exist for practices with the same median, for example QDMP 1 (have a systematic, 
structured approach to aid decision making), where the 25th-75th box was in the area of 
‘favourable practice’ for ST3, but suggests a potential need for improvement for the LT and 
ST2. The practice with the most variance across the group was QDMP 3 (criteria), indicating 
that this practice is not consistently applied across the individuals within the teams. 
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Figure 7.1 Ten Quality Decision-Making Practices (QDMPs) for individual’s decision making 
(QoDoS Part 2) for pharmaceutical company leadership team and the three sub-teams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Variance in the Quality Decision-Making Practice (QDMP) scores for 
individual’s decision making (QoDoS Part 2) for pharmaceutical company leadership 
team and the three sub-teams 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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Assessment of organisational practices 
The individuals from the three STs also evaluated their perception of the decision making of 
the LT for submitting an NDA to a regulatory authority, which was compared to the results of 
the leadership team assessing their own decision making for that same decision-making 
process (Figure 7.3). The results suggest the three STs perceive a number of practices of the 
LT as favourable, namely QDMP 6 (consider uncertainty), 7 (re-evaluate as new information 
becomes available), 8 (perform impact analysis of the decision) and 10 (effectively 
communicate the basis of the decision).  
 
On the other hand, there were some differences in the median scores across the three STs 
(relating how they each perceive the LT) for QDMP 1 (have a systematic, structured approach 
to aid decision making), 2 (assign clear roles and responsibilities), 3 (assign values and 
relative importance to decision criteria), 4 (evaluate both internal and external 
influences/biases), 5 (examine alternative solutions) and 9 (ensure transparency and provide a 
record trail), thereby indicating a need to discuss this difference in perception and any need 
for improvement in practice. Of particular interest would be to discuss the ST2 responses 
which were the largest outliers in terms of median value. 
 
The results from the three STs were generally similar to those obtained directly from the LT, 
where one of the main differences was regarding QDMP 10 (effectively communicate the 
basis of the decision), where the three STs generally agreed that this practice was favourable 
for the LT, whereas the leadership team perceived this practice as ‘needing improvement’. As 
with the assessment of the individual practices, the perceived incorporation of the ten QDMPs 
into LT’s decision making was also characterised by considerable variance, for example for 
QDMP 1 (structure), 2 (roles), 3 (criteria) and 4 (bias) (Figure 7.4). 
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Figure 7.3 Ten Quality Decision-Making Practices (QDMPs) for organisation’s decision 
making (QoDoS Part 1) for pharmaceutical company leadership team and the three sub-teams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Variance in the Quality Decision-Making Practice (QDMP) scores for 
organisation’s decision making (QoDoS Part 1) for pharmaceutical company leadership 
team and the three sub-teams 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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QDMP breakdown by QoDoS items 
A breakdown of each QDMP according to the corresponding QoDoS items, relating both to 
the individual (Table 7.4) and organisational (Table 7.5) decision making, provides further 
insight into the company responses. Interestingly, the majority of the responses were 
relatively consistent across the four teams in terms of median (min-max difference in 
median). For individual decision making (Table 7.4), the item with most variance (min-max 
difference = 2) was item 34 (‘I assign quantitative values to its decision-making criteria’) and 
44 (‘my decision making could be improved by assigning relative importance to decision 
criteria’), which suggests that this practice is not consistently applied by all the teams.  
 
The large variance in items 34 and 44 (Table 7.4) was reflected in the considerable variance 
for QDMP 3 in Figure 7.2. Consequently, the individual QoDoS items can be used to better 
understand the rationale for the QDMP median responses and variance. In addition, item 29, 
relating to transparent decision making in individuals, also received disparate QoDoS scores 
across the four teams, where the individuals on the LT felt their decision making was less 
transparent compared to the other groups.  
 
Regarding the organisation (Table 7.5), items 15 and 20, relating to decision making being 
influenced by politics and incentives or penalty payments, were characterised by the most 
variance (min-max difference = 1.5). Here, ST2 was the outlier in their rating, perceiving that 
these influences (relating to LT’s decision making) occurred more frequently compared to 
other teams. Finally, training in decision making (item 35 in Table 7.4; item 11 in Table 7.5) 
was generally provided and/or received on a “sometimes” basis. 
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Table 7.4 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); individual’s decision making 
(QoDoS Part 2) for company leadership team (LT) and the three sub-teams (STs) 
QDMP QoDoS item 
Median Min-max 
difference 
in median 
LT ST1 ST2 ST3 
QDMP1 
(Structure) 
24. My decision making is knowledge based 3 4 3 4 1 
25. My decision making is consistent 3 3 3 3 0 
27. I generate a Strengths-Weaknesses-Opportunities-Threats 
(SWOT) analysis in my decision making 
2 1 1 2 1 
30. I understand the context of the decision I am being 
asked to make 
3 3 3 3 0 
32. I use a structured approach in my decision making 2 3 2 3 1 
35. I receive training in the science of decision making 1 0.5 0 1 1 
*36. I use intuition or “gut-feeling” in my decision making 3 3 2 3 1 
*39. I have experienced “paralysis by analysis” caused by 
my slow decision making 
3 3 3 4 1 
*40. I have experienced a negative outcome by a decision 
not being made 
3 3 3 3 0 
*43. My procrastination has resulted in a negative outcome 3 4 4 4 1 
QDMP2 
(Roles) 
37. My professional experience is important when having 
to make challenging decisions 
3 4 4 4 1 
QDMP3 
(Criteria) 
33. I assign qualitative values to its decision-making 
criteria 
2 3 3 3 1 
34. I assign quantitative values to its decision-making 
criteria 
1 1.5 1.5 3 2 
44. My decision making could be improved by assigning 
relative importance to decision criteria 
3 1 1 1 2 
QDMP4  
(Bias) 
*38. Emotion is part of my decision making 3 3.5 3 3 0.5 
*42. Recent or dramatic events greatly impact my decision 
making 
3 3 2 3 1 
QDMP5 
(Alternatives) 
28. I present contingencies or achievable options as part of 
my decision making 
2 3 3 3 1 
QDMP6 
(Uncertainty) 
26. I consider uncertainty and unknowns in my decision-
making approach 
3 4 3 4 1 
*45. I  underestimate problems which adversely impact my 
decision making 
4 3 3 4 1 
QDMP7 (New 
information) 
*46. I continue with projects/products which should be 
terminated at an early stage 
3 3 3 3 0 
QDMP8 
(Impact) 
31. I understand the importance of the decisions I make 4 4 3 4 1 
*47. I feel that I could make better quality decisions 3 3 3 3 0 
QDMP9 
(Transparency) 
29. My decision making is transparent 2 4 4 3 2 
*41. In my decision making, I make the same mistakes as 
in the past 
3 4 4 3 1 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where ‘Not 
at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items categorised as 
‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, ‘Sometimes’ = 3, 
‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0. Red highlight shows median difference ≥ 1.5 
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Table 7.5 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); organisation’s decision making 
(QoDoS Part 1) for company leadership team (LT) and the three sub-teams (STs) 
QDMP QoDoS item 
Median Min-max 
difference 
in median 
LT  ST1  ST2  ST3  
QDMP1 
(Structure) 
3. My organisation’s decision making is consistent 3 3 2 2 1 
4. My organisation uses a structured approach in its 
decision making 
3 3 3 3 0 
11. My organisation provides training in the science of 
decision making 
1 1 1 2 1 
*13. My organisation has suffered a negative outcome 
due to slow decision making 
3 3 3 3 0 
*14. My organisation’s  culture has resulted in its 
inability to make a decision 
3 3 2 3 1 
QDMP2  
(Roles) 
*15. My organisation’s decision making is influenced 
by organisational politics 
2 2 1 2.5 1.5 
23. My organisation provides clear and unambiguous 
instructions for decision making 
2 1.5 1 2 1 
QDMP3 
(Criteria) 
6. My organisation assigns qualitative values to its 
decision-making criteria 
2 2 3 2.5 1 
7. My organisation  assigns quantitative values to its 
decision-making criteria 
2 2.5 3 2 1 
QDMP4  
(Bias) 
*5. My organisation’s decision making is influenced 
by external stakeholder’s demands 
1 1 1 1 0 
*17. My organisation’s decision making is influenced 
by the vested interest of individuals (e.g. conflict of 
interest) 
3 3 3 3.5 0.5 
*20. My organisation’s decision making is influenced 
by similar organisations or competitors 
2 3 2 2 1 
*21. My organisation’s decision making is influenced 
by incentives or penalty payments 
3 4 2 3 2 
QDMP5 
(Alternatives) 
8. My organisation is open to using better alternatives 
in its decision making 
2 2.5 2 3 1 
9. My organisation encourages innovative decision making 2 2.5 2 3 1 
QDMP6 
(Uncertainty) 
10. My organisation considers uncertainties in relation 
to its decision making 
3 3 3 3 0 
*18. My organisation underestimates problems which 
adversely impact its own decisions 
3 3 3 3 0 
QDMP7 (New 
information) 
12. My organisation re-examines its decision making 
as new information becomes available 
2 3 3 3 1 
*19. My organisation continues with projects/products 
which should be terminated at an earlier stage 
3 3 3 3 0 
QDMP8 (Impact) 
1. My organisation evaluates the impact of the 
decisions it makes 
3 3 3 2.5 0.5 
QDMP9 
(Transparency) 
2. My organisation’s decision making is transparent 3 2.5 2 2 1 
*16. My organisation’s decision making results in 
making the same mistake as in the past 
3 3 3 3 0 
QDMP10 
(Communication) 
22. My organisation effectively communicates the 
decisions it makes 
2 3 3 3 1 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where ‘Not 
at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items categorised as 
‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, ‘Sometimes’ = 3, 
‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0. Red highlight shows median difference ≥ 1.5 
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Part II – Regulatory authority  
Assessment of individual practices 
An analysis of the decision-making practices across the 40 assessors indicated that both pre-
market and post-market assessors perceive their practices as generally ‘favourable’ across all 
ten QDMPs (Figure 7.5). The only QDMP in the area of ‘needing improvement’, according to 
the median, was QDMP 5 (examine alternative solutions) for the post-market assessors.  
 
In terms of median, the practices were consistent between pre and post-market staff, whereas 
notable differences in median (one-point difference) were observed for QDMP 1 (have a 
systematic, structured approach to aid decision making), 4 (evaluate both internal and external 
influences/biases), 5 (examine alternative solutions) and 6 (consider uncertainty) (Figure 7.5). 
Nevertheless, the variance around the median for each of those QDMP (Figure 7.6) suggests 
that there are considerable differences around certain practices. For example, despite QDMP 
3 (assign values and relative importance to decision criteria) having a median corresponding 
to ‘favourable practice’, the variance (25th-75th percentile) was in the area of ‘needing 
improvement’, particularly for pre-market assessors, indicating that this practice should be 
further explored. 
 
Assessment of organisational practices 
The perception of organisational QDMPs by the assessors was also in the area of ‘favourable 
practice’ and the QDMP scores were similar for pre- and post-market assessors (Figure 7.7). 
Interestingly, there was more consistency between responses from pre- and post-market 
assessors on their perception of their organisation (Figure 7.7) compared to perception of own 
decision making (Figure 7.5). In terms of median, the only differences between pre- and post-
market assessors in Figure 7.7 were for QDMP 2 (assign clear roles and responsibilities), 
where pre-market responses resulted in ‘favourable practice’ compared to ‘needing 
improvement’ for post-market staff; on the other hand, QDMP 8 (perform impact analysis of 
the decision), was rated by pre-market assessors as ‘unfavourable practice’ and as ‘needing 
improvement’ by post-market assessors. Nevertheless, there was also considerable variance 
for a number of the QDMPs, such as QDMP 3 (criteria) and QDMP 5 (alternatives) for pre-
market assessors and QDMP 4 (bias) for post-market assesses (Figure 7.8). 
 
 
 
 
 
  
165 
Figure 7.5 Ten Quality Decision-Making Practices (QDMPs) for individual’s decision 
making (QoDoS Part 2) for regulatory authority pre- and post-market assessors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Variance in the Quality Decision-Making Practice (QDMP) scores for 
individual’s decision making (QoDoS Part 2) for regulatory authority pre- and post-
market assessors 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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Figure 7.7 Ten Quality Decision-Making Practices (QDMPs) for organisation’s decision 
making (QoDoS Part 1) for regulatory authority pre- and post-market assessors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8 Variance in the Quality Decision-Making Practice (QDMP) scores for 
organisation’s decision making (QoDoS Part 1) for regulatory authority pre- and post-
market assessors 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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QDMP breakdown by QoDoS items 
The QoDoS item scores were generally consistent, where the difference in median between 
the pre- and post-market assessors was one point (mix-max difference) or less as indicated in 
Tables 7.6 and 7.7. In addition, an analysis of the QoDoS items can be used to determine what 
drives the various median QDMP scores in Figure 7.5 and 7.7, as well as what is the rationale 
for the variance in QDMP scores in Figures 7.6 and 7.8.  
 
For example, for QDMP 1 (have a systematic, structured approach to aid decision making) 
the median score and the variance reflecting individual practice was more favourable for the 
pre-market assessors compared to post-market assessors (Figure 7.6), which in turn can be 
explained by individual QoDoS items in Table 7.6. Here, on average (median), the pre-market 
assessors used SWOT analyses during their decision making (item 27) more frequently 
compared to post-market assessors and always understood the decision context (30) as well as 
based their decision on their knowledge (24), which was carried out less frequently by the 
post-market assessors. Conversely, pre-market assessors seemed to be less influenced by 
potential biases and other subjective influences (and hence had higher scores compared to 
post-market assessors) as a result of intuition (item 36) or being unable to make a decision 
due to over-analysis of the situation (item 39) or experiencing a negative outcome due to slow 
decision making (40). The overall median across these individual QoDoS item scores, which 
were all higher for the pre-market compared to post-market assessors, resulted in a more 
favourable QDMP 1 for pre-market compared to post-market assessors. 
 
There are ten sets of identical QoDoS items for part 1 (Organisation) and part 2 (Individual) 
of QoDoS, as described in the method. An analysis of these pairs of items revealed that, for 
all ten cases, individuals scored themselves the same or more highly compared to the 
organisation for the regulatory authority. Individuals scored themselves more favourably 
regarding having a structured approach (item 32 in Table 7.6 and item 4 in Table 7.7); 
assigning quantitative values to decision-making criteria (item 34 in Table 7.6 and item 7 in 
Table 7.7), considering uncertainty in decision making (item 26 in Table 7.6 and item 10 in 
Table 7.7) and making the same mistake as in the past (item 41 in Table 7.6 and 16 in Table 
7.7). Finally, in terms of training in decision making, this was provided at organisational level 
and received on an individual level on a “sometimes” basis by both pre-market and post-
market assessors, which is similar to the company result. 
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Table 7.6 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); individual’s decision making 
(QoDoS Part 2) for regulatory authority pre- and post-market assessors 
QDMP QoDoS item 
Median 
Difference 
in median 
Pre-
market 
assessors  
Post-
market 
assessors  
QDMP1 
(Structure) 
24. My decision making is knowledge based 4 3 1 
25. My decision making is consistent 3 3 0 
27. I generate a Strengths-Weaknesses-Opportunities-
Threats (SWOT) analysis in my decision making 
2 1 1 
30. I understand the context of the decision I am 
being asked to make 
4 3 1 
32. I use a structured approach in my decision 
making 
4 4 0 
35. I receive training in the science of decision 
making 
1 1 0 
*36. I use intuition or “gut-feeling” in my decision 
making 
4 3 1 
*39. I have experienced “paralysis by analysis” 
caused by my slow decision making 
4 3 1 
*40. I have experienced a negative outcome by a 
decision not being made 
4 3 1 
*43. My procrastination has resulted in a negative 
outcome 
4 4 0 
QDMP2 (Roles) 
37. My professional experience is important when 
having to make challenging decisions 
3.5 4 0.5 
QDMP3 
(Criteria) 
33. I assign qualitative values to its decision-
making criteria 
3 2.5 0.5 
34. I assign quantitative values to its decision-
making criteria 
3 3 0 
44. My decision making could be improved by 
assigning relative importance to decision criteria 
1 2 1 
QDMP4 (Bias) 
*38. Emotion is part of my decision making 4 4 0 
*42. Recent or dramatic events greatly impact my 
decision making 
3.5 3 0.5 
QDMP5 
(Alternatives) 
28. I present contingencies or achievable options as 
part of my decision making 
3 2 1 
QDMP6 
(Uncertainty) 
26. I consider uncertainty and unknowns in my 
decision-making approach 
4 4 0 
*45. I  underestimate problems which adversely 
impact my decision making 
3 3 0 
QDMP7 (New 
information) 
*46. I continue with projects/products which should 
be terminated at an early stage 
3.5 3 0.5 
QDMP8 
(Impact) 
31. I understand the importance of the decisions I 
make 
4 3 1 
*47. I feel that I could make better quality decisions 3 3 0 
QDMP9 
(Transparency) 
29. My decision making is transparent 3.5 3 0.5 
*41. In my decision making, I make the same 
mistakes as in the past 
4 4 0 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where 
‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items 
categorised as ‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, 
‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0.  
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Table 7.7 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); organisation’s decision making 
(QoDoS Part 1) for regulatory authority pre- and post-market assessors 
QDMP QoDoS item 
Median 
Difference 
in median 
Pre-
market 
assessors  
Post-
market 
assessors  
QDMP1 
(Structure) 
3. My organisation’s decision making is consistent 3 3 0 
4. My organisation uses a structured approach in its 
decision making 
3 3 0 
11. My organisation provides training in the science 
of decision making 
1 1 0 
*13. My organisation has suffered a negative 
outcome due to slow decision making 
3 3 0 
*14. My organisation’s  culture has resulted in its 
inability to make a decision 
4 3.5 0.5 
QDMP2 (Roles) 
*15. My organisation’s decision making is 
influenced by organisational politics 
3 3 0 
23. My organisation provides clear and unambiguous 
instructions for decision making 
2 2 0 
QDMP3 
(Criteria) 
6. My organisation assigns qualitative values to its 
decision-making criteria 
3 3 0 
7. My organisation  assigns quantitative values to its 
decision-making criteria 
2 2.5 0.5 
QDMP4  
(Bias) 
*5. My organisation’s decision making is influenced 
by external stakeholder’s demands 
3 3 0 
*17. My organisation’s decision making is 
influenced by the vested interest of individuals (e.g. 
conflict of interest) 
4 4 0 
*20. My organisation’s decision making is 
influenced by similar organisations or competitors 
2 1 1 
*21. My organisation’s decision making is 
influenced by incentives or penalty payments 
4 4 0 
QDMP5 
(Alternatives) 
8. My organisation is open to using better 
alternatives in its decision making 
3 2 1 
9. My organisation encourages innovative decision making 1 2 1 
QDMP6 
(Uncertainty) 
10. My organisation considers uncertainties in 
relation to its decision making 
3 3 0 
*18. My organisation underestimates problems 
which adversely impact its own decisions 
3 3 0 
QDMP7 (New 
information) 
12. My organisation re-examines its decision making 
as new information becomes available 
2 3 1 
*19. My organisation continues with projects/products 
which should be terminated at an earlier stage 
3 3 0 
QDMP8 (Impact) 
1. My organisation evaluates the impact of the 
decisions it makes 
1 2 1 
QDMP9 
(Transparency) 
2. My organisation’s decision making is transparent 3 3 0 
*16. My organisation’s decision making results in 
making the same mistake as in the past 
3 3 0 
QDMP10 
(Communication) 
22. My organisation effectively communicates the 
decisions it makes 
3 3 0 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where 
‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items 
categorised as ‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, 
‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0. 
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Part III – HTA agency 
Assessment of individual and organisational practices 
The combined results across the 25 individuals from the HTA agency indicate that the 
appraisal committee members perceive their own decision-making practices as generally 
‘favourable’, both in terms of how the members perceive themselves as well as the 
organisation (Figure 7.9). The practices with unfavourable or ‘needing improvement’ medians 
were QDMP 3 (assign values and relative importance to decision criteria), QDMP 5 (examine 
alternative solutions) and QDMP 8 (perform impact analysis of the decision), which is 
interestingly similar to the results from the regulatory authority. A number of QDMPs with 
medians close to ‘favourable practice’ were characterised by considerable variance in the 
‘needing improvement’ area, for example QDMP 2 (assign clear roles and responsibilities) 
and QDMP 7 (re-evaluate as new information becomes available) regarding the individuals’ 
perception of the organisation’s decision making (Figure 7.10). 
 
QDMP breakdown by QoDoS item 
Interestingly, for the HTA agency responses, an assessment of the items which are identical 
for the organisation and the individual revealed that the median scores were either the same or 
had higher organisational score compared to individual for almost all the item pairs (nine out 
of ten) (Tables 7.8 and 7.9). The exception was regarding continuing with projects/products 
which should be terminated at an early stage (item 46 in Table 7.8 and item 19 in Table 7.9) 
where the minimal difference was 0.5 in favour of the individual. This was a contrast 
compared to the regulatory authority results. Finally, the participants indicated that they 
receive training in quality decision on a ‘sometimes’ basis, which is consistent with results 
from the company and regulatory authority. 
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Figure 7.9 Ten Quality Decision-Making Practices (QDMPs) for individual’s and organisation’s 
decision making (QoDoS Part 2 and 1 respectively) for HTA appraisal committee members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 Variance in the Quality Decision-Making Practice (QDMP) scores for HTA 
appraisal committee members 
a) Individual’s decision making (QoDoS Part 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) Organisation’s decision making (QoDoS Part 1) 
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Table 7.8 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); individual’s decision making 
(QoDoS Part 2) for HTA appraisal committee members 
QDMP QoDoS item 
Appraisal 
Committee Median 
QDMP1 (Structure) 
24. My decision making is knowledge based 3 
25. My decision making is consistent 3 
27. I generate a Strengths-Weaknesses-Opportunities-Threats 
(SWOT) analysis in my decision making 
0 
30. I understand the context of the decision I am being 
asked to make 
4 
32. I use a structured approach in my decision making 3 
35. I receive training in the science of decision making 0 
*36. I use intuition or “gut-feeling” in my decision making 2 
*39. I have experienced “paralysis by analysis” caused by 
my slow decision making 
3 
*40. I have experienced a negative outcome by a decision 
not being made 
4 
*43. My procrastination has resulted in a negative outcome 4 
QDMP2 (Roles) 
37. My professional experience is important when having 
to make challenging decisions 
3 
QDMP3 (Criteria) 
33. I assign qualitative values to its decision-making 
criteria 
2 
34. I assign quantitative values to its decision-making 
criteria 
2.5 
44. My decision making could be improved by assigning 
relative importance to decision criteria 
2 
QDMP4 (Bias) 
*38. Emotion is part of my decision making 3 
*42. Recent or dramatic events greatly impact my decision 
making 
3 
QDMP5 
(Alternatives) 
28. I present contingencies or achievable options as part of 
my decision making 
2 
QDMP6 
(Uncertainty) 
26. I consider uncertainty and unknowns in my decision-
making approach 
4 
*45. I  underestimate problems which adversely impact my 
decision making 
3 
QDMP7 (New 
information) 
*46. I continue with projects/products which should be 
terminated at an early stage 
3.5 
QDMP8 (Impact) 
31. I understand the importance of the decisions I make 4 
*47. I feel that I could make better quality decisions 3 
QDMP9 
(Transparency) 
29. My decision making is transparent 2.5 
*41. In my decision making, I make the same mistakes as 
in the past 
3 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where 
‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items 
categorised as ‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, 
‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0. 
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Table 7.9 Quality of Decision-Making Orientation Scheme (QoDoS) item median scores 
for each Quality Decision-Making Practice (QDMP); organisation’s decision making 
(QoDoS Part 1) for HTA appraisal committee members 
QDMP QoDoS item 
Appraisal 
Committee 
Median 
QDMP1 (Structure) 
3. My organisation’s decision making is consistent 3 
4. My organisation uses a structured approach in its decision 
making 
4 
11. My organisation provides training in the science of 
decision making 
1 
*13. My organisation has suffered a negative outcome due to 
slow decision making 
3 
*14. My organisation’s  culture has resulted in its inability to 
make a decision 
4 
QDMP2 (Roles) 
*15. My organisation’s decision making is influenced by 
organisational politics 
3 
23. My organisation provides clear and unambiguous 
instructions for decision making 
2 
QDMP3 (Criteria) 
6. My organisation assigns qualitative values to its decision-
making criteria 
2.5 
7. My organisation  assigns quantitative values to its decision-
making criteria 
3 
QDMP4 (Bias) 
*5. My organisation’s decision making is influenced by 
external stakeholder’s demands 
3 
*17. My organisation’s decision making is influenced by the 
vested interest of individuals (e.g. conflict of interest) 
4 
*20. My organisation’s decision making is influenced by 
similar organisations or competitors 
3 
*21. My organisation’s decision making is influenced by 
incentives or penalty payments 
4 
QDMP5 
(Alternatives) 
8. My organisation is open to using better alternatives in its 
decision making 
2 
9. My organisation encourages innovative decision making 1 
QDMP6 
(Uncertainty) 
10. My organisation considers uncertainties in relation to its 
decision making 
4 
*18. My organisation underestimates problems which 
adversely impact its own decisions 
3 
QDMP7 (New 
information) 
12. My organisation re-examines its decision making as new 
information becomes available 
1 
*19. My organisation continues with projects/products which 
should be terminated at an earlier stage 
3 
QDMP8 (Impact) 
1. My organisation evaluates the impact of the decisions it 
makes 
1 
QDMP9 
(Transparency) 
2. My organisation’s decision making is transparent 3 
*16. My organisation’s decision making results in making the 
same mistake as in the past 
3 
QDMP10 
(Communication) 
22. My organisation effectively communicates the decisions it 
makes 
3 
For QoDoS items corresponding to ‘favourable practice’, the following scores were assigned where 
‘Not at all’ = 0, ‘Sometimes’ = 1, ‘Frequently’ = 2, ‘Often’ = 3, ‘Always’ = 4. For QoDoS items 
categorised as ‘unfavourable practice’ (*), the reverse scores were assigned where ‘Not at all’ = 4, 
‘Sometimes’ = 3, ‘Frequently’ = 2, ‘Often’ = 1, ‘Always’ = 0. 
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Part IV – Demographic breakdown 
The demographic characteristics of the respondents were used to analyse the perception of the 
individual’s decision making according to gender and work experience for the combined 
dataset across the pharmaceutical company, regulatory authority and HTA agency. 
Interestingly, an analysis of the medians by gender indicated that the practices for males and 
females are generally consistent (Figure 7.11). Differences were seen for QDMP 3 (assign 
values and relative importance to decision criteria) and QDMP 5 (examine alternative 
solutions), although with considerable overlap in variance (Figure 7.12). On the other hand, 
the variance for QDMP 4 (evaluate both internal and external influences/biases) and QDMP 7 
(re-evaluate as new information becomes available) was larger and tending towards needing 
improvement for males compared to females.  
 
A breakdown by the number of years of experience (Figure 7.13), 1-12 years; 13-24 years and 
25-37 years, indicated a consistency in median across a number of QDMPs, namely 1 (have a 
systematic, structured approach to aid decision making), 2 (assign clear roles and 
responsibilities), 4 (bias), 7 (new information) and 8 (perform impact analysis of the 
decision). Differences in median were noted for QDMP 3 (criteria), 5 (alternatives) and 
QDMP 6 (uncertainty) and QDMP 9 (ensure transparency and provide a record trail), where 
the cohort with 25-37 years of experience was characterised by the highest proportion of 
‘favourable practice’. Nevertheless, there was considerable variance that differed across the 
three groups (Figure 7.14). 
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Figure 7.11 Ten Quality Decision-Making Practices (QDMPs) for individual’s decision 
making (QoDoS Part 2) for males and females for combined study cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12 Variance in the Quality Decision-Making Practice (QDMP) scores for 
individual’s decision making (QoDoS Part 2) for males and females for combined study 
cohorts 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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Figure 7.13 Ten Quality Decision-Making Practices (QDMPs) for individual’s decision 
making (QoDoS Part 2) by the number of years of work experience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14 Variance in the Quality Decision-Making Practice (QDMP) scores for 
individual’s decision making (QoDoS Part 2) by the number of years of work experience 
a) QDMPs 1-5 
 
 
 
 
 
 
 
 
 
 
b) QDMPs 6-10 
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Part V – Feedback from participants 
Informal feedback discussions were organised with the group leaders from each study. These 
confirmed the feasibility of the study method as well as initial benefits of the approach, 
including raising awareness of biases and best practices in decision making, gaining a basis 
for discussion of the issues in decision making as well as making recommendations for 
improving the lowest scoring or least consistent practices. The discussions also helped to 
uncover rationale for some differences in responses across sub-groups or when comparing 
individual and organisational perception. 
 
For example, the pharmaceutical company study uncovered that the median score for QDMP 
10 (effectively communicate the basis of the decision) regarding the decision making of the 
leadership team was more favourable regarding how this is perceived by the three STs  
compared to the median obtained from the LT directly (Figure 7.3). A potential explanation 
received during the initial feedback session was that this may be a result of efficient and clear 
communication of LT’s decisions by the sub-team managers to their direct reports in ST1, 
ST2 and ST3; this was highlighted as key to informing the day-to-day activities of the three 
STs. This difference as well as others will be explored during the formal feedback discussions 
with the study participants from each study cohort, which are planned for the second part of 
2018. In addition, these discussions will seek to determine the perceived benefits of the study 
(including completion QoDoS as well as the feedback discussions), the lessons learned as 
well as the next steps that each organisation would like to undertake as part of the project. 
 
The initial feedback discussions also facilitated a discussion on the weighting of the QoDoS 
items (favourable vs. unfavourable), for example the fact that item 5 (‘my organisation’s 
decision making is influenced by external stakeholder’s demands’) and item 36 (‘I use 
intuition or “gut-feeling” in my decision making’) are considered as unfavourable practices. 
Indeed, previous research has shown that sometimes individuals are better off with making a 
quick decision based on their ‘expert intuition’. Nevertheless, successful decision making 
relies on a balance between deliberate and instinctive thinking. Consequently, individuals 
need to be aware of gut feeling or intuition and need to understand what is behind their quick 
judgment and first impression. Moreover, individuals need to be prepared to logically and 
objectively explain as to why they feel a certain way or make a particular decision in order to 
minimise the chance of being biased (Kahneman, 2011). As a result, the weightings of the 
QoDoS scores will be reviewed before pursuing future studies in order to ensure relevance 
and clarity. 
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DISCUSSION 
Advancing the field of quality decision making 
Although there is an increasing use of framework-based simulation and modelling to aid 
decision making within the lifecycle of medicines, the various decision-making processes are 
subjective in nature and should be further explored to identify areas of best practice as well as 
those that may need improvement in order to increase process quality, consistency and 
transparency (Walker et al., 2012). Other methodologies have been utilised to measure quality 
decision making in individuals and organisations as described in Chapter 5. Nevertheless, 
these are either brief in terms of number of items (Blenko et al., 2010); go beyond decision 
making as just one aspect of quality (Salek et al., 2012); assess only some of the QDMPs 
(McKinsey 2008; Cowlrick et al., 2011; Fischer et al., 2011; McIntyre et al., 2012; Open 
University, 2013; Marangi et al., 2014); or focus only on how individuals make decisions 
without taking into account how they perceive their organisation (Wood, 2012; Mindtools, 
2013; Beyer et al., 2015). In addition, in terms of a target audience, the majority of the 
techniques are either tailored to meet specific organisational needs, or are designed for 
commercial organisations only and are therefore not generalisable with respect to agencies 
(Matheson and Matheson, 1998). The QoDoS, however, differs from these initiatives as it can 
be used across different groups involved in the development and review of medicines as well 
as for any decision process of interest in order to assess the incorporation of all ten QDMPs, 
both regarding individual practices as well as those of the organisation as perceived by the 
individuals.  
 
Key outcomes from the three case studies 
This chapter described three illustrative case studies where QoDoS was used to assess the 
incorporation of the ten QDMPs in a company, a regulatory authority and an HTA agency. 
The three studies demonstrated the practicality of QoDoS to identify favourable and 
unfavourable practices as well as to assess their consistency and transparency within each 
organisation. Importantly, this study was the first application of QoDoS in an in-depth 
organisational setting and the results confirmed the initial feasibility of the proposed method. 
All three case studies demonstrated generally favourable results across the QDMPs, where 
overall, all three organisations have incorporated the majority of the ten QDMPs. This may 
not be surprising, as the organisations that were selected for the three pilots have established 
decision-making systems based on their size and multinational status (for the company) and 
maturity level (in case of agencies).  
 
The three studies differed in terms of cohort type and decision point as described below, in 
order to demonstrate the different ways in which QoDoS can be applied. The pharmaceutical 
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company study was used to assess the decision making across four groups, where the QoDoS 
questions relating to the individual were answered regarding a decision-making processes 
specific to each group, whereas the questions relating to individual’s perception of the 
organisation were used to assess the leadership team. This demonstrated certain differences, 
first of all across the individual practices for the three STs and in comparison to the LT; as 
well as differences and similarities in how the three STs perceive the LT compared to the LT 
itself.  
 
Secondly, the regulatory authority study was used to demonstrate differences in individual 
practices and perception of the organisation by two different sub-groups as part of the same 
organisation for two specific decision-making processes (pre- and post-market approval). In 
this case, the QoDoS responses demonstrated that the perception of the organisation is 
relatively consistent for the two groups and certain differences were identified in how the 
individuals make decisions, which may be due to the different processes in place for the pre- 
and post-market process. Nevertheless, an assessment of the QoDoS items which are the same 
for the individual and organisation demonstrated that individuals generally perceive 
themselves more favourably compared to the organisation which is consistent with findings 
from a previous pilot study with a mix of participants from companies and agencies (Bujar et 
al., 2016). This could relate to factors such as an individual being more accountable at a micro 
level for the decisions they make as compared to an organisation on a macro level. On the 
other hand, as individuals make up the organisation, large differences could indicate bias or 
lack of understanding of organisational practices, areas of disparity could therefore help 
identify room for improvement to ensure that best practice is consistently applied. 
 
Lastly, the HTA case study involved one group, the appraisal committee, where the 
individuals assessed themselves and their organisation for the same decision point, where the 
results demonstrated general consistency. Nevertheless, in this case, the perception of the 
individuals regarding their own decision making compared to their organisation for the ten 
QoDoS item pairs was similar and in favour of the organisation, which is contrary to the 
regulatory agency. This may because the HTA committee members are all external i.e. not 
being employed on a daily basis by the agency (as opposed to being internal employees for 
the regulatory authority). This could result in the committee members perceiving the 
organisation more objectively as a result of not being so involved in the process. 
 
Interestingly, the QoDoS demonstrated the need for improvement across a number of 
practices, where some similarities were identified, such as the need for better assignment of 
values and relative importance of decision criteria (QDMP 3) as well as the evaluation of 
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alternatives (QDMP 5) for the three organisations and the need for a better impact analysis for 
the regulatory and the HTA agency (QDMP 8). Interestingly, both QDMP 3 and QDMP 8 
were seen as generally not incorporated into company and agency frameworks during 
medicines regulatory submission, review and HTA processes as per Chapters 3 and 4. As 
these practices were nevertheless seen as relevant by the respondents, QDMP 3 should be 
addressed  through the incorporation of more formal frameworks, such as a benefit-risk 
framework during regulatory decision making (Leong et al., 2013), as well as having 
standardised evidence criteria for HTA (EUnetHTA, 2016). In addition, impact analysis 
(QDMP 8) could be incorporated within authority and agency frameworks in two ways; 
firstly, through an assessment of linked decisions as well as relevant precedents, including 
decisions previously made by the organisation or other relevant stakeholders; secondly such 
an assessment should focus on the impact of this decision on the present and future processes 
and this should address relevant stakeholders including patients. For example, for a regulatory 
authority, impact analysis ahead of issuing a marketing authorisation would firstly assess how 
other similar medicines were reviewed within this jurisdiction as well as other regulatory 
agencies; secondly the reviewer should aim to understand the impact of the decision on other 
processes, such as HTA, as well as the ultimate impact on patients, including the approved 
label (indication) for the medicine.  
 
Whilst it was recognised that both agencies and companies felt that their decision making 
could be somehow improved, training in this area was rarely provided. This may be because 
there is limited awareness of the science of decision making which has been applied in other 
disciplines outside the regulatory environment (Phillips and Stock, 2003; Morton et al., 2009). 
Consequently, there is a need to promote education and the provision of training by the 
organisations to raise awareness of the issues in decision making and promote best practice so 
that individuals know how they can improve.  
 
Another key finding was the general variance (25th-75th percentile) around the responses 
obtained from the three groups for the incorporation of the ten QDMPs. It is important to note 
that variation is not perceived as a shortcoming as QoDoS assesses a process that is subjective 
in nature and aims to capture differences in perceptions that can then be explored through 
feedback discussions. Variance can also be investigated by evaluating the QoDoS item scores 
corresponding to each QDMP to determine the rationale of the overall QDMP scores. 
Differences in scores may be a result of a mixture of factors:  inconsistencies in individual 
practices and differences in the perception of the organisation due to poor transparency and 
documentation of the practices or different experiences within the organisation.  
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Furthermore, analysis of the responses according to gender and years of experience suggests 
further rationale for the variation in the individual QoDoS responses and the ten QDMPs 
based on differences in the characterises of the group. Some differences according to median 
were uncovered such as better incorporation of QDMP 3 (criteria) and QDMP 5 (alternatives) 
by females compared to males as well as by more experienced individuals compared to those 
with less experience; QDMP 7 (uncertainty) was also incorporated better by more 
experienced individuals compared to individuals with less experience. This therefore builds 
on the research of Beyer et al. (2015) as well as Cowlrick et al. (2011)  who evaluated the 
correlation between personality traits, functional role, education as well as gender and the 
decision making of individuals within pharmaceutical companies and regulatory authorities. 
Both studies demonstrate that these factors can explain the variability in judgments and 
decision-making techniques within organisations. Consequently, there may be other 
confounding factors, other than work experience or gender characteristics currently captured 
by QoDoS, such as personality traits, cultural differences and careers paths as well as 
differences due to training or exposure to research on decision making, which may also be 
important drivers of the differences in QDMP incorporation; this should be explored further.  
 
Next steps for improving the practices of individuals and organisations 
Structured feedback discussions are planned to take place with the study participants in order 
to further investigate the feasibility of the method used in the study, the perceived benefits as 
well as lessons learned and next steps. The initial discussions with the cohort leaders gave an 
early indication of a QoDoS study benefits, as described following a previous practicality 
study (Bujar et al, 2016).  First, simply completing the QoDoS instrument can increase an 
awareness of the biases and influences that need to be considered when making decisions, as 
well as the best practices (QDMPs) that should be incorporated into a decision-making 
framework of organisations.  Second, the QoDoS can be used to internally monitor and 
visualise an organisation’s decision making within and across different teams and divisions to 
provide a basis for discussions to build trust and to provide factual information on where 
improvements are needed in terms of the least favourable or least consistent practices. In 
addition, routine assessments using QoDoS has the ability to measure change over time in 
order to determine the impact of any improvement initiatives. The ongoing use of quality 
systems for making decisions will also reduce uncertainty around decision making and will 
result in more predictable and favourable outcomes. Finally, QoDoS can be utilised to 
externally benchmark an organisation’s decision-making practices and performance and 
compare it to those of other organisations. This in turn could be used for external discussions 
with stakeholders to identify and promote best practice as well as to build trust into key 
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strategic decisions made by organisations during medicines development, the regulatory 
review and HTA.  
 
It would be of interest to initiate similar studies with additional teams and groups to assess 
consistency of QDMPs within each of the three organisations. It would also be of value to 
involve other organisations, including smaller companies or agencies with less established 
systems, to determine how QDMPs are built into those organisations, compared to larger 
companies and agencies. It would also be of value to explore the research findings and themes 
identified above to determine their generalisability in other similar organisations. Of 
particular interest would be also to initiate more studies with HTA agencies. This chapter 
describes the first major application of QoDoS in an HTA setting and it would be important to 
continue testing the practicality of QoDoS in HTA agencies.  
 
Finally, as QoDoS represents a subjective assessment of decision making, it would be of 
interest to develop an additional instrument, which could take the form of a checklist, to 
objectively audit the results of a QoDoS study. For example if an organisation received a low 
score regarding QDMP 2 (assign clear roles and responsibilities), it would be expected that 
the organisation does not have clear SOPs and guidelines in place to establish the decision 
maker, advisor and  information provider at the start of the decision-making process. 
Secondly, if indeed areas of improvement were identified, QoDoS does not currently offer 
suggestions on how to address the least favourable practices. This could also be could be 
addressed by the checklist, which would include a set of measures and markers that agencies 
and companies could put in place to improve processes, such as the above example for 
QDMP 2. Such an approach will be explored in Chapter 8.  
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SUMMARY 
• This study was designed in the form of three cross-sectional case studies, with a 
pharmaceutical company, a regulatory authority and an HTA agency, where participants were 
asked to complete the QoDoS instrument to evaluate decision-making practices for pre-
specified decision points; sub-group analysis was also carried out for the company and 
regulatory authority responses 
• These studies aimed to demonstrate the practicality of QoDoS in identifying the incorporation 
of the ten QDMPs in three types of organisations  as well as identifying favourable and 
unfavourable practices and assessing the consistency and transparency of the ten QDMPs 
within each organisation, both regarding the individual practices and the perceived 
organisational practices 
• QoDoS demonstrated generally favourable practices across the three groups as well as the 
need for improvement across a number of QDMPs where some similarities were identified, 
such as the need for better assignment of values and relative importance to decision criteria 
(QDMP 3) as well as evaluation of alternatives (QDMP 5) for the three organisations and the 
need for better impact analysis for the regulatory and HTA agency (QDMP 8) 
• Variance around the responses may be a result of a mixture of factors:  inconsistencies in 
individual practices and differences in the perception of the organisation due to lack of 
knowledge around organisational practices or poor transparency and documentation 
• Analysis of responses according to gender and years of experience suggests some differences, 
but it is likely that there are other confounding factors, such as personality traits, cultural 
differences, careers paths as well as differences due to training or exposure to research on 
decision making, which may be also important drivers of differences in QDMP incorporation 
• Initial feedback from participants confirmed the feasibility and benefits of the study method: 
raising awareness of biases and best practices in decision making, gaining a basis for 
discussion  of the issues in decision making and making recommendations for improving an 
organisation’s practice 
• More formal discussions have been organised and will aim to determine from the entire study 
cohort the rationale for the responses, the perceived benefits of the study as well as lessons 
learned and next steps 
• Other next steps would seek to organise additional QoDoS studies in additional organisations, 
including less mature or smaller organisations as well as HTA agencies 
• In addition it would be of interest to develop a methodology to objectively audit the QoDoS 
results and thereby list the measures and markers and organisation could instigate to ensure 
the practical incorporation of the ten QDMPs, where a checklist approach will be explored in 
the next chapter. 
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CHAPTER 8 
 
 
 
 
 
 
Development of Practical Approaches for Integrating 
Quality into Decision-Making Practices in Medicines 
Development, Regulatory Review and Health 
Technology Assessment (HTA) 
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INTRODUCTION 
Decisions, ranging from the mundane to the critically important, are constantly being made 
throughout the lifecycle of medicines. Those decisions, no matter the field, are taken under 
conditions of uncertainty (Eichler et al., 2008) and without an established process for 
accounting for people’s subjective judgments in order to minimise bias. Lovallo and Sibony 
(2016) stated that, organisations “cannot afford to ignore the human factor in making strategic 
decisions. They can greatly improve their chances of making good ones by becoming more 
aware of the way cognitive biases can mislead them, by reviewing their decision-making 
processes and by establishing a culture of constructive debate.” 
 
Results from a survey of pharmaceutical companies, regulatory authorities and health 
technology assessment (HTA) agencies (Chapter 3 and Chapter 4) indicated that less than half 
the companies (41%) and only 20% of the regulatory authorities have formal assessments in 
place to periodically measure the quality of their regulatory decision making, whereas 
regarding reimbursement processes, this was carried out by 36% of the health economics and 
outcomes research (HEOR) company departments and 55% of the HTA agencies. These 
assessments included re-evaluation based on the outcome, feedback from stakeholders and 
audits of decision making. In the same survey, respondents indicated that there are ways of 
measuring the quality of decision making, relating to evaluating the actual practices as well as 
the outcomes, although such measurements are not always incorporated into the 
organisations. Nevertheless, if the quality of the decision-making process is truly key to 
increasing the probability of making good decisions and in building trust in those decisions 
(Kahneman, 2011), then the challenges that stand in the way of the measurement of decision 
making should be determined and ways to meet those challenges proposed. 
 
The Ten Quality Decision-Making Practices (QDMPs) were identified through empirical 
research to identify important issues that influence quality decision making (Donelan et al., 
2015). The QDMPs have been organised into four areas, namely, ‘Structure and Approach’, 
’Evaluation’, ‘Impact’ and ‘Transparency and Communication’. One way to measure decision 
making could be based on a pre-specified agreement regarding what a successful decision 
would look like, including an anticipated positive result.  Indeed, one of the QDMPs specifies 
the performance of an impact analysis of the decision, but this may not be a good measure of 
the total decision-making process, as indeed a good decision-making process may lead to a 
bad outcome and vice versa due to uncertainty.  However, despite the challenges to the direct 
measurement of quality decision making and its outcome, by understanding the components 
of quality decision-making practices, it may be possible to build a methodology to develop 
measures and markers against each practice to ensure that the practice is embedded within 
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organisational and individual processes. Such an approach could take the form of a checklist, 
already utilised widely in a number of industries and disciplines including medicine and 
aviation, in order to ensure a quality decision-making process (Gawande, 2011). The 
utilisation of a checklist during key strategic decision making by pharmaceutical companies, 
regulatory authorities and HTA agencies would ensure process quality, consistency and 
transparency both internally as well to external stakeholders to promote efficiency and build 
trust. 
 
The aim of this study was to develop practical approaches for integrating quality into the 
decision-making processes during medicines development, regulatory review and HTA. The 
objectives were to: 
• Identify the challenges and solutions to measuring the quality of decision 
making as defined by the ten QDMPs 
• Explore the role of external assessment of decision-making processes and 
outcomes to eliminate inherent internal biases 
• Examine how organisations should practically incorporate quality into their 
decision-making processes across the ten QDMPs 
• Develop practical approaches for reducing biases in decision making 
• Formulate the markers that organisations could instigate to ensure a quality 
decision-making process 
• Investigate if these markers could ultimately be correlated to the outcome of 
the process 
• Develop a checklist for the ten QDMPs by investigating how pharmaceutical 
companies, regulatory authorities and HTA agencies can integrate quality 
into their decision-making processes 
 
METHOD 
Design of the study 
This study was designed in the form of focus groups in order to develop and generate ideas as 
well as explore issues of shared importance for building quality into decision making 
throughout medicines development, the regulatory review and HTA. Three sets of research 
questions were generated based on the findings from other studies described earlier (i.e. 
Chapters 3-7) in order to explore different aspects of decision making. The research questions 
were initially shared by email with a small group of experts from pharmaceutical companies, 
regulatory authorities and HTA agencies with at least 15 years of professional experience in 
order to ensure that the questions were relevant and clear. In summary, the comments were 
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positive and used to make minor wording changes to the questions. Subsequently, three focus 
groups were organised for the purpose of this study (Table 8.1). 
 
Table 8.1 Research questions across the three focus groups 
Focus 
Group 
Research questions 
A 
What are the practical challenges to measuring quality of decision making within a 
company and an agency/authority; what are the potential solutions and is there a 
role for external assessment of decision-making processes and outcome to eliminate 
inherent internal biases? 
B 
How should pharmaceutical companies, regulatory authorities and HTA agencies 
practically incorporate quality into their decision-making process as defined by the 
ten QDMPs and practical approaches for reducing biases in decision making? 
C 
What could be the markers that an organisation could instigate to ensure that a 
quality decision-making process is embedded and to know if an organisation has 
improved; how could these markers ultimately be correlated to the outcome of the 
decision? 
 
Study participants 
The focus groups were organised as part of an international workshop on quality decision 
making (CIRS, 2017). Study participants were selected using purposive sampling from 
pharmaceutical companies, regulatory authorities, HTA agencies and academia based on their 
professional experience. They were all at a managerial or senior executive level within their 
respective organisations and therefore regarded as being key opinion leaders. Due to the 
complexity of the topic and a broad range of stakeholders involved, a target sample size of 20 
individuals per group was sought, as opposed to the recommended size of four to 12 (Breen, 
2006; Saunders et al., 2009). The three groups were set up in order to ensure that each was 
similar in terms of size and participant demographics (Table 8.2).  
 
Table 8.2 Demographic characteristics of the study participants 
Focus 
Group 
Total 
number of 
participants 
Number of respondents by organisation 
Number of 
respondents 
by gender 
Pharmaceutical 
companies 
Regulatory 
authorities 
HTA 
agencies 
Academia Male Female 
A 20 11 4 1 4 10 10 
B 21 13 4 1 3 9 12 
C 20 12 4 0 4 11 9 
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As recommended by Nagle and Williams (2013), each focus group was assigned a facilitator, 
based on professional experience and the willingness to participate, whose role was to 
moderate the group discussion and to ensure that the focus group functioned properly, namely 
that all members had an opportunity to actively participate, that all relevant matters were 
discussed and that effective conclusions and recommendations were made. In addition, each 
focus group was assigned a rapporteur, whose role was to record the output of the discussion 
and present it to the participants to ensure that all the relevant information has been captured. 
The session was not recorded to respect the confidentiality of the group and to encourage 
open communication as well as free exchange of ideas. 
 
Study procedure 
The focus groups were planned as three parallel sessions as part of an international workshop 
on quality decision making (CIRS, 2017). The steps carried out in order to plan and undertake 
the study are listed in Figure 8.1 and are in more detail described below. The planning phase 
was initiated approximately six months prior to the study to first define the purpose and 
research questions (Table 8.3). Approximately three months prior to the study, participants 
were invited to the workshop, which was organised in Washington DC, USA. 
 
Approximately six weeks ahead of the study, the following items were developed:  
1. The discussion notes, which firstly included definitions of a ‘framework’ (adopted from 
Chapters 3 and 4) as well as the list of ten QDMPs and secondly the background to the focus 
group discussion was described as per the introduction to this chapter;  
2. The discussion prompts relating to the ten QDMPS, as outlined in Table 8.3. 
3. Guidance notes for the facilitator and the rapporteur in order to clarify their role as 
described in the previous section (Nagle and Williams, 2013).  
The notes were shared with the participants one week prior to the study. 
 
The three focus groups were organised in June 2017 and were preceded by a half-day 
workshop session with opening presentations in order to set the scene and to introduce the 
participants to the area of quality decision making. Following this, each focus group was set-
up in a separate room as a roundtable session and started with a 30 minute introduction of the 
participants and the reading of the discussion questions and prompts. During the main two-
hour session, each group was requested to address the research questions with the aid of the 
discussion prompts (Table 8.3). Participants were also asked to make general 
recommendations in the area of measuring and incorporating quality decision-making 
practices.  
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The discussions were documented and then qualitatively summarised by the rapporteur and 
the summary was reviewed together with each focus group to ensure that all key discussions 
points, outcomes and recommendations were captured.  Following the completion of the 
focus group sessions, the rapporteurs presented the results to the workshop participants across 
the three groups in the form of ten minute presentations and the topics were subsequently 
discussed by the combined workshop group.  
 
Figure 8.1 Focus group study procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 
 
Study planning steps and preparation of the three focus groups 
Combined workshop sessions with all participants from the three focus groups 
Individual parallel focus group sessions  
Post-study steps  
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Table 8.3 Discussion prompts relating to the ten Quality Decision-Making Practice 
(QDMP) for the three focus groups 
 FOCUS GROUP A FOCUS 
GROUP B 
FOCUS GROUP C 
Quality Decision- 
Making Practice 
Practical 
challenges 
to these 
practices 
being 
measured 
Potential 
internal or 
external 
solutions to 
overcome 
the 
challenges 
Methods to 
ensure 
incorporation 
of  practices 
and 
reduction of 
biases 
Markers to 
ensure the 
practice is 
embedded 
into the 
process 
Methods to 
ultimately 
correlate 
markers with 
the outcome 
of the 
decision 
1. Have a 
systematic, 
structured 
approach to aid 
decision making 
(consistent, 
predictable and 
timely)  
     
2. Assign clear 
roles and 
responsibilities 
(decision makers, 
advisors, 
contributors)  
     
3. Assign values 
and importance to 
decision criteria  
     
4. Evaluate both 
internal and 
external 
influences/biases  
     
5. Examine 
alternative 
solutions  
     
6.Consider 
uncertainty 
     
7. Re-evaluate as 
new information 
becomes available  
     
8. Perform impact 
analysis of the 
decision  
     
9. Ensure 
transparency and 
provide a record 
trail   
     
10. Effectively 
communicate the 
basis of the 
decision   
     
 
 
  
191 
Data processing and analysis 
Following the workshop, the output from each focus group was further reviewed in order to 
convert the findings from the rapporteur presentation and discussions notes into a report based 
summary. The report, as per the results and discussion sections of this chapter, was 
subsequently shared with the participants (Walker et al., 2017). 
 
Development of the checklist for incorporating the ten QDMPs 
The stakeholder perspectives and suggestions from the three focus groups were assessed in 
comparison with the outcomes of the other major studies undertaken as part of this research 
programme, namely: 
1. Literature search (Chapter 1) and systematic literature review (Chapter 5) 
2. Evaluation of the Quality of Regulatory Decision-Making Processes in 
Pharmaceutical Companies and Regulatory Authorities (Chapter 3) 
3. Evaluation of the quality of Reimbursement Decision-Making Processes in 
Pharmaceutical Companies and HTA Agencies (Chapter 4) 
4. Assessment of the ten QDMPs in a pharmaceutical company, a regulatory authority 
and an HTA agency with the Quality of Decision-Making Orientation Scheme 
(QoDoS) (Chapter 7) 
A qualitative comparative analysis of these various outcomes highlighted the key challenges 
faced by the pharmaceutical companies, regulatory authorities and HTA agencies as a first 
step for making the necessary recommendations regarding how organisations can integrate 
quality decision making into their processes. These facilitated the proposal of a checklist for 
incorporating the ten QDMPs into the processes of the three stakeholders. 
 
RESULTS 
This study focused on identifying across the key stakeholders involved in the lifecycle of 
medicines: the challenges and solutions to measuring the quality of decision making; methods 
for incorporating the quality decision-making practices as well as markers to ensure practices 
are embedded within organisations and whether markers could correlate to the outcome of the 
decision. For the purpose of clarity the results are presented in four parts: 
• Part I: Findings from focus group A 
• Part II: Findings from focus group B 
• Part III: Findings from focus group C 
• Part IV: Recommendations from the three focus groups 
• Part V: Development of a checklist for incorporating the ten QDMPs 
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Part I: Findings from focus group A 
The aim of focus group A was to identify the practical challenges to measuring the quality of 
decision making within pharmaceutical companies, regulatory authorities or HTA agencies, 
as well as the potential solutions. In addition, the group was asked to discuss the role for the 
external assessment of decision-making processes and outcomes to eliminate internal biases. 
 
Practical challenges 
The practical challenges to measuring and ensuring quality decision making identified by the 
group are listed in Table 8.4. It should be noted that the participants also considered this in the 
wider context of developing an organisational programme in quality decision making. The 
participants discussed that in addition to the basic barrier of the natural human resistance to 
change, differing and sometimes clashing cultural perspectives and considerations regarding 
the decision-making process within and among organisations and geographic areas represent 
important challenges to measuring the quality of decision making. These cultural differences 
can include a disparity in the levels of organisational readiness for the increased transparency 
that is required to measure the quality of decision making. Organisations will also vary as to 
their ability or willingness to identify and implement objective measures to assess decision 
quality and the availability and acceptance of the tools and the training required to use them. 
There may even be a perception within an organisation that decision quality has already been 
achieved and therefore does not need to be evaluated (Spetzler et al., 2016). 
 
Table 8.4 Practical challenges to measuring quality of decision making and developing                                        
a quality decision-making programme within each organisation 
Practical challenges 
• Cultural perspective/considerations for decision-making process 
• Opinion that quality decision making has already been achieved 
• General resistance to change as part of human nature 
• Need to link quality decision-making process to outcomes in order to gain buy-in 
• Competing resources and priorities 
• Administrative/bureaucratic burden to implement a quality decision-making process 
• Management and communication of decision quality under crisis conditions only 
• Complexity of implementation of quality decision making in a project matrix structure 
• Organisational readiness for increased transparency not achieved 
• Lack of availability and/or acceptance of decision tools and training 
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It was discussed that even in organisations that recognise that quality decision making is 
important, quality processes may not be implemented because of many competing business 
priorities or because of the perception of the administrative or bureaucratic burden associated 
with implementing a quality decision-making programme. This may be particularly true when 
considering ongoing decision making within the complex project matrix structure that exists 
within most pharmaceutical companies. An additional challenge is that the communication 
and management of quality decision making is only prioritised under crisis conditions (such 
as rejection of a medicine by a regulatory authority), whereas it should be important 
regardless of the circumstances. Finally, despite knowledge of the fact that quality decision-
making practices may not result in positive outcomes, the tendency for data-driven 
organisations to link outcomes to the quality of processes may need to be overcome. 
 
Potential solutions 
The potential solutions identified by the group are listed in Table 8.5, both regarding how to 
measure quality of decision making as well as for developing an organisational programme in 
quality decision making. Participants agreed that decision quality champions are required to 
overcome organisational resistance to change. Discussants emphasised that it is important to 
differentiate between a champion, who assumes ownership of a quality decision-making 
programme and strives to convince colleagues of its applicability and effectiveness and an 
external expert, who might be more objective. Whilst an external champion for quality 
decision making can be used, they would need to be combined with an internal champion at a 
managerial level who would have the influence to drive change. A combination of internal 
champions at the operational and managerial level, that is, a combined bottom-up and top-
down approach, would seem the most effective in implementing quality decision making. 
Quality decision programmes may be adversely affected, however, with organisational shifts 
that result in the removal of the managerial champion. 
 
To mitigate individual and organisational resistance, it is important for the programme 
champion to have a value proposition in place that includes the identification and highlighting 
dissatisfaction with the status quo as well as “selling points’ for the quality decision 
programme’s ability to increase predictability and efficiency in decision making. Clear 
communication regarding the necessary separation of the quality of the decision process from 
the decision outcome is essential, as is the establishment of clear decision-making roles and 
responsibilities and the use of an established decision-making framework. Managerial or 
organisational buy-in to decision making quality programmes should include the development 
of training and the integration of the training into the employee competencies managed by 
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human resource departments, including structured and scheduled “lessons-learned” exercises 
and non-conformity reports. 
 
Table 8.5 Potential solutions to measuring quality of decision making and success factors 
for developing a decision making quality programme 
Potential solutions and success factors 
• Independent teams to review quality decision making – internal peer review 
• Quality decision making value proposition – selling points to mitigate resistance to 
decision quality 
– Increase predictability in decision making 
– Increase efficiency in decision making 
• Champions for quality decision making – management commitment 
• Training in quality decision making – integration into employee competencies 
• Identify/highlight dissatisfaction with status quo 
• Structured, regular lessons-learned exercises 
– Integration of quality decision making into quality management system  
– Consider external accreditation opportunities – ISO9001  
– Change management         
– Non-conformity reporting and assessment 
• Benchmarking/comparative data 
– In-industry    
– Comparable industries  
• Assessment of decision process – blind to the outcome 
• Define clear roles and responsibilities in the decision-making process 
 
External assessments 
Citing the peer review of decisions in place at the EMA (2010), discussants recommended the 
use of independent review teams within organisations to conduct separate evidence-based 
evaluations of those decisions (Table 8.5). Baseline decision-making data should be 
established through status quo analysis of individual organisations and data accrued for 
purposes of comparison, from both within industry and comparable business models. Case 
studies could be created for organisations that have already implemented quality decision-
making programmes and external accreditation opportunities similar to ISO9001 
(International Standards Organization; family of quality management systems standards) 
could also be considered. Any assessment of an organisation’s decision process should be 
blind to the outcome of decisions.   
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Part II: Findings from focus group B 
Focus group B was tasked with determining how pharmaceutical companies, regulatory 
authorities and HTA agencies should practically incorporate quality into their decision-
making process as defined by the ten QDMPs, as well as with developing practical 
approaches for reducing biases in decision making. 
 
Incorporation of the ten Quality Decision-Making Practices 
The discussants developed key methods for ensuring the incorporation of frameworks, 
consisting of the ten Quality Decision-Making Practices, into organisational processes (Figure 
8.2). It was agreed that not all decisions require the use of a decision framework in its full 
context and, in addition, the development of a guide for use of the framework that explains 
the rationale for its application would be beneficial.  Quality decision-making practices 
should play an important role throughout the life cycle of medicines and decision makers 
should be aware of the crucial decision points where their use may be of critical importance. 
An example of such a decision point would be when sponsors and investigators must decide 
what kind of human exposure a medicine can be given based on the data from nonclinical 
studies. It is also important to understand the potential of a framework and of QDMPs to 
accelerate critical decision making.   
 
Discussants agreed that decision making relies not only on data, but also on additional factors, 
such as early interaction and communication among all stakeholders.  In particular, 
pharmaceutical decision-making processes should incorporate the perspective of patients and 
payers as early in the life cycle as possible. In fact, patients should be considered as research 
partners throughout medicine’s development, regulatory review and HTA and in addition to 
well-designed studies, patient-generated data from new technologies may be an important 
resource in this regard.  
 
Likewise, to manage expectations before the submission of a marketing authorisation 
application, the sponsors of new medicines should request early consultations and ongoing 
meetings at key product developmental milestones with regulators as well as with health 
technology assessment agencies where possible. This approach to early, collaborative 
communication could facilitate organisations to better align their decision making, both 
externally between companies, regulatory authorities and HTA agencies as well as internally, 
for example between regulatory and HEOR departments within a pharmaceutical company. In 
addition, having different stakeholders using the QDMP-based framework could improve 
external and internal alignment and interactions. 
 
  
196 
Figure 8.2 Methods for incorporating quality decision-making practices into 
pharmaceutical companies, regulatory authorities and health technology assessment 
(HTA) agencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identifying and mitigating internal and external influences and biases  
Because the term bias has a negative connotation, it may be more helpful to consider the 
impact of internal and external behavioural influences on decision making. Practical 
approaches to mitigate these influences should be based on the objectives of individual 
decisions (Table 8.6). It was agreed that the grouping of biases/influences developed by 
Lovallo and Sibony (2010), namely action-oriented biases (e.g. having a tendency to take 
immediate action), interest biases (e.g. having a conflict of interest in committee setting), 
pattern-recognition biases (e.g. seeking evidence to support own views) and stability biases 
(e.g. tendency to do things as always), is appropriate and relevant in the context of medicines 
development, regulatory review and HTA. Furthermore, the categorisation introduces order to 
discussion around the behavioural influences within an organisation. Such discussions are key 
to raising awareness of these biases on the decision-making process of individuals and groups 
and eventually create an equilibrium in influencing the ultimate decision. Nevertheless, in 
addition to raising awareness, work is required to develop a model for mitigating biases 
within organisations. 
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Table 8.6 Approaches to mitigate influences/biases in decision making and the goals of 
those approaches 
Approaches to mitigate biases Objectives of the approach 
Discuss and categorise influences as per 
Lovallo and Sibony (2010) 
To introduce order and awareness and 
potentially create equilibrium in the group 
Openly state perspectives throughout the 
decision-making process 
To establish trust and transparency needed for 
decision making 
Examine and discuss the criteria for and 
documentation of decision making  
To determine a clear scope and ensure 
incorporation of good practice in decision 
making 
Establish committees, make decisions 
through consensus and re-examine negative 
decisions 
To bring in internal views and introduce 
objectivity into decision making 
 
Because transparency underpins trust in decision making, stakeholders should openly state 
their perspectives at the beginning and throughout the process. In addition, decision makers 
need to examine and discuss the criteria for and documentation of decision making, 
establishing a clear scope and ensuring that good practices are incorporated. The 
establishment of decision committees will bring in external views and introduce objectivity 
into decision making. Finally, where possible, decisions should be made through consensus 
and unfavourable outcomes should be followed-up by a re-examination of the decision-
making process.  
 
Part III: Findings from focus group C 
The remit of focus group C was to discuss markers that an organisation could instigate to 
ensure that a quality decision-making process is integrated with its culture and to know if it 
has improved its decision-making practices. In addition the group was asked to consider 
whether these markers of the decision-making process could be correlated to the outcome of 
the decision. 
 
Markers for a quality-decision-making process 
Participants discussed the categorisation of the ten QDMPs, currently organised into four 
groups, namely: 
• Structure and Approach (QDMPs 1 and 2) 
• Evaluation (QDMPs 3, 4, 5, 6 and 7) 
• Impact (QDMP 8) 
• Transparency and Communication (QDMPs 9 and 10). 
 
The group participants proposed reorganising the four categories as follows: 
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• Establish who, why and how decisions are made (QDMPs 1,2 and 3),  
• Ensure decision quality, relevance and importance (QDMPs 4, 6 and 7),  
• Consider decision alternatives and impact (QDMPs 5 and 8)  and  
• Ensure decision transparency and communication (QDMPs 9 and 10).     
 
Consequently, the key difference is the location of QDMP 3 (Roles and Responsibilities) and 
5 (Alternatives). It appears that the new approach proposed by the focus groups is more 
logical, as roles should be considered at the start of decision-making process, whereas 
alternatives should be discussed in the context of impact (Table 8.7). In addition, the new 
grouping results in a more balanced division of the ten QDMPs, where each of the four 
categories consists of two to three practices (as opposed to previous approach where ‘impact’ 
consisted of one practice and ‘evaluation’ of five practices).  
 
Participants further agreed that documentation is a key marker of quality decision making and 
specified that for practices 1,2 and 3, this should include documenting the decision-making 
framework utilised, the decision criteria as well as any weighting or ranking used, standard 
operating procedures (SOPs) and a list of participants including their roles and responsibilities 
(Table 8.7). The participants should be accountable for adherence to the SOPs and decisions 
should reflect their perspectives. Documentation of practises 4, 6 and 7 should include a 
summary of the approach used for evaluating biases, uncertainties that were considered and 
fully defined triggers for the re-evaluation of the decision. Documentation for practices 5 and 
8 should include a list of the alternatives to the decision that were considered and the template 
that was used to perform an analysis of the impact of the decision.  Finally, documentation for 
practices 9 and 10 should include a template to be used for the communication of the 
decision, both internally and externally. 
 
Correlating markers for quality decision-making process and outcomes 
It was discussed whether documentation as a marker for quality decision making facilitates 
linking the decision-making process and outcome, although indeed a quality process does not 
always guarantee a good outcome. By documenting the decision at the time it is made, 
including all the key markers outlined in Table 8.7, as well as documenting an expected 
outcome of the decision would provide a basis for comparison.  
 
The ability to look back and evaluate the quality of past decision making can inform future 
decisions, but this typically occurs when there has been an unfavourable outcome such as a 
lack of regulatory approval or the withdrawal of a drug for safety concerns. Re-evaluation on 
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the other hand is less common when the outcome of a decision has been favourable or as 
anticipated, when such a discussion may be considered by some to be a waste of resources.  
Nevertheless, such evaluations and comparisons should occur over multiple points in time and 
regardless of whether the outcome is positive or negative. Moreover, it is important that 
lessons are learned not only from negative, but also from the positive outcomes in order to 
highlight the use of best practices. 
 
Table 8.7 Quality Decision-Making Practices (QDMPs) according to their goal and 
specified documentation as a clear marker of quality decision making 
Quality Decision-Making Practices 
(QDMPs) 
Goal of the 
practices 
Documentation marker 
1. Have a systematic, structured 
approach to aid decision making  
2. Assign clear roles and 
responsibilities (decision makers,  
advisors, contributors)  
3. Assign values and importance to 
decision criteria  
Establish who, 
how and why 
decision is made 
• Rigorous process defined 
by SOPs 
• Decision template with 
decision framework and 
weighting criteria 
• List of participants and 
their perspectives 
4. Evaluate both internal and 
external influences/biases  
6. Consider uncertainty 
7.  Re-evaluate as new information 
becomes available  
Ensure 
information 
quality, relevance 
and importance 
• Approach used to evaluate 
bias 
•  Uncertainties that were 
considered 
•  Clearly defined triggers 
for re-evaluation 
5. Examine alternative solutions 
8.  Perform impact analysis of the 
decision  
Consider 
alternatives and 
impact 
• Alternatives that were 
considered 
• Template for impact 
analysis 
9. Ensure transparency and provide 
a record trail   
10. Effectively communicate the 
basis of the decision 
Communicate 
clearly and 
openly 
• Template for decision 
communication internally 
and externally 
 
Part IV: Recommendations from the focus groups 
Finally, the participants across the three focus groups A, B and C developed 
recommendations to advance progress in the area of measuring and incorporating good 
decision-making practices (Table 8.8). These recommendations have been categorised into 
three groups, namely recommendations relating to future research directions for building the 
evidence around quality decision-making practices; secondly recommendations for 
organisations regarding what may be the issues that need to be internally considered to build 
quality into the decision process and lastly relating to approaches for measuring the processes 
and outcomes within organisations. 
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Table 8.8 Recommendations from the focus group discussions 
Recommendation 
category 
Recommendations from the Focus Groups 
Future research 
directions for 
building the 
evidence around 
quality decision-
making practices 
• Accrue benchmarking data on organisational decision making 
quality for pharmaceutical companies, regulatory authorities and 
HTA agencies 
• Generate case studies of organisations where quality decision-
making programmes have been implemented 
• Consider a controlled pilot in which agencies and companies 
compare the results of decision making with and without a 
structured framework and the ten QDMPs   
• Organise an exercise among agencies and companies to determine 
if using the ten QDMPs improves communication and interactions  
• Analyse joint venture decision-making processes e.g. parallel 
processes between regulatory authorities and HTA agencies; 
product acquisition between companies 
• Develop a new model of bias mitigation starting with a change in 
terminology to behavioural influences 
Internal 
considerations for 
building quality 
into the decision 
process 
• Clarify that as a result of uncertainty a quality decision-making 
process may result in either a positive outcome or an unfavourable 
outcome including project termination 
• Create a value proposition/business case for decision quality that 
includes the provision of clearer articulation of decisions 
• Define clear decision-making roles and responsibilities  
• Create appropriate motivational incentives and an environment to 
balance the internal and external influences 
• Conduct post-decision-making discussions between stakeholders 
Internal 
considerations for 
measuring the 
processes and 
outcomes of 
decision making 
• Perform status quo analysis of an organisation’s decision-making 
process and continue to re-evaluate in future particularly with 
process improvement initiatives  
• Ensure the availability of documentation at the time of decision  
• Examine and highlight the importance of the rationale for quality 
decision making not just the methodology 
• Document the expected outcome at the time of the decision so 
there is a basis for comparison 
• Assess the quality of decision making across multiple decisions 
 
Part V: Development of a checklist for incorporating the ten QDMPs 
A checklist approach was supported by the focus group participants  as a way to outlining the 
practical steps for incorporating the ten QDMPs into an organisation. The participants 
highlighted, in line with previous research on checklists (Gawande, 2011) that such a 
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checklist should be clear, concise and user friendly. In order to generate the initial checklist 
items, the recommendations from the focus groups were qualitatively reviewed alongside 
other findings from the studies undertaken as part of this research programme (Figure 8.3), 
namely a review of literature as summarised in the thesis introduction and Chapter 5, as well 
as findings from other studies undertaken as part of this research project, specifically 
questionnaires undertaken with companies, regulatory authorities and HTA agencies 
described in Chapters 3 and 4 as well as decision-making studies with QoDoS summarised in 
Chapter 7. Interestingly, many overlaps were found, such as regarding the need to introduce 
approaches to bias mitigation, ensure clear communication of decision making through 
templates and ensure capacity building and education within organisations to minimise 
reluctance to quality decision making. The generated and revised items were then organised 
according to the ten QDMPs in order to outline the appropriate steps under each practice for 
incorporating quality into key strategic decision-making processes.  
 
The findings from the literature review have demonstrated that there are two key aspects of 
incorporating quality into decision making: firstly ensuring that at the management level there 
are appropriate mechanisms in place, such as templates, guidelines and process steps, to build 
quality into an organisation’s decision making (Hammond et al., 1999; Kahneman, 2011; 
Spetzler et al., 2016); secondly, as noted further by Spetzler and colleagues (2016), 
organisations need to ensure that these various mechanisms and steps are followed at the time 
of the decision making for any key strategic decisions. Consequently, a two part-checklist was 
developed (Table 8.9). The first part of the checklist should be therefore used by companies 
and agencies during general management or team meetings to prospectively plan how to 
integrate the QDMPs into its framework and project matrix structure, including key process 
steps, templates and documents that should be in place. In addition, in order to enable a 
quality process at the time of the actual decision making, part two of the checklist identifies 
process steps that organisations should establish and document in order to enable process 
quality, transparency and consistency for key strategic decisions. The development of a 
manual is beyond the scope of this study, but this could further facilitate and encourage the 
use of this checklist, including how and when it would completed and by whom. 
 
 
 
 
 
 
  
202 
Figure 8.3 Study outcomes utilised in the development of the checklist for quality 
decision making 
 
 
 
Literature review 
(Chapter 1 and 5) 
Questionnaires 
(Chapter 3 and 4) 
QoDoS studies and 
Focus Groups  
(Chapter 7 and 8) 
1. Qualitative assessment of study outcomes 
Checklist (Table 8.9) 
2. Checklist item generation 
3. Checklist item revision and categorisation according  
to the ten quality decision-making practices 
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Table 8.9 Checklist for the implementation of the ten Quality Decision-Making Practices (QDMPs) 
Part I: Steps to ensure that the practice is incorporated into the organisational framework before the decision-making process 
QUALITY DECISION-MAKING 
PRACTICE 
IS THE ITEM IS IN PLACE AT YOUR ORGANISATION AHEAD OF THE DECISION-MAKING 
PROCESS? 
YES NO 
1. HAVE A SYSTEMATIC, 
STRUCTURED APPROACH TO AID 
DECISION MAKING 
Guidelines for quality decision making   
Standard operating procedures   
Training programme for quality decision making   
Internal champion on quality decision making   
Collaboration with external experts in decision making quality   
2. ASSIGN CLEAR ROLES AND 
RESPONSIBILITIES 
Documents for ensuring adherence to SOPs and guidelines by stakeholders   
Template for documenting participants involved in decision making and their roles and responsibilities   
3. ASSIGN VALUES AND 
IMPORTANCE TO DECISION 
CRITERIA 
Template for defining decision criteria   
Template for assigning weights to criteria   
4. EVALUATE BOTH INTERNAL 
AND EXTERNAL 
INFLUENCES/BIASES 
Approaches for minimising biases/influences   
Templates for documenting potential influences and conflicts of interest   
Staff training programmes for minimising biases/influences   
5. EXAMINE ALTERNATIVE 
SOLUTIONS 
Procedure for exploring and generating multiple innovative alternatives against decision criteria   
Templates for assessing alternatives, their consequences and trade-offs    
6.CONSIDER UNCERTAINTY 
Approach for assessing data limitations   
Sensitivity analysis models for assessment of risk regarding known events and unknowns   
7. RE-EVALUATE AS NEW 
INFORMATION BECOMES 
AVAILABLE 
System for triggering re-evaluation of decision making   
Model for assessing value of new information (positive or negative)   
8. PERFORM IMPACT ANALYSIS 
OF THE DECISION 
Approach for linking relevant or similar decisions   
Template for impact analysis    
Planning tool for decision implementation   
Approach for early interactions with key stakeholders   
9. ENSURE TRANSPARENCY AND 
PROVIDE A RECORD TRAIL 
Template for recording decision at the time it was made    
Documents for internal and external audits   
10. EFFECTIVELY COMMUNICATE 
DECISION BASIS 
Templates for internal and external communication of  evidence, the deliberative process, consideration and 
uncertainties  
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Part II: Steps to ensure that the practice is followed at the time of decision making for key strategic decisions 
QUALITY DECISION-MAKING 
PRACTICE 
IS THE ITEM IS ESTABLISEHD AND DOCUMENTED AT THE TIME OF DECISION-MAKING PROCESS? YES NO 
1. HAVE A SYSTEMATIC, 
STRUCTURED APPROACH TO 
AID DECISION MAKING 
Defined decision frame including objectives, scope and decision importance   
List of data requirements, key variables and assumptions and how they relate   
Defined process steps and timelines   
2. ASSIGN CLEAR ROLES AND 
RESPONSIBILITIES 
Composition of the decision group including list of decision makers, advisors and information providers   
Clear decision-making instructions for stakeholders    
3. ASSIGN VALUES AND 
IMPORTANCE TO DECISION 
CRITERIA 
Clear and distinct decision criteria   
Criteria evaluation through rating or ranking   
4. EVALUATE BOTH INTERNAL 
AND EXTERNAL 
INFLUENCES/BIASES 
Appropriate input and participation from all relevant stakeholders   
Objective assessment of political/financial/competitor influences   
Debate and/or presence of “devil’s advocate”     
Decision preference statement prior and post debate including explicit statement of conflict of interest   
5. EXAMINE ALTERNATIVE 
SOLUTIONS 
Generation of at least two distinct options by different individuals   
Brainstorming of alternatives e.g. by assuming you cannot see any current options or by assuming that the project fails   
Assessment of consequences for each alternative and trade-off analysis   
6.CONSIDER UNCERTAINTY 
Judgment of available data and limitations   
Risk preferences to reflect probability assessment of known and unknown events   
Sensitivity analysis of alternatives and against uncertainties   
7. RE-EVALUATE AS NEW 
INFORMATION BECOMES 
AVAILABLE 
List of time or data triggers for re-evaluation of decision (positive or negative)   
Assessment of value of additional knowledge   
Feasibility of information gathering   
8. PERFORM IMPACT ANALYSIS 
OF THE DECISION 
Assessment of linked or similar decisions   
Assessment of possible and expected outcomes now and in future   
Impact on internal and external stakeholders including Implementation and contingency plans   
9. ENSURE TRANSPARENCY 
AND PROVIDE A RECORD TRAIL 
Defined decision basis and key drivers including a list of areas of disagreement   
Commitment to action plan through resource allocation   
10. EFFECTIVELY 
COMMUNICATE DECISION 
BASIS 
List of relevant stakeholders to be informed   
Internal communication plan and timelines   
External communication plan and timelines   
  
205 
DISCUSSION 
The developed checklist, as a result of the study outcomes undertaken as part of this research 
programme (Chapters 3, 4 and 5), current and previous research on decision making 
(Hammond et al., 1999; Kahneman, 2011; Heath C and Heath D, 2013; Spetzler et al., 2016) 
as well as the focus group discussions, is an advancement in the field of quality decision 
making during the lifecycle of medicines. The checklist offers a new addition to the current 
decision quality toolbox, alongside of the ten QDMPs as well as the QoDoS (Donelan et al., 
2016). Although, the ten QDMPs provide the structure in the form of  best practices for 
decision making and the QoDoS tool identifies whether these best practices are followed or 
whether there are areas needing improvement, the checklist on the other hand provides a 
practical approach for ensuring that best practices are followed within an organisation, 
including process steps for embedding quality into an organisational structure ahead of 
decision making as well as what needs to be established or documented at the time of the 
actual decision-making process for key strategic decisions.  
 
Similar approaches exist in the area of medicines development and regulatory review, such as 
scorecards for assessing the quality of the regulatory review and submissions (Salek et al., 
2012) and templates for assessing the benefits and risks of a medicine during regulatory 
review (Leong et al., 2015). Nevertheless, the developed checklist proposes a novel approach 
for incorporating best practices into the broader decision-making processes within 
organisations for any key strategic decisions made by the stakeholders, beyond just regulatory 
review/submission and benefit-risk assessment. The development of a detailed manual for the 
use of the checklist was outside the scope of this study, but there is certainly a need to 
develop such a document as well as further evaluate the checklist with the target audience in 
order to establish its practicality, validity and relevance. Of need and interest would be to 
establish firstly the potential value compared to the burden of such as an approach, the clarity, 
relevance and user friendliness of the items (including any addition or reduction) and finally 
approaches for ensuring its utilisation and adherence. 
 
The checklist was designed in part based on the issues raised and recommendations made for 
building and assessing quality decision making, developing bias mitigation techniques and 
decision quality documentation markers. Ultimately, documentation of the decision would 
facilitate re-evaluation of the process in order to build transparency and trust. There are 
already some opportunities to re-evaluate decision making during the regulatory review such 
as, is anticipated will occur in Australia, where provisional regulatory approvals that are 
scheduled to begin in 2018 will include a time-bound directive to re-examine decisions 
(Bootes, 2017). It is envisioned that building the requirement for re-examination into the 
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legislation for provisional approvals will ensure that labelling is as broad or restricted as 
appropriate and that post-marketing commitments are fulfilled. Re-evaluation of a decision 
can also be part of an appeal or dispute resolution process with a regulatory authority such as 
the US FDA when new or different information that may impact a decision has emerged 
(FDA, 2017). It may be valuable to examine a case in which a regulatory authority issued a 
different decision as the result of such an appeal.  The re-evaluation of decision-making 
quality may prove more challenging around HTA where negotiation and advocacy are part of 
the decision-making process in addition to scientific evaluation. HTA bodies are also subject 
to additional economic and political external pressures that may affect decision making and 
add to the complexity of its evaluation. Finally, it should be recognised that the quality of 
decision making can rarely be isolated and evaluated as a single decision, but must be more 
typically considered as a continuum.  
 
The key challenges for measuring the quality of decision making relating to organisational 
issues such as culture, resource allocation and organisational willingness have also been 
identified by the focus groups. Interestingly, one of the challenges identified in this study 
regarding identification of objective measures for assessing the quality of decision-making 
process has already been addressed through this research programme, namely a literature 
review evaluating available measures (Chapter 5). In addition, the methodology developed for 
benchmarking organisational decision making in order to build a business case for quality 
decision making has also been developed (Bujar et al., 2016) and has been applied through 
three case studies with a pharmaceutical company, a regulatory authority and an HTA agency 
(Chapter 7). Moreover, a number of solutions proposed by the focus groups, such as 
identifying champions, providing training and ensuring clear roles and responsibilities have 
been implemented into the QDMP checklist. The methods for ensuring incorporation of 
quality by firstly deciding which decisions are key and selecting and integrating appropriate 
practices are also consistent with the general recommendations developed by Lovallo and 
Sibony (2010) regarding the science of decision making. In addition, the approaches 
developed in this study include additional key considerations specific to the area of 
medicines, such as ensuring communication and alignment across companies, regulatory 
authorities, HTA agencies and patients in order to ensure favourable outcomes. 
 
Nevertheless, it should be noted that perspectives differ as to whether individual decisions 
have been successful, which reinforces the argument that an analysis of outcomes has major 
limitations.  Regulators may view their decisions as appropriate inasmuch as the outcomes of 
those decisions achieve the regulatory objectives of ensuring access to treatment and avoiding 
the release of less effective medicines into the marketplace. In fact, if regulatory decisions 
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achieve those objectives, regulators may consider them to be correct and not subject to 
challenge. This viewpoint may make some regulators resistant to changes in their decision-
making practices. In evaluating the outcome of their decisions regarding medicines, industry 
asks if those decisions facilitated the approval of the label that was sought in a timely way; if 
the scope of that label was appropriate in terms of the designated population and dosage as 
well as if the post-marketing commitments and manufacturing specifications and limitations 
were as expected. The affordability of medicines as part of its HTA is also an important 
outcome of decision making that may not be considered as early or as often as necessary by 
all decision makers (Tafuri, 2013).  
 
However, there is a shared desire among decision makers in the development, regulation and 
HTA of medicines for the ultimate overall outcome of their decision making to be the 
improvement of public health for patients (Liberti et al., 2013). Indeed, this has been noted by 
the focus group participants that patients should be seen as research partners and that 
decision-making processes should incorporate the perspective of patients as early in the life 
cycle as possible. Work is in progress to develop a universal framework for patient 
involvement industry-led medicines research and development, regulatory review, or market 
access decisions (Hoos et al., 2015; Boutin et al., 2016). 
 
Finally, the use of the QDMPs and checklist approach in decision making by different 
stakeholders could improve alignment and interactions for the benefit of patients and build 
trust and transparency into the process through which medicines become available. The next 
steps would be to test and validate the checklist with pharmaceutical companies, regulatory 
authorities and HTA agencies to increase its user friendliness, clarity, relevance and 
applicability. A systematic literature review of other existing checklists, such as those utilised 
in medicine, aviation and other industries (Gawande, 2011) in order to learn from best 
practice in terms of checklist format and the procedure for utilising it (e.g. who should 
complete it). The validated checklist could then be utilised in a study to determine whether it 
increases the quality and consistency of decision making and its transparency to internal and 
external stakeholders. It is hoped that this checklist approach will ultimately gain wide 
acceptability by stakeholders and will become ‘‘standard practice’’ during the key decision-
making processes throughout the research and development of medicines. 
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SUMMARY 
• Despite the challenges to the direct measurement of quality decision making and its 
outcome, by understanding the components of QDMPs, it may be possible to build a 
checklist against each practice to ensure that it is embedded within organisational culture 
and individual processes 
• The aim of this study was to develop practical approaches for incorporating quality into 
the decision-making processes during medicines development, regulatory review and 
HTA 
• This study was designed in the form of three parallel focus groups (A, B and C) with 
individuals from pharmaceutical companies, regulatory authorities, HTA agencies and 
academia in order to develop and generate ideas as well as explore issues of shared 
importance for building quality into decision making throughout medicines development, 
regulatory review and HTA 
• The focus group A discussion resulted in the development of key challenges and solutions 
to measuring the quality of decision making and considerations for external assessments 
of decision making; focus group B developed methods for incorporating quality decision 
making into organisational processes as well as practical approaches for reducing biases 
in decision making and focus group C formulated the markers organisations could 
instigate to ensure that a quality decision-making process is incorporated. 
• All three focus groups developed recommendations regarding future research directions 
for building the evidence around quality decision-making practices, recommendations for 
organisations regarding what may be the issues that need to be internally considered to 
build quality into the decision process and lastly relating to approaches for measuring the 
processes and outcomes within organisations. 
• Stakeholder perspectives and suggestions from the three focus groups were assessed in 
comparison with the outcomes of the other major studies undertaken as part of this 
research programme in order to develop a checklist for incorporating the ten Quality 
Decision-Making Practices. 
• This checklist enables an organisation to incorporate these practices into its project matrix 
structure and lists process steps that need to be established and documented at the time of 
decision making in order to enable process quality, transparency and consistency.  
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CHAPTER 9 
 
 
 
 
 
 
 
 
General Discussion 
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INTRODUCTION 
The research on decision making has been amplified over the past two decades through the 
work of Hammond and colleagues (1999), Thaler and Sustein (2009), Kahneman (2011) and 
Spetzler (2016). It would therefore seem obvious for the numerous industries, where 
decisions are made under conditions of uncertainty, to incorporate the various findings and 
recommendations into their operations to increase the efficiency and effectiveness of 
processes. Surprisingly, this has not been the case as intuition and gut reactions still prevail, 
though some progress has been made in applying the research, particularly in the areas of 
aviation, economics, environmental protection, clinical practice, nuclear safety and 
government affairs (Rafliff et al., 1999; Hunink et al., 2001; Dowding and Thompson, 2003; 
Morton et al., 2009; Gawande, 2011; Thaler and Sustein, 2009; Wagner, 2013; Avorn, 2018). 
The uptake of this research into the pharmaceutical industry, regulatory authorities and HTA 
agencies has been nevertheless been slow and occurring only in specific areas, such as the 
benefit and risk assessment and the portfolio management of medicines (Sharpe and Keelin, 
1998; Cook et al., 2014; Pignatti et al., 2015). The gap was initially addressed through the 
research of Donelan and colleagues, which resulted in defining the best practices in decision 
making in the lifecycle of medicines, namely the ten Quality Decision-Making Practices 
(QDMPs), as well as the development of the Quality of Decision-Making Orientation Scheme 
(QoDoS) that can be used to measure the incorporation of these ten practices in companies 
and agencies (Donelan et al., 2015; 2016). However, the lack of application and 
implementation of these methods demonstrates that more work is needed to address the 
research gap. Indeed, despite pressures from the public to improve decision-making outcomes 
and accountability of companies and agencies, the focus so far has been on data generation 
and review, whereas it is not always certain how key strategic decisions, which involve 
subjective judgments and preferences, are made by individuals and organisations. For patients 
and other stakeholders, this process could resemble a “black box”, where only inputs and 
outputs are visible, so there is now an urgent need to address and improve the transparency of 
the process through which decisions are made around data.  
 
Moreover, in the world of medicine development and review, decisions can be subjective, 
where the lack of approval of a medicine with high uncertainty can be perceived positively by 
regulators who protect public health, but negatively by patients who may not have access to 
the medicine, due to different levels of risk appetite (Breckenridge and Walley, 2008). High 
uncertainty also means that the rigour of the process does not always correlate to the 
perceived quality of outcomes. Therefore, organisations and individuals cannot always 
control the outcome, but they can influence the process to ensure clarity and transparency. 
This may ultimately increase the probability of best outcomes in the long term. Furthermore, 
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processes should be clearly documented to facilitate audits and lessons learned as well as 
transparent communication. The ultimate aim would be to increase public understanding of 
the decisions with an agreement from all stakeholders that this was the best possible course of 
action taken. For example, a regulator should be explicit about the rationale for a decision 
(e.g. if a medicine is not approved due to safety concerns), so that if a different decision about 
the same product is made later on by the same agency (due to more information emerging) or 
by a different agency (due to different legal or scientific considerations), it is clearly 
understood by patients (Breckenridge et al., 2011; Tafuri, 2013). Interestingly, a recent review 
of factors which influence regulatory outcomes revealed that in addition to technical factors 
(e.g., clinical trial study designs, clinical evidence of efficacy), there exist other social 
considerations (e.g. regulatory processes followed and influence of advisory committee 
recommendations) which could be used to predict regulatory outcomes (Liberti et al., 2017). 
These were also the least studied factors, compared to technical factors; this gap needs to be 
addressed to understand why organisations, such as two regulatory authorities, can arrive at 
different decisions if faced with the same data. Such differences could therefore be explained 
on the basis of benefits, harms and uncertainty, their relative importance, as well as the 
decision-making process used including the involvement of patients at the time of the 
decision (Tafuri, 2013). 
 
These various considerations were highlighted at a recent Workshop on quality decision 
making, which brought together major companies, regulatory authorities and HTA agencies in 
order to make recommendations for advancing this relatively unexplored topic (Walker et al., 
2017). Importantly, a presentation from Carl Spetzler from Strategic Decision Group (SDG) 
demonstrated that some progress has been made, with case studies from a couple of the major 
pharmaceutical companies, which have created decision quality departments to broaden the 
importance of the science of decision making during medicines R&D. Nevertheless, this has 
not yet transpired into the regulatory and Health Economics and Outcomes Research (HEOR) 
company departments and functions, or the other stakeholders, namely regulatory authorities 
and HTA agencies.  All in all, the complexity and uncertainty regarding the development and 
assessment of medicines has created a need for new approaches and methodological tools as 
well as greater transparency of decision-making processes (Eichler et al., 2008). It is this idea 
that has fuelled the research described in this thesis, where a number of unique contributions 
have been made, culminating in an overarching roadmap for improving the quality decision-
making processes for key decisions made during the medicines development, regulatory 
review and HTA that will be presented in this chapter.  
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RESEARCH OUTCOMES AND CONTRIBUTIONS 
Despite interest in characterising the decision-making processes of pharmaceutical 
companies, regulatory authorities and HTA agencies, no studies have been undertaken to 
identify the use of frameworks for decision making, the incorporation of best practices into 
those frameworks, as well as the use of tools for evaluating the quality of decision making 
within those organisations. Structured questionnaires developed for the purpose of this 
research aimed to bridge that gap, as described in Chapters 3 and 4. The results uncovered 
that pharmaceutical companies (regulatory and HEOR departments), regulatory authorities 
and HTA agencies utilise different processes, for example through the use of committees or 
having a single decision maker, in order to make decisions regarding the submission and 
approval of information to support the marketing authorisation and reimbursement of 
medicines. These studies also uncovered the composition of the various decision-making 
groups or committees, which may be of interest to organisations setting up their management 
bodies, in order to help decide the stakeholders that should be involved. Nevertheless, 
although organisations may be using different processes, they could all benefit from the use of 
formal frameworks to ensure structured and consistent processes. Interestingly, the results 
demonstrated that formal frameworks are not always utilised by organisations. Moreover, 
even those organisations with established frameworks had not incorporated all ten QDMPs 
into their processes, particularly QDMP 3 (assign values and relative importance to decision 
criteria), which should be addressed as a priority by organisations by making criteria, values 
and preferences explicit to all decision makers, as well as recording this information for the 
purpose of communication and audit. Nevertheless, all ten QDMPs were generally considered 
as relevant by the participants, thereby emphasising their appropriateness as a basis for formal 
frameworks for companies and agencies. 
 
The results from the questionnaires also revealed common challenges in decision making, 
including the influence of biases.  Interestingly, the company results in the regulatory 
questionnaire suggest that consensus decision-making or the use of formal frameworks is 
associated with less bias compared to having one individual make the decision or not having a 
formal framework.  Nevertheless, it has been appreciated that the term ‘bias’ has negative 
connotations, as explored by Kahneman (2011) and perhaps a different terminology, such as 
‘subjective influences’ could be utilised in the future. Almost all the study participants felt 
that there was room for improvement in their organisation’s decision making and suggested a 
number of solutions, including better training, education and ensuring the use of structured 
processes.  
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The organisations also stated that they do not generally perform assessments of their quality 
decision-making processes, whereas assessments of outcomes are more frequent, despite the 
former being a key first step in identifying areas for improvement in the practices (Kahneman, 
2011). In order to confirm and further understand this finding from the questionnaires, a 
systematic review of literature was undertaken to identify techniques from the public domain 
for assessing the ten QDMPs. The review identified a general paucity of research into this 
area, with 13 techniques identified in total, but only two (QoDoS and Organisational IQ) 
assessing all the QDMPs, where only QoDoS was relevant to both companies and agencies 
based on its questions. Consequently, the lack of formal assessments within organisations, as 
identified by the questionnaires, could be explained by the lack of available techniques 
revealed through the literature review.  
 
The QoDoS, aims to address companies’ and agencies’ need to assess the quality of their 
decision making with a structured and systematic approach that incorporates human 
awareness and provides the basis to achieve better practice (Donelan et al., 2015). Such 
evidence-based decision-making approach may lead to a shift to utilisation of formal 
frameworks and more systematic and structured processes for decision making. Although 
QoDoS already possesses a number of key psychometric properties, this programme of 
research further demonstrated the instrument’s internal consistency, test-retest reliability as 
well as relevance in the target audiences, including language clarity and completeness of the 
QoDoS items. In addition, a number of small clarifications have been suggested to QoDoS, 
such as revising item 27 (I generate a Strengths-Weaknesses-Opportunities-Threats analysis 
in my decision making) to (I utilise decision making tools such as Strengths-Weaknesses-
Opportunities-Threats analysis in my decision making), which will be taken account in future 
QoDoS studies.  
 
Lastly, three illustrative case studies were carried out as first in-depth applications of QoDoS 
with selected groups within a company, a regulatory authority and an HTA agency. The 
studies resulted in identifying favourable and unfavourable practices, raising awareness across 
the individuals of the issues in decision making and enabling dialogue within organisations as 
a starting point for initiating a change in practice. Moreover, the case studies demonstrated 
the overall feasibility of this method as well as confirmed the practicality of QoDoS in 
assessing decision making in three different environments. This is indeed a major advantage, 
as assessments of different organisations with a common tool could facilitate external 
discussions as well as potential alignment of decision-making practices between companies, 
regulatory and HTA agencies. Studies described in Chapters 6 and 7 also illuminated the 
difficulty in assigning favourable or unfavourable scores to the QoDoS items, such as QoDoS 
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item 36 (‘I use intuition or “gut-feeling” in my decision making’), which is scored as 
‘unfavourable practice’, as indeed the overuse of intuition could lead to bias. Nevertheless, it 
should be noted that successful decision making relies on a balance between deliberate and 
instinctive thinking. The weighting of the QoDoS items should be therefore reviewed in the 
future with an expert panel, as well as how the QoDoS items are assigned to the ten QDMPs, 
to ensure the relevance and clarity of the results. 
 
Finally, it was hypothesised that despite the challenges to the direct measurement of quality 
decision making and its outcome, by understanding the components of QDMPs, it may be 
possible to build a list of markers against each practice to ensure that each practice is 
embedded within organisational culture and individual processes. Consequently, a study with 
three focus groups from companies, agencies and academia aimed to develop practical 
approaches for incorporating quality into the decision-making processes during medicines 
development, regulatory review and HTA. All three focus groups developed 
recommendations, firstly regarding future research directions for building the evidence 
around quality decision-making practices, secondly relating to what may be the issues that 
need to be internally considered to build quality into the decision processes and lastly relating 
to approaches for measuring the processes and outcomes within organisations. One of the key 
outcomes of the focus groups has also been the reorganisation of the ten QDMPs under new 
subheadings and it is suggested that this new categorisation is taken forward in future studies 
(Figure 9.1). 
 
Figure 9.1 The re-organised ten Quality Decision-Making Practices  
 
 
Stakeholder perspectives and suggestions from the three focus groups were assessed in 
comparison with the outcomes of the other major studies undertaken as part of this research 
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programme in order to develop a checklist for incorporating the ten QDMPs. This checklist 
enables an organisation to incorporate these practices into its project matrix structure ahead of 
decision making (part 1) and lists process steps that need to be established and documented at 
the time of the decision-making process (part 2) in order to enable process quality, 
transparency and consistency.  Next steps would seek to validate the checklist in -target 
audiences to increase its user friendliness, clarity, relevance and applicability. These 
objectives could also be achieved by appraising other existing checklists through a systematic 
review of the literature, which should also be undertaken. 
 
A key challenge going forward is ensuring that this checklist is utilised and adhered to by 
organisations. Of major importance is ensuring that the roadmap is user friendly, clear and 
relevant, which is where future research could focus. Perhaps a starting point would be to 
utilise the validated checklist for training purposes using mock scenarios, so that 
organisations could understand in theory how to ensure a quality process through the 
incorporation of best practices, without creating too much strain on ongoing decision-making 
processes. Initial pilots could be used to generate case studies to demonstrate the advantages 
of such an approach. In addition, the checklist should be used primarily for important 
strategic decisions, as not every decision warrants such a detailed structured approach in order 
to balance burden compared to benefit (Kahneman, 2011). The development of a user manual 
would be essential to facilitate this. 
 
ROADMAP FOR IMPROVING QUALITY OF DECISION-MAKING PROCESSES 
It is important to note that the overall reactions to the studies carried out as part of this 
research programme have been very positive, perhaps due to this area being largely 
unexplored despite its importance, as highlighted at a recent Workshop (Walker et al., 2017).  
This therefore supported the idea of bringing together the various methods developed and 
utilised throughout this programme of research into an overarching roadmap for improving 
the quality of decision-making processes for key strategic decisions. The roadmap aims to 
encourage organisations to banish the “black box” decision-making systems which currently 
prevail. It consists of the following steps that organisations could undertake (Figure 9.2): 
• Step 1: Document the decision-making process.  For this initial step, questionnaires 
such as those utilised in Chapters 3 and 4 could be adapted and completed by 
management overseeing a specific decision-making process that would be the focus of 
improvements. This could either be a rare and key decision (for example reorganising a 
company) or a repetitive and high stake decision (initiating a clinical study phase by 
companies). Once the process is selected, the questionnaires could be applied to first 
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characterise the decision-making process (e.g. committee consensus process; one 
individual makes the decision etc.), the system (e.g. quantitative system using data and 
algorithm; qualitative system using expert judgment or a mixture), the use of frameworks 
(formal; informal) and whether or not the ten QDMPs have been theoretically 
incorporated into the framework. Of additional interest would be to determine whether it 
is perceived that the organisation is influenced by biases (subjective influences) (Lovallo 
and Sibony, 2010), as well as determining any perceived barriers and solutions to 
decision making. 
• Step 2: Perform Assessment of the ten QDMPs. Once the process has been 
characterised, the next step would be to determine whether any techniques for evaluating 
the ten QDMPs are currently utilised by the organisation either systematically (e.g. every 
year) or on ad hoc basis. Following that, an evaluation would be proposed, where the use 
of QoDoS will be encouraged due to it being a relevant and reliable technique in 
assessing the ten practices as demonstrated in Chapters 5 and 6. This step would be in line 
with case studies described in Chapter 7, which has demonstrated the feasibility of this 
approach. QoDoS would therefore be used as a diagnostic test to evaluate the process 
selected in step 1. The aim would be to assess the decision-making competence and style 
of the individuals as well as how they perceive the decision-making approaches and 
culture of their group/team/organisation. The results could be used to identify favourable 
and unfavourable QDMPs as well as the key subjective influences (biases). In addition, 
the results would provide a basis for discussions within the group as well as obtaining 
factual information to initiate a change in practices.  
• Step 3: Facilitate incorporation of the ten QDMPs. Finally, the results of steps 1 and 2 
could be subsequently used to address the least favourable and least consistently 
embedded QDMPs. This step could utilise the checklist developed in Chapter 8. The aim 
would be to determine how to best incorporate them into the organsiational matrix 
(checklist part 1) as well as what specific actions need to be followed and documented at 
the time of the process (checklist part 2). Nevertheless, if improvements are made, the 
assessments described in steps 1 and 2 of the roadmap should be periodically repeated to 
ensure the effectiveness of implementation of any changes. 
 
This roadmap therefore describes the steps an organisation could undertake to improve the 
quality of key decision-making processes, namely by first defining the decision, evaluating 
the ten QDMPs and subsequently better incorporating them into their organisational 
framework.  It is based on the methods and tools developed and/or utilised and validated 
throughout this programme of work, namely the questionnaires (Chapters 3 and 4), the 
QoDoS (Chapter 5, 6 and 7) and the checklist (Chapter 8),  
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Figure 9.2 The roadmap for improving the quality of decision-making processes for key 
strategic decisions made by pharmaceutical companies, regulatory authorities and 
health technology assessment (HTA) agencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
? 
Current system 
Decision-making  
“black-box” 
INPUT OUTPUT 
Evidence and 
opinions 
Outcome  
Roadmap for improving the quality of decision-making processes 
STEP 1: DOCUMENT THE DECISION-MAKING PROCESS  
AIM: Define and document a key decision-making process in terms of: 
• Use of decision-making groups (committee) 
• Process: consensus, vote or one individual deciding 
• Quantitative, qualitative or mixed system 
• Use of formal or informal frameworks 
• Perceived subjective influences (biases) 
• Challenges and solutions to the quality of the process 
PROPOSED METHOD: Questionnaires (Chapters 3 and 4) 
 
STEP 2: PERFORM ASSESSMENT OF THE TEN QUALITY 
DECISION-MAKING PRACTICES (QDMPS) 
AIM: Determine any existing techniques in place to evaluate the ten 
QDMPs for the process. Utilise the technique to: 
• Determine perception of how individuals believe 
they make decisions vs. their organisation 
• Identify favourable and unfavourable QDMPs 
• Gain a basis for discussion and factual information 
to determine scope of improvements 
PROPOSED METHOD: QoDoS case studies (Chapter 7) 
 
STEP 3: FACILITATE INCOROPORATION OF THE TEN QDMPs  
AIM: Utilise results from Steps 1 and 2 to identify 
areas for improvement including least favourable and 
least consistently embedded QDMPs. Subsequently 
determine how to best incorporate them into the 
organsiational matrix as well as specific steps taken at 
the time of the decision-making process.  
PROPOSED METHOD: Checklist (Chapter 8) 
 
Iterative process to be to be repeated periodically to 
ensure consistency and best practice 
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The implementation of the roadmap in companies, regulatory authorities and HTA agencies 
could also contribute to a better alignment between the various stakeholders, as the various 
methods outlined in steps 1-3 have been tested and were demonstrated as relevant to all three 
environments. Moreover, the roadmap could be used as a basis for communicating with the 
public, for example through annual company and agency reports to illustrate how well the 
organisational framework adheres to the ten QDMPs (Steps 1 and 2) as well as through public 
reports specific to the assessment of a medicine, where the checklist could be used as a basis 
for demonstrating the process utilised to arrive at a specific outcome (Step 3).  
 
Nevertheless, the challenge is how to ensure the implementation of such a roadmap, as indeed 
the perceived burden may seem higher than the benefit. A key to success would be having 
internal and external decision-making champions within each organisation or creating 
departments whose role it would be to increase the awareness of quality decision making and 
facilitate a change in culture at the operational level, including the development of training 
programmes for all staff as well as international accreditation programmes, for example 
through ISO9001 (International Standards Organization; focus on Quality Management 
Principles). Indeed certain companies, such as Eli Lilly, have already undertaken such steps 
(Walker et al., 2017). Endorsement from management would be essential to enable and 
encourage changes; case studies could be developed for that purpose to demonstrate the 
importance of a quality decision-making process.  
 
As many organisations are primarily interested in outcomes, it would be of key importance to 
ultimately demonstrate that the use of the ten QDMPs improves the probability of better 
outcomes, although this would be challenging due to the high uncertainty and multifactorial 
nature of the decision-making process. The focus could be initially placed on strategic 
management meetings as well as training and educational programmes to increase awareness 
of the important considerations in improving decision making, with the hope that with 
organisational buy-in, the QDMPs could also be used in time during real-life scenarios to 
demonstrate that they increase the overall probability of better outcomes. This approach , for 
example, could be used by company or agency decision-making committees when evaluating 
alternatives, both by mature organisations to set a benchmark, as well as by smaller or less 
mature companies and agencies in order to train staff and improve practices. 
 
Of interest would be also to incorporate the ten QDMPs, as well as the roadmap, into the 
growing body of internationally accepted guidelines to help companies and agencies 
implement systems for making better decisions. For regulatory authorities and pharmaceutical 
companies, the ten QDMPs and the associated roadmap could be introduced through the 
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World Health Organisation (WHO), which already offers guidance relating to good review 
practices. For HTA agencies, it could be the European Network for Health Technology 
Assessment (EUnetHTA) or the International Network of Agencies for Health Technology 
Assessment (INAHTA), which facilitate European and international cooperation on HTA in 
Europe and globally and could incorporate the ten QDMPs into their tools and resources. The 
aim would be to ensure the use of the QDMPs and the roadmap at the international level and 
therefore facilitate alignment and convergence of best practices globally. 
 
STUDY LIMITATIONS 
As with any research there are a number of limitations including the following:   
• For Chapter 3 (regulatory questionnaires), a pilot study was planned with companies 
and agencies in order to validate the acceptability and content of the questionnaires. 
However, this did not take place due to a lack of responses from the pilot participants 
despite repeated follow-ups with emails and phone calls. The questionnaire 
nevertheless went ahead as this was an exploratory, fact finding study and it was 
validated internally within the research team for format and language clarity.  
• Whilst the regulatory and reimbursement questionnaires (Chapters 3 and 4) were 
international in nature, information was not obtained from agencies in certain key 
European jurisdictions, such as German or French HTA agencies or the Swiss 
regulatory authority, due to a lack of responses despite multiple attempts to contact 
those organisations. Whereas the response rate achieved for regulatory and HTA 
agencies as well as regulatory company departments were very good (~70%), this 
was only satisfactory for HEOR company departments (46%). This may be due to the 
lower level of maturity of those departments, which are generally newer compared 
with the regulatory departments, as well as due to the changing nature of the decision-
making processes within companies to adapt to the dynamic HTA environment.  
• The systematic literature review to identify techniques for assessing the quality of 
decision making presented in Chapter 5 was limited to articles in English language 
and covered a period from 1996 to 2017. Consequently, other techniques, if any, 
published in other languages and outside this timeframe were not identified. 
Nevertheless, the period identified reflects the proliferation of publications in this 
area, whereas the majority of the tools were published or translated into English due 
to their international importance.  
• For Chapter 7, only one company, regulatory authority and HTA agency were 
selected to demonstrate the practicality of QoDoS for identifying the incorporation of 
the ten QDMPs and generally to demonstrate the feasibility of the method. This 
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sampling was considered nevertheless appropriate as the aim was to produce 
illustrative pilot case studies for testing the practical application of the methodology, 
as opposed to generating aggregated trends or extrapolating the results to other 
organisations. Furthermore, the formal feedback discussions with the study 
participants have not yet taken place, but are planned for the second part of 2018. The 
objectives would be to discuss the rationale for the results obtained as well as to 
establish the suitability and benefits of the study method. 
 
RECOMMENDATIONS 
As a result of this research, there are a number of recommendations: 
• Pharmaceutical companies, regulatory authorities and HTA agencies should place 
greater emphasis on the quality aspects of decision making for key strategic 
processes, as specified by the ten QDMPs. This could be facilitated through the 
creation of quality decision-making departments, the involvement of champions and 
encouraging training and education in the science of decision making. The aim would 
be to raise awareness of the issues, biases and best practices in decision making. 
• The QoDoS should be applied as a diagnostic instrument within teams, committees or 
departments in pharmaceutical companies, regulatory authorities and HTA agencies. 
The results could serve as a basis for identifying and discussing favourable and 
unfavourable practices and obtaining factual information underpinning a change 
within an organisation. Furthermore, the routine application of QoDoS has the 
potential to change the organisational culture and the individual’s approach to 
decision making with an increased focus on process quality. 
• The ten QDMPs should be incorporated into organisational frameworks within 
companies and agencies. The checklist could be further utilised to identify how each 
QDMP, especially if identified as unfavourable by QoDoS, could be incorporated into 
the organisational matrix structure as well as embedded during strategic decision-
making processes. The ten practices, as well as the overarching roadmap, could be 
furthermore incorporated into recognised international guidelines (e.g. WHO) for 
companies and agencies to promote best practice and alignment of decision-making 
processes. 
 
FUTURE WORK 
• It would be of value to apply the questionnaires described in Chapters 3 and 4 to less 
mature regulatory authorities and HTA agencies, as well as small and medium 
enterprises (SMEs). This would aim to identify differences and similarities compared 
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to larger, more established organisations in terms of the decision-making processes, 
the use of frameworks as well as perceived challenges and solutions in decision 
making. 
• Of interest would also be to further evaluate the importance and influence of biases 
during the lifecycle of medicines. Subsequently, the results could be used to develop 
a new model of bias mitigation, starting with a change in terminology to behavioural 
influences.  
• Future QoDoS studies, as described in Chapter 7, should be organised with other 
mature and established organisations, including different committees, groups and 
departments. In addition, studies with less mature regulatory authorities and HTA 
agencies, as well as smaller companies, including SMEs could also be organised in 
order to identify further similarities and differences. One example could be a greater 
need for improvement across the QDMPs within maturing organisations or a bigger 
demand for accountability of the decisions made for smaller companies.  
• Additional QoDoS studies could also be used to address the focus group 
recommendations (Chapter 7), such as to compare the results of QoDoS for 
organisations with and without a structured framework; to analyse joint venture 
decision-making processes e.g. parallel processes between regulatory authorities and 
HTA agencies or product acquisition between companies.  
• Datasets from previous and future studies could be accrued to create a QoDoS 
benchmarking database. The aim would be to identify any trends in how companies 
and agencies make decisions, as well as other overarching themes, such as the 
differences in how individuals perceive themselves compared to their organisation, as 
well as the influence of gender and the number of years of experience on decision 
making.   
• The checklist developed as a result of the study outcomes provides an initial list of 
items that need to be considered in implementing the ten QDMPs, once areas for 
improvement have been identified with QoDoS. The next steps would be to develop a 
user manual and subsequently validate the checklist with pharmaceutical companies, 
regulatory authorities and HTA agencies in order to establish its practicality, clarity 
and relevance; a systematic literature review of other checklists utilised in other 
industries would also be of interest. Once the checklist is validated, the QoDoS could 
then be utilised to determine whether a better implementation of the ten QDMPs with 
the checklist results in a more favourable QoDoS score, thereby demonstrating the 
sensitivity of QoDoS to detect a change in practice over time.  
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• Finally, of interest would be to pilot the checklist with an organisation over time, 
where it could be used for a number of similar decision-making processes. The 
organisation could complete the checklist for each decision, thereby documenting 
their process and subsequently this could be compared to the outcome of the decision 
once it emerges. The aim would be to perform an impact analysis in order to 
determine whether unfavourable outcomes could be tied to persistent deficiencies in 
the process, as documented by the checklist. 
 
CONCLUSION 
This programme of research marks a milestone in addressing the gap between the well-
recognised science of decision making with that addressed in the area of regulation and 
reimbursement of medicines. The studies undertaken have for the first time, using well-
defined methods and techniques, evaluated both the decision-making practices as well as their 
implementation during the lifecycle of medicines. The overall outcome was the development 
of a roadmap for improving the quality of decision making for the key strategic processes 
undertaken by pharmaceutical companies, regulatory authorities and health technology 
assessment agencies. This has the potential to not only fundamentally change the culture 
within those organisations, but will ensure a greater emphasis on decision making as opposed 
to just evaluating the data.  This could therefore revolutionise the way companies and 
agencies make decisions, which may ultimately increase the probability of favourable 
outcomes, with the final goal of building public trust and accountability into the key strategic 
decisions made by all three stakeholders. 
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